{"title": "PDF", "author": "PDF", "url": "https://www.blacpma.usach.cl/sites/blacpma/files/006-004.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Bolet\u00edn Latinoamericano\ny del Caribe de Plantas \nMedicinales y Arom\u00e1ticas\nVolumen 6, N\u00famero 4 \nEspecial Regulaci\u00f3n de Fitomedicinas / \nSpecial Issue on Regulation of PhytomedicinesEditor/Coordinador: Jose M. Prieto\nA vision for medicinal plants.\nG.A. Cordell\nLa regulaci\u00f3n global de los medicamentos herbarios.J.M. Prieto\nThe Traditional Herbal Medicine Directive within the European \nregulatory framework for Herbal Products.\nW. Peschel\nThe Impact of the European Traditional Use Directive on the Herbal Product Markets in the United Kingdom, Germany and \nSpain.\nW. Peschel\nAntecedentes y situaci\u00f3n reguladora de la medicina herbaria \nen Cuba.\nM. Gonz\u00e1lez Ram\u00edrez, D. Rem\u00edrez, O. L. Jacobo \nPhytomedicines in Jamaica: regulatory issues.D. Robertson\nAn Overview on the Development in Regulation and Control of \nMedicinal and Aromatic Plants in the Indian System of \nMedicine.\nP.K. Mukherjee, M. Ventakesh, V. Kumar\nCon el auspicio de\nRegistrada e indexada en: \nQUALIS\u00ae, INDEX COPERNICUS\u00ae, LATINDEX\u00ae, \nIMBIOMED\u00ae, REDALYC\u00aeISSN 0717 7917\nwww.blacpma.cl\n \n \nBLACPMA \n \nBol. Latinoam. Caribe Plant. Med. Aromat. Vol. 6 (4) 2007 i Fundadores:  \nJos\u00e9 L. Mart\u00ednez (Chile) - Jorge Rodr\u00edguez (Cuba) \nEditor Jefe:  Jos\u00e9 L. Mart\u00ednez (Chile) \nEditor Jefe Cient\u00edfico:  Jos\u00e9 M. Prieto (Reino Unido) \nEjecutivo: Gabino Garrido (Cuba) \nAsociado:  Patricia Arenas (Argentina) \nAsociado: Carla Delporte (Chile) \nCo-editores \nArnaldo Bandoni (Argentina) \nFrancisco Mor\u00f3n (Cuba) \nPatrick Moyna (Uruguay) \nDamaris Silveira (Brasil) \nPresidente de la SLF (2005 - 2008) \nHoracio Heinzein (Uruguay) \nConsejo Editorial \nChristian Agyare (Ghana) \nRoc\u00edo Alarc\u00f3n (Reino Unido) \nJorge Alonso (Argentina) \nGiovanni Apendino (Italia) \nElizabeth Barrera (Chile) \nGeofrey Cordell (Estados Unidos) \nMarco Dehesa (Ecuador) \nRene Delgado (Cuba) \nEduardo Dellacasa (Uruguay) \nLuis Doreste (Venezuela) \nMildred Garc\u00eda (Costa Rica) \nMartha Gattusso (Argentina) \nNorman Farnworth (Estados Unidos) \nMichael Heinrich (Reino Unido) \nAmelia Henriques (Brasil) \nArmando Herrera (M\u00e9xico) \nPeter Houghton (Reino Unido) \nMar\u00eda In\u00e9s Isla (Argentina) \nAna Ladio (Argentina) \nPatricia Landazuri (Colombia) \nClaudio Laurido (Chile) \nOlga Lock (Per\u00fa) \nVicente Mart\u00ednez (Guatemala) \nErnesto Medina (Nicaragua) \nPedro Melillo de Magalhaes (Brasil) \nLeonora Mendoza (Chile) \nJohn A.O. Ojewole (Sudafrica) \nMahendra Rai (India) \nLuca Rastrelli (Italia) \nElsa Rengifo (Per\u00fa) \nJos\u00e9 Lu\u00eds R\u00edos (Espa\u00f1a) \nAlicia Rodr\u00edguez (Cuba) \nMarcela Samarotto (Chile) \nAurelio San Mart\u00edn (Chile) \nGuillermo Schinella (Argentina) \nDjaja D. Soejarto (Estados Unidos) \nYen-Jen Sung (Taiw\u00e1n) \nPeter Taylor (Venezuela) \nNilka Torres (Panam\u00e1) \nRen\u00e9 Torres (Chile) \nCarlos Vicente (Argentina) \nMarcelo Wagner (Argentina) \nElisabeth Williamson (Reino Unido) OBJETIVOS DEL BOLET\u00cdN \nEstimular a los grupos de trabajo existentes en \nLatinoam\u00e9rica, sean investigadores, productores, \nfuncionarios o simplemente interesados en las plantas medicinales y arom\u00e1ticas, poniendo a su disposici\u00f3n \neste Bolet\u00edn para la difusi\u00f3n y la divulgaci\u00f3n de sus \ninvestigaciones y de las actividades que en general desarrollen en torno a plantas. \nSer una herramienta de difusi\u00f3n para la Sociedad \nLatinoamericana de Fitoqu\u00edmica, principalmente, y de otras sociedades y agrupaciones que se sientan \nrepresentadas por este Bolet\u00edn. \nConstituir un nexo entre los profesionales de habla \nhispana, francesa, portuguesa e inglesa de la regi\u00f3n, \nrelacionados con el tema central del Bolet\u00edn \n \n \nEl BOLET\u00cdN LATINOAMERICANO Y DEL CARIBE DE PLANTAS MEDICINALES Y AROM\u00c1TICAS (BLACPMA), ISSN 0717 7917, es una publicaci\u00f3n cient\u00edfica electr\u00f3nica bimensual dirigida a diversos profesionales y t\u00e9cnicos vinculados al campo de las plantas medicinales y \narom\u00e1ticas. BLACPMA es una entidad sin \u00e1nimo de \nlucro. Aunque auspiciada por la Sociedad Fitoqu\u00edmica Latinoamericana (SLF), este bolet\u00edn no es propiedad de Club o Asociaci\u00f3n alguna. Ni BLACPMA ni la SLF son responsables en ning\u00fan momento de las opiniones vertidas en sus p\u00e1ginas, \nque son responsabilidad \u00fanica de sus respectivos \nautores. Todo el material gr\u00e1fico ha sido creado de \nmanera genuina o bien remitido por sus autores con \nel permiso de \u00e9stos. Todas las marcas y logos \nreferidos en estas p\u00e1ginas son propiedad de sus respectivos autores o empresas. En Chile, 1 de Enero \nde 2007. \n \nBLACPMA WEB Site: www.blacpma.cl\nEnvio de trabajos Online a nuestra editorial \n(Online Submission) \nBlacpma_editorial@hotmail.com\nblacm@direct\nBLACPMA esta Indexada por: \nINDEX COPERNICUS (Impacto 3.75) \nwww.indexcopernicus.com\nIMBIOMED www.imbiomed.com.mx   \nLATINDEX www.latindex.unam.mx\nQUALIS www.capes.gov.br  \nREDALYC  redalyc.uaemex.mx   \n  \n \nInstrucciones para los autores \n \nBol. Latinoam. Caribe Plant. Med. Aromat. Vol. 6 (4) 2007 ii  El BOLET\u00cdN LATINOAMERICANO Y DEL \nCARIBE DE PLANTAS MEDICINALES Y AROM\u00c1TICAS (BLACPMA), ISSN 0717 7917,  \nes una publicaci\u00f3n cient\u00edfica electr\u00f3nica bimensual dirigida a diversos profesionales y t\u00e9cnicos \nvinculados al campo de las plantas medicinales y \narom\u00e1ticas y en general dedicados a los productos naturales de inter\u00e9s medicinal o nutraceutico. Se aceptar\u00e1n trabajos relacionados con las \u00e1reas que cubre el Bolet\u00edn y que son: agronom\u00eda, antropolog\u00eda \ny etnobot\u00e1nica, aplicaciones industriales, bot\u00e1nica, \ncalidad y normalizaci\u00f3n, ecolog\u00eda y biodiversidad, \neconom\u00eda y mercado, farm acolog\u00eda, fitoqu\u00edmica, \nfarmacognosia, legislaci\u00f3n, informaciones y difusi\u00f3n \nde eventos, cursos, premios, reglamentaciones, noticias, cuestiones de mercado, ponencias, \nbibliograf\u00eda, o cualquier otro tipo de material que se \ncrea importante comunicar. \nSe podr\u00e1n presentar trabajos de revisi\u00f3n y de investigaci\u00f3n cient\u00edfica original , comunicaciones \ncortas , as\u00ed como ensayos  y escritos para debate  \nescritos en idioma espa\u00f1ol, ingl\u00e9s, portugu\u00e9s o franc\u00e9s de libre extensi\u00f3n siempre que razonablemente se ajuste al objetivo del trabajo. Los anuncios, noticias y otros no deber\u00e1n exceder la cuartilla. En todos los casos est\u00e1n incluidas las tablas. \nLos trabajos ser\u00e1n presentados en lenguaje de Microsoft Word (versi\u00f3n 3.1 o superior, con letra Times New Roman  n\u00famero 11) y enviados por correo electr\u00f3nico a la siguiente direcci\u00f3n: blacpma_editorial@hotmail.com o en su lugar por \ncorreo a\u00e9reo en disquete de 3.5 pulgadas a: Lic. Jos\u00e9 \nLuis Mart\u00ednez, Editor, Casilla de Correos 70036, Santiago 7, Chile.  \nLos trabajos se acompa\u00f1ar\u00e1n de una relaci\u00f3n de los correos electr\u00f3nicos y/o direcciones postales de \ntodos los autores. El autor principal se \nresponsabilizar\u00e1 de la conformidad de cada uno de ellos con su publicaci\u00f3n en BLACPMA, as\u00ed como de cualquier problema surgido por la autor\u00eda y/o originalidad del trabajo. \nUna vez recibidos, los trabajos se enviar\u00e1n a dos \nevaluadores que decidir\u00e1n su aprobaci\u00f3n o rechazo.  \nLos trabajos se dividir\u00e1n en Introducci\u00f3n, Materiales \ny M\u00e9todos, Resultados, Discusi\u00f3n y Conclusiones y Bibliograf\u00eda. En cualquiera de las modalidades en la cual se presenten los trabajos, en la primera p\u00e1gina \ndeber\u00e1 aparecer: T\u00edtulo del trabajo (en espa\u00f1ol e ingl\u00e9s), autores, instituci\u00f3n a la cual pertenecen los \nautores, direcci\u00f3n del autor principal y correo electr\u00f3nico. Deber\u00e1 aparecer adem\u00e1s un resumen en espa\u00f1ol e ingl\u00e9s de no m\u00e1s de 100 palabras, un t\u00edtulo corto y un m\u00e1ximo de 6 palabras clave. Los n\u00fameros de \nlas tablas y las figuras deben ser ar\u00e1bigos. \nLas citas en el texto deber\u00e1n incluir apellido del autor y \na\u00f1o, separados por coma y colocados entre par\u00e9ntesis (ejemplo: Bruneton, 1995); si hay m\u00e1s de una trabajo del mismo autor, se separar\u00e1n por comas (ejemplo: \nBruneton, 1987, 1995, 2001). Si hay dos autores se \ncitar\u00e1n separados por \u201cy\u201d o su equivalente, respetando el idioma original de la fuente. Si hay m\u00e1s de dos autores, s\u00f3lo se citar\u00e1 el primero seguido de la expresi\u00f3n et al. destacada en it\u00e1lica (ejemplo: Dixon et al., 1999), en tanto que en la bibliograf\u00eda deber\u00e1n \nfigurar todos los autores. Si hay varios trabajos de un \nmismo autor y a\u00f1o, se citar\u00e1 con una letra en secuencia \nadosada al a\u00f1o (ejemplo: Mayer et al. 1987a, 1987b). Si un trabajo no tiene autor, se lo citar\u00e1 como An\u00f3nimo seguido de la fecha de publicaci\u00f3n. Si hubiera m\u00e1s de \nuna cita de este tipo en el mismo a\u00f1o, se adosar\u00e1 una \nletra correlativamente (An\u00f3nimo, 2002a, An\u00f3nimo, 2002b). \nLa bibliograf\u00eda incluir\u00e1 s\u00f3lo las referencias citadas en el texto, ordenadas alfab\u00e9ticamente por el apellido del primer autor, sin n\u00famero que lo anteceda y sin sangr\u00eda. \nApellido/s del autor seguido de las iniciales del nombre \nsin puntos ni separaci\u00f3n entre ellas.  \nEl nombre de la revista se colocar\u00e1 abreviado seg\u00fan normativa ISO y en it\u00e1lica de acuerdo con el Botanico Periodicum Huntianum, (disponible solamente en \nedici\u00f3n impresa) o con el mas conveniente Pubmed \nJournals Database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Journal , ISO abbreviation), que ofrece la posibilidad de chequear online el nombre y abreviatura (en ambos \nsentidos) de un enorme n\u00famero de revistas. Por ultimo \nse citar\u00e1 el volumen de la publicaci\u00f3n, mejor si seguido del n\u00famero entre par\u00e9ntesis, dos puntos y el n\u00famero de \np\u00e1gina desde x hasta y, sin espacios entre medio.  \nLas citas de libros deben explicitar que p\u00e1ginas fueron \nconsultadas y el a\u00f1o de edici\u00f3n (presten atenci\u00f3n a no \nequivocar el a\u00f1o de la prim era edici\u00f3n con el de la \nedici\u00f3n que est\u00e1n Uds. consultando).  \nNo se admitir\u00e1n citas inco mpletas y todo defecto ser\u00e1 \nmotivo de retraso del art\u00edculo hasta su correcci\u00f3n \nacuerdo a estas normas. Instrucciones para los autores \nBol. Latinoam. Caribe Plant. Med. Aromat. Vol. 6 (4) 2007 iii  MODELOS \nPublicaciones peri\u00f3dicas \nSoto H, Rovirosa J, San Mart\u00edn A, Argando\u00f1a V. \n1994. Metabolitos secundarios de Dictyota \ncrenulata. Bol. Soc. Chil. Qu\u00edm.  39(3):173\u2013178. \nLibros \nDurand E, Miranda M, Cuellar A.1986. Manual de \npr\u00e1cticas de laboratorio de Farmacognosia. Ed. \nPueblo y Educaci\u00f3n, La Habana, Cuba, pp. 90, 120-121.  \nCap\u00edtulos de libros editados \nLopes de Almeida JM. 2000. Formulaci\u00f3n \nfarmac\u00e9utica de productos f itoterap\u00e9uticos, pp. 113-\n124. En Sharapin N: Fundamentos de tecnolog\u00eda de \nproductos fitoterap\u00e9uticos. Ed. CAB y CYTED, Bogot\u00e1, Colombia. \nTesis  (aceptable s\u00f3lo si no hay fuente alternativa) \nGonz\u00e1lez de Cid D. 2000. Estudio de cianobacterias \ncon efectos nocivos (delet\u00e9reos y t\u00f3xicos) en \nambientes acu\u00e1ticos de la  provincia de San Lu\u00eds. \nTesis Doctoral, Universidad Nacional de San Lu\u00eds, Argentina, pp. 234, 245-244.  \nComunicaciones a Congresos \nSi no hay libro oficial de abstracts: \nNovak A, Pardo de Santayana M, Prieto JM. 2006. Antioxidant activity and fingerprinting of Spanish Bupleurum  species used as anti-inflammatory \nremedies. Comunicaci\u00f3n a la British Pharmaceutical \nConference 2006 (Royal Pharmaceutical Society of \nGreat Britain, Manchester, UK, 4-6 Septiembre). \nSi hay libro oficial de abstracts: \nNovak A, Pardo de Santayana M, Prieto JM. 2006. Antioxidant activity and fingerprinting of Spanish Bupleurum  species used as anti-inflammatory \nremedies. Res\u00famenes de la British Pharmaceutical Conference 2006 (Royal Pharmaceutical Society of Great Britain, Manchester, UK, 4-6 September) p. 23. \nSi los res\u00famenes fueron a su vez publicados en una \nrevista se menciona S\u00d3LO a la revista como si fuera \nun art\u00edculo m\u00e1s. \nNovak A, Pardo de Santayana M, Prieto JM. 2006. Antioxidant activity and fingerprinting of Spanish Bupleurum  species used as anti-inflammatory \nremedies. J. Pharm. Pharmacol. 58(Suppl. 1): 82. \nRecursos electr\u00f3nicos \nNota: Si hay que partir alguna direcci\u00f3n se recomienda hacerlo despu\u00e9s de una barra inclinada \nATENCION: hoy existen mu chos otros tipos de \ndominios que no son http. Por ejemplo los hay https \no ftp. Igualmente existe n muchos dominios que no \nson www, sino www2 u otros. Por tanto preste atenci\u00f3n a la direcci\u00f3n completa y no asuma que por defecto van a ser http o www.  \nDuncan R. 2000. Nano-sized particles as \n\"nanomedicines\u201d. http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=con2022821&RevisionSelectionMethod=Latest . [Consultada el 6 de Octubre de 2006]. \nEn caso de no haber un autor, o cuando no hay un responsable principal, se toma la instituci\u00f3n responsable como equivalente al autor, y en el texto se cita (CNN, 2000). \nCNN. Cuba's health care manages despite embargo. \nhttp://www.cnn.com/TRANSCRIPTS/0108/18/yh.00.ht\nml [Consultada el 5 octubre de 2006]. \nBoletines o revistas on-line con ISSN, la fuente debe ser citada como cualquier otra revista. \nPrieto JM. 2005. El B\u00e1lsamo de Fierabr\u00e1s. BLACPMA 4(3):48-51. \n \nImportante NOTA sobre la citaci\u00f3n de p\u00e1ginas Web \nEn estos d\u00edas se esta comprobando el creciente ABUSO de la \ncitaci\u00f3n de paginas Web para av alar afirmaciones cient\u00edficas \nhechas por los autores. Resulta muy peligroso para su credibilidad como autor, y para la credibilidad de este Bolet\u00edn, citar informaci\u00f3n obtenida en p\u00e1ginas Web que no \ntengan ninguna entidad cient\u00edfic amente reconocida que se \nhaga responsable de la susodicha informaci\u00f3n. Las p\u00e1ginas \nWeb \u201can\u00f3nimas\u201d Solo deben ser usadas en casos muy \njustificados y ante la absoluta ausencia de ninguna otra \nfuente primaria cient\u00edficamente reconocida. El Comit\u00e9 \nEditorial de esta revista realizar \u00e1 todo esfuerzo para eliminar \nel recurso f\u00e1cil a p\u00e1ginas Web pseudo-cient\u00edficas y desde \nluego los autores deben en todo caso dar una explicaci\u00f3n de \nporque han recurrido a este tipo de fuentes. Todo abuso ser\u00e1 \nmotivo de rechazo para publicaci \u00f3n, incluso si este ya fue \n(err\u00f3neamente) aceptado por los revisores. Si se trata de \nboletines o revistas on-line con ISSN, la fuente debe ser citada como cualquier otra revista. \n \nAutoridad Final de La Editorial \nLos editores se reservan el derecho de corregir o alterar \nlos manuscritos enviados para publicaci\u00f3n en BLACPMA. Este procedimiento se ejecutara en los casos en los que los manuscritos no se avengan a est\u00e1ndares cient\u00edficos generalmente aceptados o si el \ncontenido es innecesariamente largo o poco claro. Estas \nalteraciones pueden ser requeridas directamente al autor y en todo caso retrasaran la publicaci\u00f3n del manuscrito. \n \nGracias de antemano por sus contribuciones \nEl comit\u00e9 editorial de BLACPMA  \n \nEditorial \n \nBol. Latinoam. Caribe Plant. Med. Aromat. Vol. 6 (4) 2007 88 Estimados lectores, \nA todos nosotros nos une la pasi\u00f3n por las plantas \nmedicinales pero tambi\u00e9n la preocupaci\u00f3n por su \nfuturo regulado y sostenible. BLACPMA pretende ser un foro de comunicaci\u00f3n, actualizaci\u00f3n y \ndiscusi\u00f3n de todos los profesionales implicados en el \ncultivo de plantas medicinales y la investigaci\u00f3n, desarrollo y producci\u00f3n de medicamentos herbarios.  \nPor tanto es misi\u00f3n obligada de este su bolet\u00edn \nacometer, de vez en cuando, una auditoria de la \nsituaci\u00f3n del sector. Para ello el comit\u00e9 editorial de \nBLACPMA ha decidido abordar la situaci\u00f3n actual de la regulaci\u00f3n de los medicamentos herbarios (o fitomedicinas) en forma de n\u00fameros monogr\u00e1ficos, para los cuales hemos invitado a autores de todo el mundo a explicar los \u00faltimos desarrollos reguladores \nen las distintas \u00e1reas geogr \u00e1ficas y econ\u00f3micas de su \ncompetencia. \nPara empezar en esta primera entrega se recoge la \nparticular visi\u00f3n de las plantas medicinales de un \nreferente mundial en el tema, Geoffrey Cordell, quien \nadem\u00e1s de Profesor Em\u00e9r ito de Farmacognosia en \nChicago, es activo miembro del comit\u00e9 de este \nbolet\u00edn (Cordell, 2007). \nUn primer bloque trata de enmarcar el tema con \nuna somera visi\u00f3n de los movimientos pasados y actuales a nivel regulador regional y global (Prieto, \n2007) a lo cual sigue una presentaci\u00f3n de la situaci\u00f3n \neuropea como primer ejemplo mundial de regulaci\u00f3n transnacional en materia de medicinas herbarias (Peschel, 2007a) y una discusi\u00f3n de las peculiaridades nacionales a la hora de implementar \n(\u00a1o no!) estas directivas (Peschel, 2007b). Los dos \nautores trabajamos en el Centro de Farmacognosia y Fitoterapia de la Universidad de Londres que ha \ntomado un papel leader  en la organizaci\u00f3n de \nencuentros sobre la regulaci\u00f3n de Medicinas \nTradicionales Herbarias Europeas (Heinrich, 2007). \nDos art\u00edculos sobre la situaci\u00f3n reguladora de MH \nen Jamaica (Robertson, 2007) y Cuba (Ram\u00edrez et al., \n2007) proveen una excelente perspectiva de la \ndiversidad de aproximaciones normativas en la Regi\u00f3n del Caribe. Las autoras trabajan todas \nactivamente en la regulaci\u00f3n de MH en sus \nrespectivos pa\u00edses a nivel privado e institucional respectivamente. \nPara cerrar este n\u00famero, el Profesor Mukherjee, \neditor regional en Asia de Journal of \nEthnopharmacology , y sus colaboradores nos explican como el subcontinente Indio trata de establecer un marco \u00fanico para la multitud de sistemas tradicionales que esta zona alberga as\u00ed como las miles de plantas medicinales y drogas minerales y animales que forman parte de los mismos . Es un buen ejemplo de lo \ncomplejo que puede llegar a ser poner orden y concierto \nen un campo tan rico y diverso como la medicina tradicional. \nEn una pr\u00f3xima entrega trataremos de hablar de \nSudam\u00e9rica y Centroam\u00e9rica, Norteam\u00e9rica (M\u00e9xico, \nEstados Unidos y Canad\u00e1), China y \u00c1frica. Esperamos \nque este en sus manos antes de Mayo pr\u00f3ximo. \nAprovecho para invitarles a visitar nuestra p\u00e1gina \nWeb, que acorde al cambio del bolet\u00edn ha crecido en \ncomplejidad. Ahora cuenta con servicios de b\u00fasqueda interna y descarga de separatas, entrega electr\u00f3nica de \nart\u00edculos para su publicaci\u00f3n, noticias y mucho m\u00e1s. \nSin m\u00e1s pre\u00e1mbulo, les dejo  con la esperanza de que \nencuentren \u00fatil e informa tivo todo este material que \nhemos preparado con nuestra mayor ilusi\u00f3n. \nLes saluda cordialmente, \nDr. Jos\u00e9 Maria Prieto \nCoordinador del Especial Regulaci\u00f3n de Fitomedicamentos \nEditor Cient\u00edfico Jefe de BLACPMA \n \nReferencias \nCordell GA. 2007. A vision for medicinal plants. BLACPMA  \n6(4):  89 \u2013 91. \nGonz\u00e1lez Ram\u00edrez M, Rem\u00ed rez D, Jacobo OL. 2007. \nAntecedentes y situaci\u00f3n reguladora de la medicina \nherbaria en Cuba. BLACPMA  6(4):118-124. \nHeinrich M. 2007. Future of UK herbal industry good as long \nas it adapts to new framework. Pharm. J . 278:286. \nMukherjee PK, Ventakesh M, Ku mar V. 2007. An Overview \non the Development in Regulation and Control of Medicinal and Aromatic Plants in the Indian System of Medicine. BLACPMA  6(4):129-136. \nPeschel W. 2007a. The Traditional Herbal Medicine Directive \nwithin the European regulatory framework for Herbal Products.  BLACPMA  6(4):102-111. \nPeschel W. 2007b. The Impact of the European Traditional \nUse Directive on the Herbal Product Markets in the United Kingdom, Germany and Spain. BLACPMA  \n6(4):112-117. \nPrieto JM. 2007. La regulaci\u00f3n global de los medicamentos \nherbarios.  BLACPMA  6(4):92-101. \nRobertson D. 2007. Phytomedicines in Jamaica: regulatory \nissues. BLACPMA 6(4):125-128  \n \n\u00a9 2007 Los Autores \nDerechos de Publicaci\u00f3n \u00a9 2007  Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 89 - 91 \nBLACPMA ISSN 0717 7917 \nEspecial Regulaci\u00f3n de Fitomedicinas / Sp ecial Issue on Regulation of Phytomedicines \nA vision for medicinal plants \n[Una visi\u00f3n de las plantas medicinales] \nGeoffrey A. CORDELL \nUniversity of Illinois at Chicago, Chicago, IL 60612 USA \nContact: cordell@uic.edu   \nSubmitted on 11th October 2007; Accepted on 2nd November 2007 \nAbstract \nIn the past few years, the author has written a number of artic les discussing a vision for the development of medicinal plants.  This article will \ntherefore present only a brief synopsis of some of the more sali ent features of those articles , resulting in the presentation o f four, clear, \ncoalescing visions for the future of medicinal plants: enhanced  quality control, sustainability for medicinal plants, pharmacog nosy in a \nsuitcase, and finding a strong \u201cvoice\u201d at th e political table of global health care. \nKeywords: medicinal plants, regulatory affairs, pharmacogn osy, quality control, sustainability, global health care. \nResumen \nEn el pasado pocos a\u00f1os, el autor ha escr ito un cierto n\u00famero de art\u00edculos en los que discut\u00eda su visi\u00f3n de l desarrollo de la c iencia y \nregulaci\u00f3n de las plan tas medicinales. Este art\u00edculo pret ende hacer una s\u00edntesis  de algunas de las caracter\u00edsticas m\u00e1s saliente s de esas visiones \nde los art\u00edculos, dando por resultado la pres entaci\u00f3n de cuatro claras y complementaria s visiones para el futuro de plantas med icinales: \ncontrol de calidad realzado, sostenibilidad para las plantas medicinales, farmacognosia \u201cen una maleta\u201d, y encontrar una \u201cvoz f uerte\u201d en el \ncampo de la pol\u00ed tica del cuidado m\u00e9dico global. \nPalabras clave: medicamentos herbarios, farmacognosia, regulaci\u00f3n, control de cali dad, desarrollo sostenible, cuidados m\u00e9dicos globales. \n \nIn the past few years, the author has written a \nnumber of articles discussing a vision for the \ndevelopment of medicinal plants (Cordell, 2000; \n2002; Cordell and Colvard, 2005; 2007). This article \nwill therefore present only a brief synopsis of some of the more salient features of those articles, resulting in the presentation of four, clear, coalescing visions for the future of medicinal plants in global health care. \nIn \u201cA Still Forest Pool \u201d the venerated Thai monk, \nAjahn Chah opined that \u201cIf you are on the fifth step and you think that you are too high, you will never make it to the sixth step\u201d.  What I believe that he is saying, at many different levels, is there is always room for improvement, and don\u2019t be so complacent as \nto think that all is known that can be known, or that \nthe best that can be done is being done.  It is a philosophy that later came to be known in western management parlance as continuous quality improvement (CQI), questioning how further improvement of a system was possible.   In my view, as far as medicinal plants in public health care globally are concerned, we are just beginning to \nLOOK at the first step.  Yes, it is a public health care \nissue, although in some countries it is not seen that way, and thus the paucity of effective local regulations based on science.  A recent WHO survey showed that of the 192 countries surveyed only 53 had any form of regulations for traditional medicines, and for only \n18% of the countries were medicinal plants included \nin the National Pharmacopoeia (WHO, 2002).  Yet, at least 64% of the global population use medicinal plants as their primary form of health care (Farnsworth et al., 1985), and this percentage will rise \nsteadily as the global population reaches 10 billion in \nthe next 30 years. \nThe lack of attention to the regulation of medicinal \nplants has occurred for a number of reasons, two of which are that: i) it is often assumed that these A vision for medicinal plants Cordell \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 90 medicinal agents, because th ey have been used for \nhundreds or thousands of years, are safe (and thus \ndon\u2019t need regulation), and ii) their supply is \nunlimited.  These are both myths which need to be \ndispelled. \nAs we think about the future of medicinal plants in \nhealth care, there are two burgeoning issues to be addressed: quality control and sustainability.  For most of the countries of the world, pharmaceutical \ncompanies will not be provid ing the medicinal agents \nfor local prevalent diseases, and for those diseases that \nare global, the drugs are likely to be very expensive.  The question for these health care systems is how to address those issues, for optimum local health care.  \nMedicinal plants, all over the world, are sold in a \nmanner which has changed little in hundreds, may be \nthousands, of years.  That is not something medicinal \nplant scientists should either be proud of, or condone.  Quite the reverse, they should be irate that their \nscience is having such a limited impact on public \nhealth. \nFrom a public health perspective, what is a \nreasonable time frame to enhance quality control through the application of science and technology to traditional medicine?  What can be done in 5 years, \nwhat in 10 years, and what in 15 years? Can a \nstrategic health care plan which incrementally enhances the safety and effectiveness of traditional medicines for the benefit of the patient be developed?  Where do we start to make these improvements?  \nWhat are the sciences and the technologies that need \nto be involved?  Are there enough scientists locally who are trained to do the work?  Are governments prepared from a regulatory and science enforcement \nperspective?  And of course, who will fund all those \nstudies and protocol developments? \n \nThis is not the place to be addressing in great detail \nall of the steps to achieve a safe and efficacious traditional medicine, but a brief overview is presented (Cordell, 2000; Cordell and Colvard, 2005): i) All \nresearch programs begin with a literature evaluation.  \nIn the field of medicinal plant research, one of the \nhighest priorities must be the determination of what is known and what questions need to be answered with a view to not duplicating previous research and wasting precious human and fiscal resources; ii) It is rare \nindeed that ethnomedical research is conducted with \nthe scientist and clinician doing field evaluations  of \nparticular remedies usi ng standardized clinical \nevaluation methodologies.  Such strategies will markedly enhance the veracity of medicinal plant claims; iii) Plants are complex factories for secondary metabolites.  A determination of the active \nprinciple(s) and their mechanism of action  is \ncritical for the development of systems for chemical and biological standardization;  iv) Given the diversity \nof medicinal plant materials that are now in global \ncommerce, it is critical that there be analytic standards in place to eliminate contaminants and adulterants  \nwhich might pose a health hazard, are illegal, or which \ngive a non-reproducible, false biological responses;  v) \nStandardization of a given preparation for the patient should be based on a three-fold botanical, chemical, \nand biological standardization  so that on a lot-to-lot \nbasis there is a safety and efficacy guarantee for the \npatient.  Botanical standardization based on PCR \nanalysis, chemical standardization based on a known active principle (or principles), and biological standardization based on a cheap, relevant, and validated in vitro  bioassay; vi) The age of a traditional \nmedicine is an important issue, but is rarely given.  For each preparation there will need to be stability \nand safety studies, since it cannot be assumed that a preparation that has been used for hundreds of years is necessarily \u201csafe\u201d.  Neither can it be assumed that the active principles, and therefore the clinical \neffectiveness of the product, will be stable for the \nshelf life of the product; vii) These botanical, chemical, biological, and stability studies should \nculminate in a demonstration of clinical \neffectiveness  for a well-defined, standardized \npreparation in an appropriate clinical trial; viii) There \nis the need to report and register observed plant \ndrug \u2013 drug interactions  which occur.  Some of \nthese may be adverse interactions causing unwanted side effects, while others might be synergistic interactions causing potentiation of activity, and \nrequiring dose modulation; ix) Finally, there is the \nneed for sustainable development of a commercial medicinal plant. \nThe forests and the mountains are already being \ndepleted of medicinal plants as demand increases; and \nmany desirable medicinal plant species are now listed \nas endangered in their native habitats.  Relatively little attention is being given to  this aspect of medicinal \nplant development because the science to discern which plants are the most effective has not yet provided priorities for sustainable development.  As \nthe UN Millennium Ecosystem Assessment indicates \n(Millennium Ecosystem Assessment, 2005), we can no longer assume that the plant materials that are used as resources today will be there tomorrow.  Consequently, and if the world is to have plant-based A vision for medicinal plants Cordell \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 91 medicinal agents in the future for a rapidly expanding \nglobal population, we must think of plant-based drugs as a fundamental health care requirement.  For \ncontinued availability, we mu st therefore regard an \neffective medicinal plant as a sustainable, renewable \nresource; a sustainable drug .  For most people that is \na new concept; many medicinal plant scientists do not think in those terms. \nNew strategic thinking is also needed as to how \nmedicinal plants are initially validated.   We need to consider how to reverse the paradigm of collecting medicinal plant materials, identifying them macroscopically, drying them, bringing them back to the laboratory, extracting them, and testing the \nextracts for biological and pharmacological activities.   \nSupposing the \u201claboratory\u201d, the techniques needed to accomplish all of the steps just described, was taken to the field, and the preliminary determination regarding a level of interest for further experimentation made on \nsite.  Is there the potential to determine the \nauthenticity and the chemical and biological potential \nof a medicinal plant in the field ?  What are the \nimplications for future studies of medicinal plants if that strategy can be successful?  What are the range of technologies that need to be assembled for the botany, \nchemistry, and biology to be conducted?  What are the \nnano technologies which can be applied to realize this?  What areas of the required technologies need further development?  Are there other barriers to the realization of this goal?  What would \u201cpharmacognosy \nin a suitcase\u201d look like? \nThese are my three very clear visions for medicinal \nplants: enhanced quality control, sustainability for medicinal plants, and pharmacognosy in a suitcase.  They are significant regulatory, scientific, technological, economic and social challenges.  They \nwill take many years to accomplish, and many people \nto educate about the validity and absolute need for the \napproach. That brings me to my fourth vision... which is that medicinal plants, and their study for the future of the health of humankind, will find a strong \u201cvoice\u201d \nat the political table of global health care for the sake \nof future generations. \nLITERATURE CITED \nCordell, G.A. 2000.  Biodiversity and drug discovery - a \nsymbiotic relationship. Phytochemistry  55:463-480. \nCordell, G.A. 2002.  Natural products in drug discovery - \ncreating a new vision.  Phytochem. Revs . 1: 261-273. \nCordell, G.A., Colvard, M.D. 2005. Some thoughts on the \nfuture of ethnopharmacology. J. Ethnopharmacol. 100: \n5-14, and references therein. Cordell, G.A. and Colvard, M.D.  2007. Natural Products in \na World Out-of-Balance.  Arkivoc  vii:97-115. \nWHO. 2002. Traditional Medici nes. Secretariat Report. \n111th Session 12 December 2002. Provisional agenda \nitem 5.7 12 December. Freely available  at: \nhttp://www.who.int/gb/ebwha/pdf_files/EB111/eeb1119.pdf\nFarnsworth, N.R., Akerele, O., Bingel, A.S., Soejarto, D.D., \nGuo, Z., 1985. Medicinal plants in therapy. Bull WHO \n63, 965-981. \nMillennium Ecosystem Assessment, 2005. Ecosystems and \nHuman Well-being: Synthesis. Island Press, Washington, DC. Freely available at \nhttp://www.millenniumassessment.org/en/Synthesis.aspx\n [Last accessed 1st November 2007].  \n \n\u00a9 2007 Los Autores \nDerechos de Publicaci\u00f3n \u00a9 2007  Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 92 - 101 \nBLACPMA ISSN 0717 7917 \nEspecial Regulaci\u00f3n de Fitomedicinas / Sp ecial Issue on Regulation of Phytomedicines \nLa regulaci\u00f3n global de los medicamentos herbarios \n[The global regulation of herbal medicines] \nJos\u00e9 Maria PRIETO \nCenter for Pharmacognosy and Phytotherapy, Sc hool of Pharmacy, Un iversity of London, \n29-39 Brunswick Square, WC1N  1AX London, United Kingdom \n*Contacto: jose.prieto@pharmacy.ac.uk\nRecibido el 1 de Noviem bre de 2007; Aceptado el 3 de Noviembre de 2007 \nAbstract \nThis paper gives an overview on the regiona l and global regulatory efforts towards a homogenization of the normative about herb al \nmedicines. The pioneering work of the WHO and the recent implementation of the first transnational directive on herbal medicine s in Europe \nhave laid the legal and scientific foundations  to help a fast implementation of transn ational regulations el sewhere. The most a dvanced \nregional frameworks are those of Latin America and the Asiatic eas t. China has started a process of internal regulation to faci litate the \nglobalisation of its traditional medicinal system. Africa is work ing towards the regulation of th e traditional medicines as a p revious step to \ntheir transnational regulation. If a global regulation for herbal  medicines is still far away, several organisations already st arted this process by \nintroducing this subject into the agenda of the periodic meetings of national re gulatory agencies all around the world. \nKeywords: Globalisation, transnational regulatio ns, herbal medicines, regulatory affairs. \nResumen \nSe pretende presentar una visi\u00f3n conjunta de los esfuerzos region ales y globales para homogeneiz ar las normativas relativas a l a regulaci\u00f3n \nde medicamentos herbarios. El impulso inicial dado por los trabajos de la OMS y el ejemplo de la primera regulaci\u00f3n trasnaciona l, en la \nforma de la Directiva de Medicinas Tradicionales Europeas, han sentado las bases documentales ci ent\u00edficas y legales para ayudar  a una r\u00e1pida \nimplementaci\u00f3n de medidas trasnacionales en otros continentes. La implementaci\u00f3n de distintos consensos regionales sobre esta m ateria esta \nmuy avanzada en Latinoam\u00e9rica y el Este Asi\u00e1tico. China ha em prendido un camino de implementaci \u00f3n de normativas que le permitan  la \nglobalizaci\u00f3n de su sistema de medicina tradicional. \u00c1frica trabaj a intensamente en la regulaci\u00f3n a nivel nacional de las medic inas \ntradicionales como un paso previo a su regulaci\u00f3n transnacional. Sin bien una regulaci\u00f3n global ta rdar\u00e1 en conseguirse, diverso s organismos \nya han emprendido este camino en form a de encuentros regulares entre agen cias reguladoras de  todo el mundo. \nPalabras clave: Globalizaci\u00f3n, regulaciones trasna cionales, medicamentos herbarios, regulaci\u00f3n. \n \nINTRODUCCION \nLas medicinas herbarias (MH), o si se prefiere \nfitomedicinas, est\u00e1n mas que nunca en el ojo \nregulador de naciones, organizaciones trasnacionales y entes internacionales. En casi todo el mundo las legislaciones nacionales se encuentran bajo una doble \npresi\u00f3n: la de un p\u00fablico que demanda mayor calidad \nen los productos, y la de los responsables de salud p\u00fablica que exigen mayor seguridad.  \nLas grandes industrias del sector tienen diferentes \nposturas dependiendo del marco en que tradicionalmente se han movido: pasividad si gozan \nde mercados protegidos y af\u00e1n regulador en espacios \necon\u00f3micos abiertos a la competencia, sin olvidar que muchas ven en todo ello una oportunidad de reducir la competencia de las peque\u00f1as compa\u00f1\u00edas que no podr\u00e1n afrontar los altos costes derivados de la elevaci\u00f3n de los remedios herbarios a la categor\u00eda \nde \u2018medicamento\u2019. Hay que resaltar el hecho de que \nel concepto de medicamentos herbarios esta destinado a situarse dentro de una l\u00ednea \u2018blanda\u2019 de registraci\u00f3n, donde se exige una calidad garantizada pero no una eficacia probada cient\u00edficamente. \nEl factor clave desencadenante del vendaval \nregulador ha sido la exitosa globalizaci\u00f3n de las medicinas tradicionales y complementarias (MT/MC). Hoy en d\u00eda se consumen productos procedentes de la Medicina Tradicional China (MTC) o Ayurveda o europea o sudamericana e incluso \nafricana en casi todos lo s pa\u00edses desarrollados, \ngenerando una demanda creciente del mercado a \nnivel mundial. Aqu\u00ed es donde resalta por su ausencia una regulaci\u00f3n internacionalmente homog\u00e9nea: en los \npa\u00edses de origen hay generalmente falta de Regulaci\u00f3n global de los medicamentos herbarios Prieto \ninformaci\u00f3n sobre el productor, y adem\u00e1s no existe \ncomunicaci\u00f3n entre las agencias reguladoras nacionales de pa\u00edses exportadores e importadores, \ntodo ello creando una constante fuente de problemas \npara los servicios aduaneros y sanitarios en todo el mundo. \nMuchos pa\u00edses han comenzado ya la regulaci\u00f3n de \nsus mercados nacionales de MH mediante enmienda de sus leyes. La mayor\u00eda de ellas datan de los a\u00f1os \nsesenta y setenta y entonces casi ninguna \ncontemplaba la categor\u00eda de MH. Otros pa\u00edses no parecen tener mayor preocupaci\u00f3n por establecer una categor\u00eda aparte para lo que hasta ahora se comercializa principalmente como suplemento \nalimentario, EE.UU. por ejemplo.  \nExisten numerosos desarrollos de regulaci\u00f3n de \nmedicamentos a niveles subregionales y regionales, \nalgunos ligados a la creaci\u00f3n de espacios econ\u00f3micos comunes. Sin embargo el nivel de actividad \nreguladora en el campo de los MH dentro de cada \nuna de ellas var\u00eda considerablemente. Entre los cuales destacan: \n \n\u2022 Association of South-East Asian Nations (ASEAN) \n\u2022 Andean Community (CAN) \n\u2022 Collaboration Agreement of Drug Regulatory Authorities in European Union Associated \nCountries (CADREAC) \u2013 most (10) countries \ninvolved entered EU in 2004  \n\u2022 European Union (EU) \n\u2022 Gulf Cooperation Council (GCC) \n\u2022 International Conference on Harmonisation (ICH) \n\u2022 International Conference of Drug Regulatory Authorities (ICDRA) \n\u2022 MERCOSUR (Southern Common Market)  \n\u2022 Pan American Network on Drug Regulatory Harmonization (PANDRH) \n\u2022 Southern African Development Community (SADC) \n\u2022 Cada una de las seis regiones de la OMS \n \nLos principales problemas que afrontan las \nautoridades a la hora de regular el sector de MH son la falta de datos cient\u00edficos, la falta de mecanismos efectivos de control, y la falta de educaci\u00f3n, \nformaci\u00f3n y especializaci\u00f3n del personal relacionado \ncon la producci\u00f3n, distribuci\u00f3n, prescripci\u00f3n, uso y seguimiento del uso de MH (Zhang, 2006). LA OMS COMO FUENTE REGULADORA GLOBAL \nTras el reconocimiento por parte de la OMS del \nvalor de la medicina tradicional como fuente de salud y de biodiversidad en la C onferencia de Alma Ata de \n1979 (OMS-UICN-WWF, 1993; OMS, 2002), se han venido financiando grupos de  trabajo internacionales \ny regionales, as\u00ed como proyectos locales, para estudiar y fundamentar su uso regulado (WHO, 2001, \n2005), la redacci\u00f3n de monograf\u00edas de control de \ncalidad (WHO, 1998), de buenas pr\u00e1cticas agr\u00edcolas (GAP) (OMS, 2003), de buenas practicas de producci\u00f3n (GMP), de normas para asegurar la \nseguridad de los productos herbarios (WHO, 2004a), \ny de estrategias para su correcto uso en los sistemas \nde salud primarios (WHO, 2004b). Muchos pa\u00edses en v\u00edas de desarrollo han podido regular las medicinas herbarias en sus respectivos territorios nacionales bas\u00e1ndose en este cuerpo documentario, lo cual \nhubiese sido imposible desarrollar \u00fanicamente a nivel \nlocal. De hecho la necesidad del impulso de la OMS hoy en d\u00eda es aun alt\u00edsima, con solo un m\u00ednimo de pa\u00edses realmente autosuficientes para regularse como muestra la Figura 1 (Zhang, 2006).  \nFigura 1. Dependencia de la OMS en cuanto a regulaci\u00f3n de MH \n(Zhang, 2006). \n836870676650\n444847504455\n4753912\n0 1 02 03 04 05 06 07 08 09 0InformacionSeguridadInvestigacionBases de datosRegulacionReuniones\nN. de paises\nTotalmente dependientes Parcialmente dependientes\nIndependientes\n \nLeyenda: Reuniones (Congresos  globales sobre regulaci\u00f3n); \nRegulaci\u00f3n (Talleres sobre regula ci\u00f3n de MH); Bases de Datos \n(Necesidad de bases de datos con informaci\u00f3n sobre MH); \nInvestigaci\u00f3n (Gu\u00edas generales de investigaci\u00f3n de la eficacia de \nMH); Seguridad (Talleres sobre se guimiento de la seguridad de \nMH); Informaci\u00f3n (Necesidad de reuniones para intercambio de \ninformaci\u00f3n sobre asuntos de regulaci\u00f3n)  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 93 Regulaci\u00f3n global de los medicamentos herbarios Prieto \nLa OMS realizo dentro de este contexto un \ninforme sobre el estado de cada una de las \nlegislaciones nacionales de 141 pa\u00edses sobre \nMT/MCA (WHO, 2004c, 2005). El resultado fue que \nel 65% de los pa\u00edses consultados dispon\u00edan de regulaci\u00f3n de TM/CAM y el 42% est\u00e1n en el proceso de regulaci\u00f3n. La evoluci\u00f3n en los \u00faltimos tiempos puede observarse en la Figura 2. \nFigura 2 : Numero de pa\u00edses con legislaci\u00f3n Nacional sobre \nregulaci\u00f3n de MH o TM/CAM (WHO, 2004; 2005). \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 94 14182325334053697883\n0102030405060708090\nBefore 1986\n1986 - 1987\n1988 - 1989\n1990 - 1991\n1992 - 1993\n1994 - 1995 1996 - 1997\n1998 - 1999\n2000 - 2001\n2002 - 2003Numero acumulativo de Paises\n \nREGULACION TRASNACIONAL EN \nAMERICA \nSe est\u00e1n llevando a cabo distintas iniciativas \nregionales y continentales para llegar a una homogenizaci\u00f3n de categor\u00edas y caracter\u00edsticas de los distintos productos herbales de consumo humano en Am\u00e9rica. Por un lado la Organizaci\u00f3n Panamericana de Salud (OPS o PAHO) auspicia encuentros \nregulares entre los responsables reguladores de los \ndistintos pa\u00edses del continente. Por otro lado existen m\u00faltiples iniciativas regionales a cargo de asociaciones de libre comercio como MERCOSUR, \nANDEAN, y CARICOM por ejemplo. \nMercosur \nMERCOSUR cuenta como miembros de pleno \nderecho Argentina, Brasil, Paraguay, Uruguay y \nVenezuela, mientras que Bolivia, Chile, Colombia, Ecuador y Per\u00fa son estados asociados y M\u00e9xico y Nicaragua estados observadores. \nEn este espacio com\u00fan econ\u00f3mico se vienen \nrealizando diversas reuniones bajo el nombre de MERCOFITO donde se de baten todos aquellos \naspectos relacionados con la incorporaci\u00f3n de fitomedicamentos en los sistemas de salud, el \ndesarrollo de polos productivos regionales a trav\u00e9s de \nla incorporaci\u00f3n de cultivos de plantas medicinales, la posibilidad de crear una Farmacopea del Mercosur para este tipo de productos, mostrar los trabajos cient\u00edficos as\u00ed como coordinar ensayos cl\u00ednicos en la regi\u00f3n, sin olvidar la impl ementaci\u00f3n de estrategias \npara concienciar a la pobl aci\u00f3n sobre el uso racional \nde este recurso, y debatir pol\u00edticas regionales en com\u00fan para la ense\u00f1anza en foros acad\u00e9micos de la Fitomedicina en consona ncia con los enunciados \npropuestos por la Organizaci\u00f3n Mundial de la Salud. Para una descripci\u00f3n mas detallada de sus objetivos \nver Cuadro 1) (Mercofito, 2007). \nMercofito esta compuesto por diversos entes tanto \ngubernamentales como privados, incluyendo Ministerios de Salud del Brasil, Argentina y Paraguay, agencias nacionales como la Agencia \nNacional de Vigilancia Sanitaria de Brasil \n(ANVISA), instituciones acad\u00e9micas (Universidad Nacional de Asunci\u00f3n) y profesionales (Asociaci\u00f3n Argentina de Fitomedicina) as\u00ed como diversas organizaciones locales como por ejemplo el Comit\u00e9 \nGestor de Plantas Medicinales de Itaip\u00fa Binacional, \nF\u00f3rum por la Vida \u2013 Proyecto Plantas Vivas de la Asamblea Legislativa de Rio Grande do Sul (ALERGS), ONG Agraci\u00f3n, Asociaci\u00f3n del Centro \nIntegrado de Educaci\u00f3n, Naturaleza y Salud \n(ACIENS-Brasil). \nCaribe \nLa regi\u00f3n caribe\u00f1a tiene plena conciencia de que \nsus productores y ciudadanos en general est\u00e1n poco o nada capacitados para beneficiarse de sus recursos locales debido a una falta tanto de visi\u00f3n como de \ninversi\u00f3n. Los principales problemas econ\u00f3micos que \nimpactan negativamente sobr e la industria herbolaria \ncaribe\u00f1a son: intercambio con el extranjero limitado, poca tasa de empleo y poca capacitaci\u00f3n de la industria local, pobreza, poca especializaci\u00f3n en la mano de obra, ausencia de colaboraci\u00f3n entre \nsectores econ\u00f3micos clave y falta de estructuras para \nel transporte de mercanc\u00edas entre las Islas de la regi\u00f3n \n(Robertson, 2007a). \nLa situaci\u00f3n a nivel regional es muy complicada. \nCuba lleva a cabo una intensiva implementaci\u00f3n de \nlos medicamentos herbales en su sistema de salud \npara paliar las consecuencias de una dif\u00edcil situaci\u00f3n internacional. Entre el resto de Islas de habla hispana no existe ninguna actividad intergubernamental sobre el tema digno de menci\u00f3n aparte de la llevada a cabo dentro de los foros regionales de la OMS u OPS.  \n Regulaci\u00f3n global de los medicamentos herbarios Prieto \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 95 Cuadro 1. Propuestas y objetivos de MERCOFITO.  \n\u2022 Elaboraci\u00f3n de una Farmacopea Herb aria del Mercosur, que permita el rescate del conocimiento tradicional sumado al aporte del \nconocimiento cient\u00edfico. \n\u2022 Incorporaci\u00f3n de la ense\u00f1anza de la Fitoterapia dentro de las disciplinas obligat orias de grado y posgrado en las carreras \nuniversitarias del \u00e1rea de la salud, as\u00ed co mo la ense\u00f1anza de la misma como asignatura dentro de los planes de formaci\u00f3n entre los \nagentes de atenci\u00f3n primaria de la salud. La propuesta de ense\u00f1anza sobre plantas medicinales comprender\u00e1 tambi\u00e9n las \u00e1reas de \nense\u00f1anza universitaria de las carreras agra rias, sociales, ambientales y antropol\u00f3gicas . Se debatir\u00e1, adem \u00e1s, crear una Univer sidad \ndel Mercosur donde puedan desarrollarse carreras relacionadas con las \u00e1reas antes descritas. \n\u2022 Creaci\u00f3n de la Red Mercofito \u2013 una red de cooperaci\u00f3n t\u00e9cnico-cient\u00edfica \u2013 in tegrada por gobiernos, unive rsidades, laboratorios \nnacionales, asociaciones profesionales, funda ciones y empresas con compromiso social pertenecientes al Mercosur, cuyo objetivo \nser\u00e1 priorizar la cadena productiva y el desarrollo socioecon\u00f3 mico regional a trav\u00e9s del cu ltivo de plantas medicinales y \nelaboraci\u00f3n de medicamentos fitoter\u00e1picos. A su vez, se propone crear un Fondo de Investigaci\u00f3n, Producci\u00f3n y Formaci\u00f3n de \nRecursos Humanos, por medio de los di ferentes integrantes de la red. \n\u2022 Elaboraci\u00f3n de una pol\u00edtica en com\u00fan consensuada sobre plantas medicinales y medicamentos fitoter\u00e1picos entre los pa\u00edses \nintegrantes del Mercosur (socios activos y adherentes). Se propone la creaci\u00f3n de un Ente Coordinador sobre Plantas Medicinales \npara cada pa\u00eds miembro (a excepci\u00f3n de aque llos pa\u00edses que ya lo tengan). Asimismo, lo s diferentes Minister ios de Salud de cada  \npa\u00eds establecer\u00e1n las medidas necesarias pa ra la incorporaci\u00f3n de medicamentos fitoter\u00e1 picos en los Vadem\u00e9cums de Remedios, as\u00ed \ncomo las pol\u00edticas necesarias que tiendan a incorporar este tipo de recurso en los centros de Atenci\u00f3n Primaria de la Salud. \n\u2022 Integraci\u00f3n entre los Ministerios de Relacione s Exteriores de los pa\u00edses miembros del Mercosur, para establecer pautas o criter ios \nde trabajo para la toma de decisiones pol\u00edticas inherentes a las experiencias de la cadena productiva de plantas medicinales y \nmedicamentos fitoter\u00e1picos para el Mercosur. \n\u2022 Tareas de coordinaci\u00f3n y di\u00e1logo entre los integrantes del III\u00b0  Mercofito y de PLANSUR con las C\u00e1maras empresariales de \nfitomedicamentos y las entidades que nuclean  al sector agrotecnol\u00f3gico de cultivo de especies medicinales,  de manera tal que \npermitan fortalecer la cadena productiv a agroexportadora de estos productos. \n\u2022 Rescate y reconocimiento del patrimonio et nom\u00e9dico correspondiente a los pueblos originarios de los pa\u00edses integrantes del \nMercosur. Dentro de dicha pauta se propone incorporar a las dis tintas etnias al sector producti vo para el desarrollo de polos \nagr\u00edcolas elaboradores de materias primas a partir de plantas medicinales. \n\u2022 Elaboraci\u00f3n de un Manual sobre Plantas Me dicinales y Medicamentos Fitoter\u00e1picos para el Mercosur, el cual contemplar\u00e1 \ninformaci\u00f3n de uso tradicional, validaci\u00f3n cien t\u00edfica de dichos usos, asp ectos toxicol\u00f3gicos, gal\u00e9nicos, bot\u00e1nicos, indicaciones de \nuso y agrotecnolog\u00eda de cultivo de las especies incorporadas. \n\u2022 Establecimiento de un Comit\u00e9 de Expertos que permita la optimizaci\u00f3n de  la cadena productiva, por medio de la normatizaci\u00f3n de \nprocedimientos que aseguren la calidad de la materia prima, la correcta selecci\u00f3n de especies de acuerdo a las necesidades \nepidemiol\u00f3gicas y la preservaci\u00f3n y manutenci\u00f3n del germoplasma. \n\u2022 Generar los marcos regulatorios adecuados para armonizar aspectos  legislativos, asistenciales, t\u00e9cnico-cient\u00edficos, comerciales  y \nsobre propiedad industrial (Ley de Patentes). \n \nLas islas angl\u00f3fonas son mas activas y ya est\u00e1n \norganizadas y sensibilizadas sobre el tema. Como \nprimer paso se realizo un estudio sobre las especies caribe\u00f1as de mayor importancia industrial para una primera fase de explotaci\u00f3n financiado por el CTA (Centre for Technical Agriculture) en colaboraci\u00f3n \ncon Holanda  y el IICA (Inter-American Institute for \nCooperation on Agriculture). Por otro lado, se han creado dos asociaciones de car\u00e1cter no gubernamental para propulsar la coordinaci\u00f3n a nivel regional: la \nCaribbean Association of Researchers & Herbal \nPractitioners (CARAPA) y Caribbean Herbal Business \nAssociation (CHBA). \nCARAPA, que se creo en 1998, esta formada por \nherbolarios, cient\u00edficos y personal sanitario y pretende integrar el sistema tradicional en el sistema convencional de salud, c on una especial preocupaci\u00f3n \nrespeto a eficacia, estudios cl\u00ednicos y seguridad de su uso (\nCARAPA , web site). \nPor su lado la CHBA pretende llegar a crear un \ngrupo industrial operacional regional ( Industrial  Cluster Operation) para lo cual organiza talleres de trabajo para el control de calidad con la ayuda del CDE (Center for Development Enterprise) bajo el auspicio del ICS-UNIDO. A nivel legislativo se trabaja en la enmienda del actual marco legal para ponerlo a la altura de los tiempos y sacar de la \ndesregulaci\u00f3n al sector (Roberton, 2007a). \nIniciativas Latinoamericanas \nRedes de trabajo internacionales como CYTED y \nRIPROFITO financian estudios de Legislaci\u00f3n sobre \nFitof\u00e1rmacos en Am\u00e9rica Latina como parte de sus \nSubprogramas, as\u00ed como libros de monograf\u00edas de \nplantas espec\u00edficamente latinoamericanas (Gupta, 2003; Garc\u00eda y C\u00e1ceres, 2000). Las conclusiones de dichos trabajos reflejan la enorme heterogeneidad en la terminolog\u00eda empleada para describir las especialidades herbarias, as\u00ed como faltas importantes \nen el sentido de que a menudo no hay una clara \ndefinici\u00f3n de la materia prima y del principio activo, poca uniformidad en los re quisitos de registro y Regulaci\u00f3n global de los medicamentos herbarios Prieto \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 96 posterior comercializaci\u00f3n as\u00ed como enormes \ndiferencias entre las normas de calidad, seguridad y eficacia. Para resolver es tos desfases se trabaja en: \nPromover y fortalecer el intercambio de informaci\u00f3n sobre Plantas Medicinales; Pr omover la garant\u00eda de la \ncalidad, seguridad y eficacia de Plantas Medicinales en las Am\u00e9ricas, incluyendo el desarrollo de un programa de vigilancia y control; Desarrollar propuestas armonizadas en el tema de Plantas \nMedicinales: Apoyar a los pa\u00edses en la \nimplementaci\u00f3n de las mismas promoviendo \nprogramas y actividades de educaci\u00f3n para \nproveedores de servicios de salud, consumidores y p\u00fablico en general (Gupta, 2003). \nIniciativas americanas de armonizaci\u00f3n de sistemas ind\u00edgenas y convencionales \nLa armonizaci\u00f3n del espacio americano esta siendo \nfacilitado por una iniciativa que en principio persegu\u00eda documentar y reconocer oficialmente los sistemas de \nmedicina y terapia ind\u00edgenas, asign\u00e1ndoles un puesto \ndentro de los respectivos sistemas de salud, lo que se ha denominado \u201cProceso de armonizaci\u00f3n de sistemas ind\u00edgenas y convencionales\u201d. Desde 1993, la OPS ha trabajado en esta Iniciativa de Salud de los pueblos Ind\u00edgenas. Primariamente ten\u00eda el objetivo de mejorar \nla salud y bienestar de dichas comunidades culturales. \nSin embargo este trabajo esta derivando en la homogenizaci\u00f3n de pol\u00edticas regionales para regular la medicina tradicional y con ella los medicamentos \nherbarios. En 1997 se culmino la primera etapa de este \nproyecto con las resoluciones CD37.R5 y CD40.R6 \nque apelan a los estados miembros a velar por soluciones sostenibles que tengan en cuenta las barreras geogr\u00e1ficas, econ\u00f3micas y culturales de los grupos mas vulnerables, incluyendo los ind\u00edgenas.  \nEn 1999 la OPS/OMS organizo un grupo de \ntrabajo en Medicinas tradicionales complementarias y alternativas como actividad conjunta de la Divisi\u00f3n de desarrollo de Sistemas y servicios (HSP) y el departamento de pol\u00edticas de drogas y medicinas esenciales. Los participantes recomendaron promover \nactividades para apoyar los conocimientos de \nmedicina tradicional, complementaria y alternativa e identificar estrategias para contribuir a la organizaci\u00f3n y creaci\u00f3n de sistemas de salud adecuados en toda Am\u00e9rica que reconozcan expl\u00edcitamente la \ncontribuci\u00f3n a la salud p\u00fablica de las medicinas \nind\u00edgenas. Para ello apel aron a la coordinaci\u00f3n entre \nOPS/OMS y entidades de reconocido prestigio en \nmedicinas tradicionales como la Universidad de Illinois en Chicago (UIC), EE.UU., y el Centro de medicina complementaria y alternativa del instituto nacional de salud (NCCAM-NIH). \nDurante 2000-2001 se desarrollo una segunda fase \ndel proyecto que focalizaba en la medicinas herbarias, Ind\u00edgenas y las Tradicionales, Alternativas y Complementarias, con el objetivo de promover e integrar la medicina ind\u00edgena en los sistemas de salud primaria. Ahora se trata de continuar los trabajos en estas \u00e1reas espec\u00edficas dentro del marco de una \nEstrategia Global para la Me dicina Tradicional, cuya \nculminaci\u00f3n fue el \u2018global meeting\u2019 que tuvo lugar en \nOttawa, Canad\u00e1 (IRCH, 2005). \nTodo este esfuerzo esta teniendo ya una traducci\u00f3n \nconcreta a nivel de pol\u00edticas nacionales. Argentina y \nChile han consentido en la formaci\u00f3n de personal \nespecializado en medicina Mapuche y la creaci\u00f3n de dispensarios de medicina tradicional Mapuche f\u00edsicamente situados en los centros de salud p\u00fablicos (Linares Calvo, 2007; Ylarri, 2007; Orrego Guerrero, \n2002). Ecuador y Panam\u00e1 podr \u00edan seguirlos en breve \nya que llevaron a cabo estudios previos de \ndocumentaci\u00f3n de la contribuci\u00f3n de las medicinas y terapias ind\u00edgenas en la atenci\u00f3n de salud primaria y se dise\u00f1aron instrumentos y metodolog\u00edas para entender la seguridad y eficacia de dichos sistemas \ntradicionales con la ayuda de la OPS (PAHO, 2002). \nIniciativas panamericanas \nLa Reuni\u00f3n del grupo de trabajo de la PAHO \nrealizada en Curitiba (Brasil) (PAHO, 2006) hizo \npropuestas para avanzar en la homogenizaci\u00f3n del \nsector fitoter\u00e1pico a nivel continental: \na. Propuesta de definici\u00f3n de Plantas Medicinales a \nser adoptada por todos los pa\u00edses;  \nb. Propuesta armonizada de requisitos para plantas \nmedicinales basada en criterios cient\u00edficos;  \nc. Necesidad de asegurar la calidad, eficacia y \nseguridad de las plantas medicinales;  \nd. Promoci\u00f3n y educaci\u00f3n para proscriptores y \nconsumidores. \nSin embargo el peso de la actividad reguladora lo \nlleva sobre todo la Pan American Network for Drug Regulatory Armonizaci\u00f3n (PANDRH) que se dedica a \nidentificar problemas en el desarrollo de la armonizaci\u00f3n global de regulaci\u00f3n de todo tipo de medicamentos, incluidos los MH para facilitar lo que definen como \u201chemispheric drug regulatory harmonization\u201d. Esto se c onsigue siguiendo de cerca \nlos desarrollos de grupos subregionales y recomendando estrategias y acciones. La PANDRH incluye reguladores de la Andean, Caricom, Mercosur, \nNAFTA, SICA, as\u00ed como de la Industria y la Regulaci\u00f3n global de los medicamentos herbarios Prieto \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 97 Academia. La regulaci\u00f3n hom og\u00e9nea futura de los \nMH se incluyo dentro de las prioridades identificadas \ntras las tres conferencias realizadas en Washington \n(1997, 1999 y 2002) lo que sin duda refleja la \nimportancia de estos productos en los mercados americanos (Molz\u00f3n, 2003). \nREGULACI\u00d3N TRASNACIONAL EN AFRICA \nLos intentos de regulaci\u00f3n pan-africanos \nempezaron en 1985 con la redacci\u00f3n de una \nFarmacopea Africana en dos vol\u00famenes bajo los \nauspicios de la Organization of African Unity Scientific Technical Research Commission (OAU/STRC) (CAMH, 2005). Con este cuerpo documental mas los producidos por la OMS, la OAU \ntomo la decisi\u00f3n en Julio de 2001 de declarar la \nprimera d\u00e9cada del s. XXI como la \u201cD\u00e9cada de la Medicina Tradicional\u201d (Min isters of Health of the \nWHO African Region. 2007). El Foro Africano para el \nDesarrollo (ADF) es una iniciativa conducida por la \nComisi\u00f3n Econ\u00f3mica Africana (ECA) para impulsar \nuna agenda conducida por organismos netamente Africanos sobre programas espec\u00edficos como la \u201cDeclaraci\u00f3n de Abuja acerca de HIV/AIDS, Tuberculosis y otras enfermedades infecciosas\u201d (African Development Forum, 2000).  \nLas tareas a afrontar son establecer pautas para la \nformulaci\u00f3n, puesta en pr\u00e1ctica, supervisi\u00f3n y evaluaci\u00f3n de un marco jur\u00eddico para la pr\u00e1ctica de la medicina tradicional en los diferentes pa\u00edses; establecer un c\u00f3digo \u00e9tico para su implementaci\u00f3n en \nel sistema de salud; crear un marco regional para el \nregistro de medicinas tradicionales y sobre todo un marco regulador para la pr otecci\u00f3n de los derechos de \npropiedad intelectual y del conocimiento ind\u00edgena de medicinas en la regi\u00f3n del africana de la OMS (Kofi-\nTsekpo, 2004). \nLa consecuci\u00f3n de los obj etivos previstos de la \nsensibilizaci\u00f3n de la d\u00e9cada (2001 - 2010) y de la \npopularizaci\u00f3n de la medicina tradicional en todos los Estados miembros (CAMH, 2005) proveer\u00e1 de facto  \nlas bases para una regulaci\u00f3n continental de las MH. \nAparte existen ciertas iniciativas a nivel sub-africano \ncomo la Southern African Development Community (SADC) que entre otras tareas coordina una parte del esfuerzo com\u00fan de diversos  pa\u00edses sudafricanos en \nfrenar el SIDA d\u00e1ndole a la medicina tradicional un papel relevante. \n \n \nCuadro 2:  Objetivos de la  D\u00e9cada Africana de la MT. 1. Adopci\u00f3n de pol\u00edticas nacionales sobre medicina \ntradicional. \n2. Establecimiento de marcos jur\u00eddicos y de la legislaci\u00f3n \nnecesaria sobre medicina tradicional en todos los \nEstados miembros.  \n3. Adopci\u00f3n por parte de los Estados miembro de las \nherramientas de WHO/AFRO y de EMRO para \ninstitucionalizar la medicina tradicional en los sistemas \nde la salud.  \n4. Establecimiento de estructuras permanentes en los \nministerios de la salud para poner en ejecuci\u00f3n \nprogramas de medicina tradicional en todos los Estados \nmiembros. \n5. Inauguraci\u00f3n de mesas nacionales de la medicina \ntradicional para regular su pr\u00e1ctica y sus productos. \n6. Adopci\u00f3n de pol\u00edticas nacionales para la protecci\u00f3n del \nacceso a la biodiversidad y del conocimiento m\u00e9dico \ntradicional (ley modelo del AU). \n7. Establecimiento de centros de colaboraci\u00f3n de \nexcelencia/OMS para la inve stigaci\u00f3n y el desarrollo \nde las medicinas tradicionales usadas para el \ntratamiento de las enfermedades prioritarias. \n8. Instituci\u00f3n en todos los Estados miembros de una \nsemana nacional de la medicina tradicional. \n9. Creaci\u00f3n de el ambiente pol\u00edtico, econ\u00f3mico y \nregulador necesario para permitir el desarrollo de la \nproducci\u00f3n local y la conservaci\u00f3n de plantas \nmedicinales y arom\u00e1ticas. \n10. Promoci\u00f3n de la investigaci\u00f3n precl\u00ednica y evaluaci\u00f3n \ncl\u00ednica, desarrollo, produ cci\u00f3n local y comercializaci\u00f3n \nde medicinas tradicionales estandardizadas. \n11. Registro de medicinas tradicionales estandardizadas en \nla lista esencial nacional de medicinas tradicionales. \n12. Prescripci\u00f3n, uso racional y supervisi\u00f3n de medicinas \ntradicionales estandardizadas en sistemas de cuidado \nm\u00e9dico p\u00fablicos y privados. \nREGULACI\u00d3N TRASNACIONAL EN ASIA \nOriente Pr\u00f3ximo \nEn noviembre de 2001, las autoridades reguladoras \nde los Estados miembros del WHO del Este de la \nRegi\u00f3n Mediterr\u00e1nea se reunieron en El Cairo para \ndiscutir la regulaci\u00f3n regional de las  medicinas \nherbarias. Las medicinas tradicionales son ampliamente utilizadas en esta regi\u00f3n pero la mayor parte de estos pa\u00edses no tiene ninguna ley sobre el \ncontrol de calidad de medicinas herbarias. Algunos pa\u00edses, tales como la Rep\u00fablica Isl\u00e1mica de Ir\u00e1n, la \nRep\u00fablica \u00c1rabe Siria y de Yemen, tienen \nmonograf\u00edas para las medi cinas herbarias. Las \npreocupaciones de las autoridades reguladoras en la regi\u00f3n se refieren generalmente m\u00e1s a la falta de seguridad en las MH que a su eficacia. Hay una gran \nnecesidad de personal expert o para controlar a los Regulaci\u00f3n global de los medicamentos herbarios Prieto \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 98 productores de medicinas herbarias. Por tanto las \nprioridades regionales en el \u00e1rea de medicinas herbarias incluyen el entrenamiento de los \nprofesionales de salud, la educaci\u00f3n p\u00fablica, el \nfomento de intercambio de informaci\u00f3n y la formaci\u00f3n de expertos nacionales para registrar MH y auditar en GMP, sin olvidar la necesidad de referencias para las plantas medicinales traducidas a los lenguajes de la regi\u00f3n y la creaci\u00f3n de una \nestrategia de protecci\u00f3n de los recursos vegetales. \n(Ren y Keller, 2002) \nASEAN \nLos pa\u00edses de la Association of South-East Asian \nNations (ASEAN) que son Brunei, Darussalam, Indonesia, Malasia, Filipinas, Singapur, Tailanda y \nVietNam (y en un futuro pr\u00f3ximo Camboya, Laos y \nMyanmar) han creado un espacio com\u00fan econ\u00f3mico y est\u00e1n apostando fuertemente por la constituci\u00f3n de un polo biotecnol\u00f3gico regional estableciendo colaboraciones estrat\u00e9gicas con otros espacios \necon\u00f3micos, empezando por Europa, lo cual se ha \nmaterializado en el ECAP (EC-ASEAN Intellectual Property Rights Co-operation Programme). \nLa ASEAN comenz\u00f3 su esfuerzo integrador ya en \nin 1979. En la practica los primeros proyectos en el sector de medicamentos empezaron a implementarse \nhacia 1982, con la ayuda de WHO, UNDP y JPMA. \nDentro de las m\u00faltiples actividades de homogenizaci\u00f3n de sus merc ados farmac\u00e9uticos, la \nestandardizaci\u00f3n, control de calidad y uso de MH en la ASEAN es parte los objetivos generales del \nprograma llamado ASEAN TCAC Pharmaceuticals \nque persigue reforzar el se ctor farmac\u00e9utico mediante \nel cumplimiento de las recomendaciones de la OMS/DAP y conseguir en la regi\u00f3n una autosuficiencia en recursos humanos especializados. \nEl uso de MH en todos los pa\u00edses ASEAN se \nestimula por la necesidad de  incrementar la cobertura \nde salud y por la de aprovechar los recursos locales en una regi\u00f3n en la que el uso de MH es tan extendido e intenso. Para ello se constituyo el Traditional Medicines & Health Supplements Product Working \nGroup (TMHS \u2013 PWG). Su primera prioridad ha sido \nla de obtener materiales de referencia como premisa para establecer las normativas y directrices de calidad, as\u00ed como para atacar los problemas actuales de la regi\u00f3n en materia de medicina tradicional que \nconsisten principalmente en la proliferaci\u00f3n de \nproductos adulterados o fals ificados, confusi\u00f3n de \nnombres, combinaciones de plantas con potencial efecto toxico, contaminaciones de metales pesados y \nuso no sostenible de plantas inmaduras. \nLos resultados del esfuerzo com\u00fan en ASEAN han \nsido la creaci\u00f3n de un manual de cultivo, producci\u00f3n y uso de MH en la salud prim aria, la concretizaci\u00f3n de \nacuerdos de elaboraci\u00f3n de MH siguiendo GMP, la publicaci\u00f3n de un primer volumen de 36 monograf\u00edas de MH medicinales de inter\u00e9s regional, a lo que se suma la de otras 14 monograf\u00edas de drogas crudas y la \ncreaci\u00f3n de mas de 40 herbarios a disposici\u00f3n de las \nautoridades locales. Los lideres de los pa\u00edses miembros de ASEAN acordaron que en 2010 las MH y suplementos diet\u00e9ticos deben estar regulados en su \nespacio com\u00fan (ASEAN, 2007a; 2007b; Zhang, \n2006). \nChina - Europa \nChina quiere globalizar su sistema tradicional y \nasegurar que las pol\u00edticas reguladoras en marcha en \nEuropa y otros pa\u00edses no le cierren el paso a sus exportaciones de plantas medicinales. Para ello en \n2005 ha actualizado la edici \u00f3n de su farmacopea bajo \nla supervisi\u00f3n de expertos europeos con el objetivo de \nacercar las normas de calidad chinas a los par\u00e1metros \noccidentales que hacen hincapi\u00e9 en la determinaci\u00f3n de marcadores qu\u00edmicos y sustancias bioactivas. Este aspecto marca la evoluci\u00f3n de la aproximaci\u00f3n china \ncl\u00e1sica a la calidad del material vegetal que se basaba \nmas en la identificaci\u00f3n del material y su procesamiento principalmente. \nPor otro lado China y la Uni\u00f3n Europea han \nestablecido un canal privilegiado para la regulaci\u00f3n de \nlas drogas vegetales usadas en la medicina tradicional \nchina (MTC) con vistas a la homologaci\u00f3n de las monograf\u00edas de la farmacop ea china que permitan su  \nimportaci\u00f3n, venta y dispensaci\u00f3n en Europa. Esta voluntad ha cristalizado en un reciente encuentro al m\u00e1ximo nivel en Roma (Ministry of Science and \ntechnology of RRPP China, Ministero Della Sanita de \nItalia, Directorate General for Research EU, 2007) y provee un segundo espacio com\u00fan Sino-Europeo para \nlos medicamentos herbarios. \nHong Kong, que siempre ha sido el punto de \nenlace entre China y el Occi dente, se sit\u00faa velozmente \nen este papel en cuanto a la globalizaci\u00f3n de la MTC \nse refiere. En esa ciudad se han creando distintas organizaciones para potenciar este proceso. Ejemplos son la Modernized Chinese Medicine International \nAssociation (\nMCMIA ) formada por cient\u00edficos y \nprofesionales de la industria y que pretende poseer un \nfuerte car\u00e1cter multi-disciplinar. El Consortium for Regulaci\u00f3n global de los medicamentos herbarios Prieto \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 99 Globalization of Chinese Medicine ( CGCM ) creado \nen diciembre de 2003 agrupa a 19 instituciones de \ntodo el mundo y pretende avanzar en las metodolog\u00edas \nrequeridas para el control de calidad de los MH \naplicando las mas modernas tecnolog\u00edas, crear una base de datos con informaci\u00f3n completa sobre MH chinos y coordinar ensayos  cl\u00ednicos de acorde a \nnormas internacionalmente validas. \nREGULACION TRASNACIONAL EN EL AREA \nDEL PACIFICO \nWestern Pacific Regional Forum for the \nHarmonization of Herbal Medicines (FHH) \nLa necesidad prioritaria de este grupo, compuesto \npor Australia, China, Japon, Republica de Korea, \nSingapur, Viet Nam y Hong Kong (SAR China) es el \nde regular la MTC, que es usada activamente en estos pa\u00edses con las mismas pautas filos\u00f3ficas que en China. Sin embargo existe una disparidad de normas de calidad que impiden el comercio fluido de MH en la \nregi\u00f3n (Zhang, 2006). \nLa FHH es un foro t\u00e9cnico en el que participan las \nautoridades reguladoras de los pa\u00edses miembros. Se \nredactan documentos de con senso t\u00e9cnico y cient\u00edfico \nen materia de seguridad, eficacia y calidad de MH, evitando la duplicaci\u00f3n del esfuerzo regulador, \ncreando las bases de un uso sostenible de recursos \nvaliosos y resolviendo la fa lta de normativa en \u00e1reas \nimportantes de la salud publica. \nREGULACION TRASNACIONAL EN EUROPA \nLa Uni\u00f3n Europea, recientemente ampliada a 27 \nmiembros, y un total de 470 millones de consumidores, provee un espacio altamente regulado para la armonizaci\u00f3n del mercado. La Agencia Europea del Medicamento (EMEA) que fue creada como organizaci\u00f3n reguladora trasnacional de la Uni\u00f3n en materia de medicamentos, ha desenvuelto su \npapel de manera tan exitosa que la OMS la ha tomado \ncomo modelo de sistema de gesti\u00f3n de informaci\u00f3n y \nla promueve como referencia en todos sus foros regionales (Lepakhin, 2004). \nLa regulaci\u00f3n inexorable de todos y cada uno de \nlos productos europeos ha llegado a los productos herbarios que, desde 2004, est\u00e1n en la cuenta atr\u00e1s de su regulaci\u00f3n obligatoria como Medicamentos Tradicionales Herbarios o a su degradaci\u00f3n a la categor\u00eda de suplemento alim entario a partir de 2011. \nPara mas detalles l\u00e9ase el art\u00edculo escrito por Peschel \n(2007) en este mismo n\u00famero. Cumplido este objetivo de regular la medicina herbaria \u201coccidental\u201d, Europa \nse ha embarcado en la creaci\u00f3n de canales privilegiados con China y ASEAN para la futura \nintegraci\u00f3n de la MTC y otros productos del Sudeste \nAsi\u00e1tico en el mercado eur opeo (Ministry of Science \nand technology of RRPP China, Ministero Della Sanita de Italia, Directorate General for Research EU, 2007; ASEAN, 2007a, 2007b. \nREGULACION GLOBAL: SITUACION \nACTUAL \nExisten algunos movimientos de car\u00e1cter m\u00e1s o \nmenos mundial que pretenden la coordinaci\u00f3n de los \nentes reguladores de medicinas. Una de ellas es la International Conference of Drug Regulatory \nAuthorities (ICDRA), que desde 1980 sostiene \nreuniones bianuales. Es una iniciativa de la OMS para proveer un foro \u00fanico par a las autoridades reguladoras de todos sus estados miembros, determinando las prioridades de acci\u00f3n a nivel \nnacional e internacional de regulaci\u00f3n de medicinas, \nvacunas, biomedicinas y medicamentos herbarios \n(WHO, 2007; Lepakhin, 2004). \nLos objetivos de ICDRA son definir criterios y \nnormas de calidad para medicinas herbales, alimentos \nfuncionales y suplementos diet\u00e9ticos entre todos los \nestados miembros y junto a la  OMS, la cual continuara \na desarrollar gu\u00edas de calidad, seguridad y eficacia de \nMH y sus combinaciones. La OMS tambi\u00e9n pretende impulsar un programa de monitorizaci\u00f3n de uso y seguridad de MH, iniciativa que debe ser fortalecida e \nimplementada pos los estados miembros. La OMS \ntambi\u00e9n seguir\u00e1 proporcionando apoyos a estados miembros, especialmente en v\u00edas de desarrollo, para desarrollar programas de informaci\u00f3n sobre el adecuado uso de MH por parte del p\u00fablico. A nivel \ngubernamental, la OMS provee asesoramiento en la \neducaci\u00f3n del personal sanitario. La ICDRA \ncoordinara toda la inform aci\u00f3n generada a trav\u00e9s de \nestos programas. (WHO, 2007; Lepakhin, 2004)).  \nOtra iniciativa global de la OMS es la llamada \nCooperaci\u00f3n Internacional en materia de \nReglamentaci\u00f3n de los Medicamentos Herbarios \n(IRCH), cuyo objetivo principal es el de fomentar y facilitar el uso seguro de los medicamentos herbarios a nivel mundial, a trav\u00e9s de iniciativas regionales, del intercambio de informaci\u00f3n y del di\u00e1logo (ICDRA 2006). Esta aun en su fase inicial y ahora se centra en \nla creaci\u00f3n de una red de intercambio de informaci\u00f3n \nsobre aspectos t\u00e9cnicos de la regulaci\u00f3n de MH \nmediante comunicaci\u00f3n electr\u00f3nica a diario entre los Regulaci\u00f3n global de los medicamentos herbarios Prieto \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 100 \u201cInformation Focal Point\u201d nominados por cada \nmiembro del IRCH y la organizaci\u00f3n de reuniones anuales bajo el nombre de la \u201cGlobal Strategy for \nTraditional Medicine\u201d, cuyo grupo de trabajo acord\u00f3 \ndesarrollar una segunda serie de monograf\u00edas de Plantas medicinales en sus reuniones de Ottawa (Canad\u00e1) en 2005 (IRCH, 2005) y Beijing (China) en 2006, donde asistieron autoridades reguladoras de cada uno de los grupos de las seis regiones/sub-\nregiones de la OMS as\u00ed co mo grupos de cooperaci\u00f3n \ninternacional incluyendo FHH, PANDRH, the \nEuropean Herbal Medicines Committee, the ASEAN \nProduct Working Group on Traditional Medicines and Health Supplements (TMHSPWG) y el parlamento \nLatino Americano (PARLATINO) (Zhang, 2006).  \nEn contraposici\u00f3n a estos movimientos de \nglobalizaci\u00f3n \u201cpopulista\u201d mediante foros y  \norganizaciones cuya pertenencia esta abierta a todos los pa\u00edses, y dotados de organizaci\u00f3n interna flexible \nse sit\u00faan los modelos \u201ccorporativos\u201d de armonizaci\u00f3n \nglobal de medicinas, como la ICH. La opci\u00f3n corporativa esta caracterizada por una estructura altamente formal y definida, cuya pertenencia es restringida, que establece objetivos y fechas de entrega de resultados (Molz\u00f3n, 2003).  \nLa ICH es una organizaci\u00f3n internacional en la que \nparticipan pa\u00edses europeos, Jap\u00f3n y EEUU as\u00ed como el Ministry of Health, Labour and Welfare de Japon (MHLW), la European Federation of Pharmaceutical Industries Associations (EFPIA), la Japan \nPharmaceutical Manufacturers Association (JPMA), \nFood and Drud Administration (FDA) y la America's Pharmaceutical Research Companies (PhRMA) para el desarrollo de requerimientos t\u00e9cnicos homog\u00e9neos para productos medicinales. Aunque las normativas \ndesarrolladas en este foro so lo aplican a los pa\u00edses \nmiembros, es evidente que el peso de los mismos en el \nmercado marcan las pautas a seguir a nivel global. Existe un Comit\u00e9 dedicado a MH dentro de esta organizaci\u00f3n, aunque no existen aun desarrollos tangibles. \nLA AMENAZA BIOTERRORISTA COMO FUERZA REGULADORA \nHechos totalmente al\u00edenos al mundo de las plantas \nmedicinales han impulsado una regulaci\u00f3n global de \nfacto  para las plantas medicinales. Los atentados del \n11 de septiembre de 2001 dieron lugar a la aprobaci\u00f3n \ndel acta de bioterrorismo de la FDA ( regulation 21 \nCFR Part 1, Subpart I), de acuerdo a la cual todos los \nproductores de suplementos alimentarios (categor\u00eda que en EEUU corresponde a los MH) que quieran registrarse en esta agencia deben cumplir las GMP. China ha sido una de las mas afectadas debido al alto \nvolumen de especialidades herbarias exportadas desde \neste pa\u00eds (Chan, 2003; FDA, 2003). \nCONCLUSIONES \nSe ha iniciado un movimiento a escala planetaria \nde globalizaci\u00f3n de los distintos sistemas de medicina tradicionales as\u00ed como de homogenizaci\u00f3n del \nmercado de medicamentos herbales y plantas \nmedicinales. El impulso inicial dado por los trabajos de la OMS y el ejemplo de la primera regulaci\u00f3n trasnacional, en la forma de la Directiva de Medicinas Tradicionales Europeas, han sentado las bases \ndocumentales y legales pa ra ayudar a una r\u00e1pida \nimplementaci\u00f3n de medidas trasnacionales en otros \ncontinentes. Podemos pronosticar que en la pr\u00f3xima d\u00e9cada la implementaci\u00f3n de distintos consensos regionales sobre esta materia, siendo los m\u00e1s \navanzados aquellos que se desarrollan dentro de \nespacios econ\u00f3micos comunes, como MERCOSUR o \nASEAN. \u00c1frica ha comenzado por la creaci\u00f3n de un marco estable a nivel continental para la medicina tradicional como paso previo a la regulaci\u00f3n trasnacional. Tanto \u00c1frica como ASEAN se han \nmarcado el 2010 para cumplir estas perspectivas. Si \nbien una regulaci\u00f3n global tardara en conseguirse, diversos organismos ya han emprendido este camino \nen forma de encuentros regulares entre agencias reguladoras de todo el mundo. \nBIBLIOGRAF\u00cdA \nAfrican Development Forum. 2000. The Abuja framework \nfor action for the fight against HIV/AIDS, Tuberculosis \nand other related infectious diseases in Africa . 3-7 \nDecember, Addis Ababa, Ethiopia.  \nASEAN. 2007a. Executive Summary. Technical \nCooperation Project in pharmaceuticals \nASEAN. 2007b Technical Cooperation Project in \npharmaceuticals .  \nCAMH. 2005. Plan of acti on on the AU decade of \nTraditional medicine (2001-2010): implementation of \nthe Lusaka summit of heads of State and Government \n(AHG/DEC.164 (XXXVII). 2nd Ordinary session of \nthe conference of African ministers of health (2) Gaborone, Botswana, 10 \u2013 14 October. \nChan R. 2003. Challenges in the globalization of Chinese \nherbal medicine. Second International Conference & Exhibition of the Modernization of Chinese Medicine \n& Health Products (ICMCM) \u2013 Hong-Kong, Republica \nPopular China, 14-18 August. Regulaci\u00f3n global de los medicamentos herbarios Prieto \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 101 FDA. 2003. The Public Health Security and Bioterrorism \nPreparedness and Response Act of 2002  (the \nBioterrorism Act). \nGarc\u00eda M, C\u00e1ceres A. 2000. Legislaci\u00f3n en Iberoam\u00e9rica \nsobre Fitof\u00e1rmacos y Productos Naturales . Ed. \nCYTED-LEBi-ASACIMSS-EU, Costa Rica. \nGupta MP. 2003. Legislaci\u00f3n sobre Productos Herbarios en \nCentro Am\u00e9rica y los Pa\u00edses Andinos. Presentaci\u00f3n en \nICS-UNIDO Training Course, Panam\u00e1 City, Panama. \n21-25 de Noviembre. \nICDRA. 2006. Herbal medicines: safety through quality. \n12th ICDRA Proceedings, pp 38-39. \nIRCH. 2005. Proceedings of the meeting of the Working \ngroup on regulatory cooperation on herbal medicines. Ottawa, Canada, 28 to 30 November. \nKofi-Tsekpo M. 2004. Ins titutionalization of African \nTraditional Medicine in Health  Care Systems in Africa. \nAfrican J Health Sci.  11(1-2):1-2. \nLepakhin VK. 2004 Regulatory challenges: Health Sector \nReform and Drug Regulatory Capacity. Eleventh International Conference of Drug Regulatory Authorities (ICDRA), 16 - 19 February, Madrid, Spain \nLinares Calvo X. 2007. Imposici\u00f3n de manos en un \nhospital . La Nacion (Argentina) 10 de agosto.  \nMERCOFITO. 2007. Res\u00famenes del Congreso. Organizado \npor la Comisi\u00f3n de Salud y Deporte, Comisi\u00f3n de Acci\u00f3n Social y Salud P\u00fablica y la Asociaci\u00f3n Argentina de Fitomedicina) Buenos Aires CF, \nRepublica Argentina, 14 y 15 de Junio. \nMinisters of Health of the WHO African Region. 2007. \nDeclaration on Traditional Medicine , fifty-seventh \nsession of the Regional Committee for Africa \nBrazzaville,. Republic of the Congo, 31st August. \nMinistry of Science and technology of RRPP China, \nMinistero Della Sanita de Italia, Directorate General for Research EU, 2007. Handbook for Sino-European \nconference on tradicional chinese medicine. Roma, \nItalia, 27 de Junio. \nMolzon JA. 2003. Models for Regional Cooperation In \nDrug Regulation. The 2003 Symposium on APEC, Network of Pharmaceutical  Regulatory Science. \nTaipei, Taiwan, November 18. \nOMS, UICN, WWF. 1993. Direct rices sobre conservaci\u00f3n \nde plantas medicinales. UICN, Gland, Suiza. \nOMS. 2002. Estrategias de la OMS sobre la Medicina \nTradicional 2002-2005. WHO/EDM/TRM/2002.1, Ginebra, Suiza,  \nOMS. 2003. Directrices de la  OMS sobre buenas pr\u00e1cticas \nagr\u00edcolas y de recolecci\u00f3n (BPAR) de plantas medicinales. Ediciones de la OMS, Ginebra, Suiza. \nOrrego Guerrero M. 2002. Validando la Medicina \nTradicional.  Ecoportal  20 de marzo de 2002. \nPAHO. 2002. Traditional, Complementary and Alternative \nMedicines and Therapies: Evaluation Plan of Work \n2000-2001 and Plan of Work 2002-2003 . Washington, \nD.C. US. PAHO, 2006. Actas de la II Reuni\u00f3n del grupo de trabajo \nde plantas medicinales. Curitiba, Brasil, 29-31 Marzo. \nPeschel. 2007. The Traditional Herbal Medicine Directive \nwithin the European regulatory framework for Herbal Products. BLACPMA 6(4):102-111. \nRen D, Keller K (moderators). 2002. Herbal medicines . The \nTenth International Conference of Drug Regulatory Authorities (ICDRA), Hong Kong, China, 24\u201327 June,  \nRobertson D. 2007a. The Untapped Wealth of Caribbean \nHerbs. C.A.P. Confer ence, Caymans Island \nRobertson D. 2007b. Jamaica: regulatory issues. BLACPMA  \n6(4):125-128. \nThe American Herbal Pr oducts Association 2007. \nTraditional Medicines Congress. Calls for Comments on \u201cIdeal Regulatory Model\u201d. \nhttp://www.ahpa.org/\nWHO. 2004. Global Survey and Database of National \nPolicy and Regulation of TM/CAM and Herbal Medicines including information from 141 countries. Editions of the OMS, Geneva, Switzerland. \nWHO. 2005. Summary report of the global survey on \nnational policy on traditional medicine and regulation of herbal medicines. Editions of the OMS, Geneva, \nSwitzerland. \nWHO. 1998. Quality Control Me thods for Medicinal Plants \nMaterials. Editions of the OMS, Geneva, Switzerland. \nWHO. 2001. Legal Status of Traditional Medicine and \nComplementary/Alternative Medicine: A Worldwide \nReview. WHO/EDM/TRM/2001.2. Editions of the \nOMS, Geneva, Switzerland. \nWHO. 2004a. WHO Guidelines on Safety Monitoring of \nHerbal Medicines in Pharmacovigilance Systems, Editions of the OMS, Geneva, Switzerland. \nWHO. 2004b. WHO Guidelines on Developing Consumer \nInformation on Proper Use of Traditional, \nComplementary and Alternat ive Medicine. Editions of \nthe OMS, Geneva, Switzerland. \nWHO. 2005. National Policy on Traditional Medicine and \nRegulation of Herbal Medicine . Report of WHO \nGlobal Survey. Editions of the OMS, Geneva, \nSwitzerland. \nWHO. 2007. International Conference of Drug Regulatory \nAuthorities (ICDRA) , WWW.  \nYlarri PA. 2007. Incorporan medicina ind\u00edgena al sistema \nformal.  DyN 11.08.2007 URL [U ltimo acceso 1/11/07] \nZhang X. 2006. International Regulatory Cooperation on \nProper Use of Traditional Medicine. Oral Presentation \nin the International Regulatory Cooperation on regulation of Herbal medicines (IRCH) 29 March, \nBrazil.  \n \n\u00a9 2007 Los Autores \nDerechos de Publicaci\u00f3n \u00a9 2007  Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 102 - 111 \nBLACPMA ISSN 0717 7917 \nEspecial Regulaci\u00f3n de Fitomedicinas / Sp ecial Issue on Regulation of Phytomedicines \nThe Traditional Herbal Medicine Directive within the European \nregulatory framework for Herbal Products  \n[La Directiva Europea de Medicamentos Herbales Tradic ionales en el contexto Europeo de Productos Herbales] \nWieland PESCHEL \nCentre for Pharmacognosy and Phytotherapy, Sc hool of Pharmacy, Univ ersity of London,  \n29-39 Brunswick Square, WC1N  1AX London, United Kingdom \n*Contacto: wieland.peschel@pharmacy.ac.uk\nRecibido el 13 de Abril de 2007; Aceptado el 19 de Julio de 2007 \nAbstract \nA series of new European guidelines specifically for herbal medi cine has been generated over the last 10 years, which is embedded in the \ngeneral harmonisation process of medicines regulation within the European Union.  Although not generally welcomed, the need for quality \nand safety standards has been backed by a number of adverse ev ents associated with herbal pr oducts often affecting several Euro pean \nmember states simultaneously. Within this framework, the Europ ean Directive (2004/24/EC) for a simplified registration of tradi tional herbal \nmedicinal products established a new harmonised way of marketing authorisation under consideration of national peculiarities. T his paper \ngives an introduction to the current five regulatory pathways  and the eligible guidance for herbal medicine in Europe. \nKeywords: Traditional European Medicine, he rbal medicine regulation, safety, quality. \nResumen \nEn el ultimo decenio se han generado una se rie de guias europeas sobre medicamentos herbarios que se enmarcan en un proceso de \narmonizacion general del Mercado farmaceutico en la Union Europea.  Aunque no siempre bien recibidas, la aparicion de efectos ad versos ha \nveces afectando a varios paises miembros simultaneamente, han creado necesidad de reforzar las normas de seguridad y calidad A.  Es en este \ncontexto que aparece la Directiva Europea (2004/24/EC) para la registraci\u00f3n simplificada de productos medicinales herbarios tra dicionales ha \nestablecido una nueva via de arm onizacion del mercado considerando las peculiarid ades nacionales existent es. Este articulo pret ende \nintroducir al lector en las cinco diferentes  maneras de registro y la eligibilidad pa ra los medicamentos herbarios en Europa. \nPalabras clave: Medicinas Tradicinales Europeas, Me dicamentos herbales, regul aci\u00f3n,seguridad, calidad. \n \nList of Abbreviations: \nBfArM: Federal Institute for Drugs  and Medical Devices (Germany) \nCHMP: Committee for Human Medicinal Products \nCP: Centralised Procedure  \nCTD: Common Technical Document \nDCP: Decentralised Procedure  \nEC: European Commission \nEMEA: European Medicines Agency \nESCOP: European Scientific Cooperative on Phytotherapy \nHMP: Herbal Medicinal Product \nHMPC: Committee for Herbal Medicinal Products  \nHMPWP: Herbal Medicina l Products Working Party \nMA: Marketing Authorisation \nMHRA: Medicines and Healthcare Products Regulatory Agency (UK) \nMP: Medicinal Product \nMRP Procedure of Mutual Recognition between Member States \nPh Eur Pharmaco poeia Europea \nSPC Summary of Prod uct Characteristics \nTHMP Traditional Herbal Medicinal Product \nWEU Well Established Use \nWHO World Health Organisation The Traditional Herbal Medicines European Directive Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 103  1 THE CHALLENGE TO REGULATE HERBAL \nMEDICINAL PRODUCTS IN EUROPE \nHerbal products for health purposes have been \nused traditionally in all European countries, most of them now member of the European Union with all legal consequences. In the past, the way of market access and legal handling is almost as heterogeneous as the botanical and ethnopharmacological patchwork of the plants behind these products. The herbal \nmedicinal market in Europe is currently affected by \nsubstantial changes of the regulatory environment. \nEfforts are driven by the general intention to \nharmonise the regulation of medicinal products, food \nand other consumer goods at centralised European \nlevel. On the other side, authorities are particularly \nreacting to a changing European market and cases of adverse events linked to the consumption of herbal products. Safety issues arose both from well known HMPs registered or licensed for years in the EU \n(Hypericum, Kava-Kava ) but also from imported \nproducts due to the increasing popularity of non-\nEuropean traditional herbal medicine, mainly the Chinese one [Stickel et al. 2003, Singh 2005, Nortier & Vahherweghem 2002]. The first group is characterised by the increasing scientific knowledge \nabout side effects/interactions, but also by the \ngrowing public awareness including the media and competitors from the synthetic drug market that herbal medicine is not in  general harmless [Elvin-\nLewis, 2005]. The second group of \u201cimports\u201d is \naccompanied by a series of new challenges which in \nthis extent were not rele vant for a more national \n\u201cpure\u201d European market so far. This refers to the \nincreasing numbers of poor or wrong declarations \nand adulteration with heavy metals, other toxic plants \nor synthetic drugs [Ernst, 2002]. \nBoth trends caused a series of adverse events, \nsome of them with fatal outcomes. But also arose \noften exaggerated conclusi ons and warnings about \nthe toxicity of HMP. Herbs and derived products can face a general condemnation, even when case reports \nare characterised by obvious overdosing, unclear \nsources, or doubtful products which than is compared 1:1 to the correct use of standardised products [Gruenwald et al. 2003]. However, in order to differentiate the good, the bad and the ugly, each consumer, manufacturer, regul ator and journalist has \nto face some key issues, which differ from synthetic MP: the heterogeneity of the starting material itself \n(chemical composition, natural variability, diverse sources), the heterogeneity of plant preparations \n(plant part used, type of preparation, manufacturing process), and the lack of accurate quality/safety data \nfor often non-standardised low price products. All \nthree points require a careful analysis of any adverse \nevent in particular when it comes to the transfer of \ndata and some kind of \u201cc lan liability\u201d for products, \nwhich are not comparable. Furthermore it can be \nstated that certain toxicity is well accepted for \nsynthetic MP according to risk benefit assessments, \nwhereas the \u201c generally regarded as safe\u201d  paradigm \nand subsequent poor regulation level of HMP worldwide can cause certain overreaction. \nHerbal medicinal products are classical borderline \nproducts and the term herbal medicinal product as such an umbrella term for a complex variety of products which have only in common to be of herbal \norigin and to be health related [Barnes 2003]. The very natural grey area between food and medicine, \ncosmetics and medicine etc. will always cause \ndemarcation problems, even more when the very competitive food/cosmetic market tends to use health claims for marketing reasons. Understandably, small manufacturers of medicine try to avoid the \nconsiderable burden of medicinal law and customers \nprefer low price products if no risks are associated \nwith them. Therefore, the priority of medication or nutrition/ cosmetic use, the duration and frequency of the application, and \u201cnatural or enriched\u201d concentration of natural substances affecting \nphysiological functions might be of decisive \nimportance for product classification (see also Table 1). This interface is getting more complicated when the miscellaneous mixture of herbal products itself and all kind of combinations can cause the allocation of the same plant/product into various categories, not \nonly by the intention of use but by the concentration \nand daily dose or only the type of package declaration on otherwise identical preparation. \nBeyond this primary borderline a secondary one \nexists within the herbal medicinal products \nthemselves. Traditional herbal medicinal products \njoin now the well established use category and the full marketing authoris ation and homeopathic \nmedicinal products at European level. Thus, the manufacturer has often various options for which licensing process to go (Table 1). \nThe complexity of the matter multiplies when \nquality/safety standards shall apply for the entire European level. The heterogeneity of the European market (diverse cultures and traditions, import market, immigration), but also the heterogeneity of The Traditional Herbal Medicines European Directive Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 104  the regulatory handling (National peculiarities, \nborderline to food and cosmetics) and subsequent diverse manufacturer and c onsumer patterns require \nbalanced and cautious changes. The patchwork of regulatory tradition within the EU includes countries which traditionally deal with HP predominantly as medicinal product (Germany, Austria, Denmark), as \u201ctraditional\u201d medicinal product (France, Spain, Sweden) or exempted from medicine law mostly \nregistered as food (UK, Benelux, Portugal). Usually \nall member states accept various categories for herbal \nmedicine from the legal point of view and few efforts \nare made to clarify grey areas and to suit action to the word [Benzi & Ceci 1997]. \n2 EUROPEAN REGULATORY BODIES AND LISTING/MONOGRAPH SYSTEMS \nThe European Union is tackling these \nuncertainties of the herbal sector for a decade now and has established a decent framework of guidelines \nwhich at least in part will harmonise the European \nmarket (Table 2). However, national peculiarities will remain and a comparable degree as for synthetic products with single chemical entities will probably never be reached. The new traditional herbal medicine directive 2004/24/EC (embedded in \n2001/83/EC art. 16) plays a central role amending the \nwell established use category (2001/83/EC art. 10a \u2013 \n2003/63/EC) as an alternativ e between food (almost \nno health claims possible) and full marketing \nauthorisation including efficacy (2001/83/EC Art. 8). \nBeside the upgrading of the EMEA based herbal \nmedicinal products working party (HMPWP) to the committee level (HMPC) with the guideline EMEA/HMPC/139800/2004, herbal specific guidelines of different binding level are focussing now on four key areas: demarcation/classification \n(e.g. directive 2004/24/EC), quality (e.g. guideline  \nCPMP/QWP/2819), safety (e.  g. public statement \n138139/2005) and on standardisation/declaration \nproblems (e.g. EMEA/HMPC/CHMP/CVMP/287539/2005)  (for an \noverview see Table 2). This package has to be understood as amendment to  general medicine law \nfocusing on the peculiarities of herbal products and providing either detailed extension or useful simplification considering their specific status. That means for instance, if the full quality part 2.1 of the \ncommon technical document is required, it includes \nalso the GMP conform production process \u2013 a specific challenge (and sometimes not manageable hurdle) for small manufacturers. On the other hand,, the time and effort of quality control, stability tests and declaration of multicompound mixtures can by \nfar exceed single chemical entity products. This \nrequires expertise and sensitivity at \ncommissions/authorities to balance well between \nsafety and appropriate expenditure. \nBefore the European Commission, and the \nEMEA/HMPC became the key players for the \nregulation of the herbal market, there has been other \norganisations facing the acclamation of diverse national situations. This refers mainly to the European Directorate for the Quality of Medicines (EDQM) with the Commission of the European \nPharmacopoeia (Ph Eur) in Strasbourg and the \nEuropean Scientific Cooperative on Phytotherapy (ESCOP, founded 1989). The EDQM includes 36 European Member States and 20 observers such as \nthe American FDA and the WHO. Its role is to \nharmonise the quality standards for use by healthcare \nprofessionals. The Ph Eur is the only official pharmacopoeia in Europe to be used for international \ntrade and it is mandatory in European marketing authorisation dossiers in 36 member states. The group of experts from the Ph Eur is proposed by all \nnational authorities and appointed by the Ph Eur \ncommission. The ESCOP was a voluntary organisation in order to extent European HMP quality standards to the scientifically approved effective and safe use. The first national data based approach of \nmajor dimension was the German so called \nCommission E within the Federal Health Institute. This means, on the basis of national monographs there was already the attempt to create standards in terms of quality (EDQM), safety/efficacy (ESCOP) for the most common plants at the European level. \nThese monographs usually represent the state of the \nart and provide the basis for well established use (WEU) applications (for a comparison see Table 3). Subsequently ESCOP and Ph Eur monographs are now the starting point for the WEU and THMP \nmonographs established successively by the HMPC. \nThis development is of course discussed controversially either criticising double standards as well as fearing simplification to a European gold standard without consideration of traditionally/scientifically ju stified product diversity. \nLikewise, other herbal medicine specific topics have not only there national, but also international anticipators. The Good Agricultural Practice guideline for herbal starting materials (246816/2005) for instance has been built on guidelines from the The Traditional Herbal Medicines European Directive Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 105  EUROPAM (The European Herb Growers \nAssociation, first version 1998), and the WWF Traffic network, starting together with other \norganisations 1993 with the Guidelines on the \nConservation of Medicinal Plants. \nThe division of legal, administrative and \nenforcement tasks and responsibilities between the European commission (Enterprise and Industry Directorate General, F/2 Pharmaceuticals) in \nBrussels, the EMEA in London (HMPC, quality \ngroup, CHMP, etc) and national authorities of the member states (e.g. MHRA in UK, BfArM in Germany, AGEMED in Spain) is not always as transparent for non-insiders as it should be. \nFurthermore different types of European law of either \nguiding (\u201csoft law\u201d) or directly binding character as \nwell as the differentiation between direct EU \nregulations, EU directives to be implemented by the \nmember states into national law, and pure national \nlaw will cause some confusion for any HMP \nmanufacturer. However, by now and in the near future, the herbal sector practically will mainly deal with national authorities as either for a national MA or for the MRP procedure. The adoption and legibility of European law is task of the national \nregulating authority and their advice is fundamental \nfor the final decisions. A good communication basis with the national authority for an expertise driven exchange of opinions is the key for pragmatic solutions in this virgin soil of pan-European HMP \nregulation. There are only a few experiences yet with \nthe new regulations; hence their practicability has to be shown in the future. There are only 8 products in three member states registered under the new traditional use legislation so far. 79 applications in 12 MS are reported [Woodfield 2007]. Both statistics \nreflect the difficulties in the implementation. Already \nnow, key issues crystallise such as the community \nmonograph/listing process, the demarcation between \nWEU and TU, the different law interpretation of \nnational authorities, the proof of traditional use, the \nflexibility in product adaptation in terms of strength \nand posology (\u201ccomparable\u201d preparations, \u201cminor\u201d changes, \u201cessentially similar\u201d, modern dosage forms etc.), the handling of comb ination products, but also \naspiration to protect the partially strong herbalist and food supplement sector established in some MS \n[Roether 2006, Krisper 2007].  3. HMP WITH FULL MARKETING \nAUTHORISATION AND BIBLIOGRAPHIC APPLICATION (WEU) \nAccording to 2001/83/EC as for any other \nmedicinal product HMP MA can be obtained under central procedure (CP), decentralised procedure (DCP) or mutual recognition of national MA (MRP). However, many herbal medicinal products are still licensed on a national basis due to the differences in \nnational practices with respect to such products. \nHMP for which sufficient evidence is available to support the quality, safety and efficacy of the product must apply for a full MA. Applications with full \nsupporting data, as usual for so called new chemical \nentities (NCE), are rare; more common is to go for \nthe \u201cwell-established use\u201d provision of a bibliographic application according to Article 10 of Directive 2001/83/EC on the basis of published literature (see alsoTable 1). In the broadest sense are \nthese generic applications, whereby the comparator referred to is not an already established product after data protection time but a monograph and/or other \naccepted scientific core-data. This means also, that those products will usually not be accepted as THMP, as efficacy/safety data are available and have not to \nbe replaced by the proof of traditional use. But \ndifferences of the product and authority practice in \nthe member states will cause doubling e.g. a Harpagophytum  product is licensed as traditional \nmedicine in UK whereas Harpagophytum  products \nare not \u201ctraditional\u201d but \u201cwell established\u201d for German authorities due to sufficient safety and efficacy data. By now, only one HMP is listed for the CP (a Boswellia  extract), no experiences exist for the \nDCP yet and less than 20 products have successfully received MA under MRP. \n\u201cCore-data\u201d (previously called core-SPCs) as \noutlined in section before, originate from the monographs produced by WHO, ESCOP, and are increasingly replaced by community herbal monographs elaborated by the HMPC according to \nstandard procedures (107436/2005 and \n182352/2005). These core-data can facilitate the authorisation process but are not legally binding. Whenever such monographs have been adopted the registration holder will be  required to amend the \nregistration dossier to comply with the new \nmonograph. Only when no such monographs have \nbeen established, other appropriate monographs, publications or data may be  referred to. The process \nof monograph and list establishment can be followed The Traditional Herbal Medicines European Directive Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 106   \nTable 1. General overview on EU regulation types for health related herbal products \n \nCategory Subcategory Legal ba sis Main characteristics \nHMP with MA Full dossier new MA, \n(DCP, MRP, CP) \u00a78(3) directive 2001/83/EC \n full CTD including \nsafety/efficacy data \n Bibliographic application (well established use), \n(MRP, DCP) \n \u00a710a directive 2001/83/EC WEU defined by Annex 1 of 2001/83/EC \namended by 2003/63/EC \n no individual but \nbibliographic \u2013\nsafety/efficacy data (mixed \napplications possible) \nHMP with \nsimplified \nregistration \n Registration as Traditional \nHerbal Medicinal Product \n(THMP) \u00a7 16a directive 2001/83/EC, \namended by 2004/24/EC full quality part, safety replaced by expert statement, \nefficacy replaced by traditional use (30/15 years) \n \n Homoeopathic MP \nAnthoposophic MP (treated legally as \nhomoeopathic according \ndirective 92/73/EEC) \u00a7 14-15 directive 2001/83/EC simplified registration, no individual safety/efficacy data \n \nHP outside \nmedicine \nlegislation Food supplements \nCosmetic products \nConsumer goods e.g. 178/2002/EC for demarcation \nfoodstuffs-MP, 2002/46/EC for \nfood supplements; \nCosmetic Directive 76/768/EEC + 93/35/EEC mainly notification only \n \n \non the EMEA website and also pharmaceutical \nmanufacturers can comment the drafts before adoption (\nhttp://www.emea.europa.eu/htms/human/hmpc/ \nmpclist.htm) . \nOne of the main actions of the HMPC is to \nfacilitate the use of the mutual recognition procedure for herbal medicinal products. This means that in contrast to the THMP (see section below), the HMPC has only supporting functions for the fully \nresponsible CHMP in case of full dossier and WEU \napplications. This is bei ng done in part by updating \nthe guidance documents relating to bibliographical applications and by promoting the core-data documents as a means of facilitating the assessment \nof safety and efficacy.Considering the still missing \nexperience with CP and DCP, here only some key \npoints for a bibliographic application via MRP are \noutlined: In general the format for an application for \nMA must be based on the Common Technical Document (CTD), consisting of 5 modules, whereby \nthe results of non-clinical tests and clinical trials \n(modules 4 and 5) are replaced by references to published scientific literature. The content of modules 1 (includes SPC), 2 (administrative data) and 3 (quality) is equivalent to any other MP as \nspecified in Directive 2001/83/EC, including some \nlegally binding specific details in Annex 1. Further \u201csoft law\u201d guidance is given in Chapter 1 Volume 2A and 2C of the Notice to Applicants and in various HMPWG/HMPC guidelines. These are for instance: guidelines addressing quality in general \n(CPMP/QWP/2819/00); specifications and test \nprocedures (CPMP/QWP/2820/00) and biopharmaceutical characterisation (EMEA/HMPWP/344/03). During the consolidation period of HMPC monographs/lists, the Ph Eur \nmonographs provide still e ligible quality standards \nand it is also possible to obtain EDQM certification. \nManufacturers meeting the criteria set out in this list/monographs will not have to demonstrate \nindividually compliance with the criteria for WEU \nand safety, but will still have to meet the normal \nrequirements regarding quality. This means first of \nall that the principles and guidelines of GMP apply. Annex 7 of the GMP guide provides specific guidance for herbal medicinal products (EC Eudralex Volume 4). Annex 18 of the GMP guide relating to \nrequirements for pharmaceutical active ingredients \nshould also be considered, while factors concerned with the primary production and processing of the herbal drug is covered by the already mentioned good agricultural and collection practice guideline \nEMEA/HMPC/246816/2005. The Traditional Herbal Medicines European Directive Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 107  Table 2. Herbal medicine specific guidelines within the EU regulation according to the main areas classification, quality, safety/ \npharmacovigilan ce and efficacy \n \nClassification/demarcation/standardisation/declaration  \nDIRECTIVE 2004/24/EC of the European parliament and of the Council of 31 March 2004 amending \u2026 Directive \n2001/83/EC on the Community code relating to medicinal products for human use \nEMEA/HMPC/261344/2005 Concept paper on CTD for traditional herbal medicinal products \nEMEA/HMPC/CHMP/CVMP/287539/2005 Guideline on Declaration of Herbal Substances and Herbal Preparations \nin Herbal Medicinal Products/Traditiona l Herbal Medicinal Products in the SPC3 \nEMEA/HMPC/107436/2005  Template for a community herbal monograph (Rev. 2) \nEMEA/HMPC/182320/2005  Procedure for the preparation of community monographs for traditional herbal medicinal \nproducts \nEMEA/HMPC/182352/2005  Procedure for the preparation of community monographs for herbal medicinal products \nwith well established medicinal use \nQuality  \nCPMP/QWP/2819/00 Guideline on the Quality of  Herbal Medicinal products/Traditional Herbal Medicinal Products \nCPMP/QWP/2820/00 Guideline on Specifications: Test procedures and acceptance criteria for Herbal Substances, \nHerbal Preparations and Herbal Medicinal Products/Traditional Medicinal Products \nEMEA/HMPC/125562/06  Reflection Paper on the use of Fumigants \nEMEA/HMPC/CHMP/CVMP/58222/06  Concept Paper on Quality of Combination Herbal Medicinal \nProducts/Traditional Herbal Medicinal Products \nEMEA/HMPC/246816/2005  Guideline on Good Agricultural and Collection Practice (GACP) for starting materials on \nherbal origin \nSafety + Pharmacovigilance \nEMEA/HMPC/ 104613/2005  Guideline on the assessment of clinical safety and efficacy in the preparation of \nmonographs/lists for traditional herbal medicinal products/substances/preparations \nEMEA/HMPC/317913/06  Reflection Paper on the risks associated with  furocoumarins containe d in preparations of \nAngelica archangelica  L.  \nEMEA/HMPC/413271/06  Concept paper on the development of a guideline on the assessment of genotoxic \nconstituents in herbal substances/preparations \nEMEA/HMPC/ 138139/2005  Public statement on the allergenic potency of herbal medicinal products containing Soya \nor Peanut Protein \nEMEA/HMPC/ 138309/2005 Public statement on Chamomilla containing herbal medicinal products  \nEMEA/HMPC/32116/05  Guideline on Non-Clinical Documentation for Herbal Medicinal Products in Applications for \nMarketing Authorisation (Bibliographical and Mixed Applications) and in Applications for Simplified Registration \nEMEA/HMPC/246736/05 Public Statement on \"CPMP List of Herbal Drugs with serious risks, dated 1992\" \nEMEA/269259/06  EMEA Public Statement on herbal medicinal products containing Cimicifugae racemosae rhizoma  \n(Black cohosh, root) \nEMEA/HMPC/269258/06  rev 1  Assessment of case reports connected to  herbal medicinal products containing \nCimicifugae racemosae rhizoma  (Black Cohosh, root) \nEMEA/HMPC/139215/05  Public Statement on the use of herbal medicinal products containing asarone \nEMEA/HMPC/138381/05 Public Statement on the risk s associated with the use of  herbal products containing \nAristolochia species \nEMEA/HMPC/138386/05  Public Statement on the use of herbal medicinal products containing pulegone and \nmenthofuran \nEMEA/HMPC/138379/05  Public Statement on Capsicum /capsaicin containing herbal medicinal products \nEMEA/HMPC/137212/05 Public Statement on the use of herbal medicinal products containing estragole  \nEMEA/HMPC/138363/05  Public Statement on the use of herbal medicinal products containing methyleugenol  \nEfficacy \nEMEA/HMPC/104613/05 Guideline on the assessment of clinical safety  and efficacy in the preparation of community \nherbal monographs for well-established and of community herbal monographs/entries to the community list for \ntraditional herbal medicinal products/substances/preparations \nEMEA/HMPC/166326/05  Guideline on the Clinical Assessment of fixed Combinations of Herbal Substances /Herbal \nPreparations \n The Traditional Herbal Medicines European Directive Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 108  4. TRADITIONAL HERBAL MEDICINAL \nPRODUCTS \nThe so called \u201cTraditional Use Directive\u201d \n2004/24/EC had to be implemented by member states (MS) by 30/10/2005. This has been realised by most MS with some delay (except Check Republic, Ireland, Netherlands, and Norway as associated MS). However, difficulties in the transition and establishment of enforcement rules still remain in 15 \nMS [EFPIA Draft Document: Status of Implementation of the European Union \nPharmaceutical Legislation at Member State Level, \n16/05/2007]. A transitional period is given for \ntraditional herbal medicinal products which were \nalready on the market on the 30/04/2004 (date of \nentry into force of Directive 2004/24/EC). This allows sufficient time for regulators/manufacturers to adapt to the new requirements and to accumulate evidence of usage in the EU of existing products. By \n2011 all old/new herbal medi cinal products will have \nto licensed/registered in order to stay on the market. \n2004/24/EC can apply when applicants provide evidence relating to traditional use, quality and safety in accordance with the requirements detailed in Articles 16b and 16c 2001/83/EC (Table 4). This \nallows a derogation from the standard efficacy \nrequirements when justified by the product\u2019s safety profile, i.e. safe traditional use for a minimum of 30 years thereof 15 within the EU. To prove this, bibliographic or expert evidence will be required \neither for the product concerned or \u201ca corresponding \nproduct\u201d. Whereas efficacy data are completely replaced by the traditional use, a bibliographic review of safety data together with an expert report will be \nrequired as it is usual for the WEU (see section \nabove). In critical products it can happen that the \nauthority request own data necessary for accessing \nthe safety of the product. This may apply specifically in response to actual developments or recent safety issues, as happened with the interaction potential of various HP. \nWhen relating to a corresponding (\u201eor \ncomparable\u201c) product, active ingredients, the intended purpose, the route of administration have to be the same or similar, and equivalent strength and posology are expected as well. The law allows only that the number/quantity of ingredients may have \nbeen reduced during the qualifying period of \ntraditional use. The practical interpretation of the legal terms \u201ccomparable\u201d, \u201csimilar\u201d, \u201cequivalent\u201d and the usefulness of combinations and removal of single ingredients will cause some discussion and vary possibly between the regulators of different MS. \nThe directive implies further restrictions for \ntraditional-use registrations as the intention for use without the intervention of a medical practitioner, whether for diagnostic purposes, prescription or monitoring of treatment. Any intravenous and intramuscular administrations are excluded and \nTHMP restricted to herbal medicines that are taken \norally, or are for external use or inhalation. \nThe borderline to food is addressed when stating: \n\u201cRegistration of traditional herbal medicinal products \ncombined with vitamins or minerals may be possible, \nwhere there is evidence of safety and where the \naction of the nutrient is ancillary to that of the herbal active ingredients.\u201d Also the borderline to WEU and homoeopathic products is explicitly mentioned: \n\u201cHerbal medicinal products  which can be given a \nmarketing authorisation on the basis of supporting safety and efficacy data (e.g ., using publis hed papers) \nwill not be eligible for the simplified procedure. Likewise homeopathic medicines will be excluded.\u201d  \nThe format and content of application for a \ntraditional use registration application will be based \non the Common Technical Dossier (CTD). Specific \nrequirements for herbal products will apply accordingly to full MA ap plications, which includes \nthe use of core data by positive lists and monographs. Likewise to WEU products the normal quality \nrequirements applicable to a licensed medicinal \nproduct will apply. Thus compliance with GMP (including Directive 2003/94/EC) will be required. GMP will also apply to herb active ingredients used \nas active substances. There will be a requirement to \nhold a Manufacturer\u2019s Licence and/or Wholesale \nDealers Licence as appropriate. Release of \nmanufactured/ imported batches will require certification by a qualified person. In addition to the requirements of Articles 16b and 16c many of the other provisions of Directive 2001/83/EC will apply \nfor THMP. These are listed in Article 16(g) and \ninclude aspects such as pharmacovigilance, labelling (including Braille) and user testing of patient information leaflets. \n5. REGISTRATION OF HOMOEOPATHIC HMP \nHomoeopathic remedies inclusive anthroposophic \nremedies are the other exemption from normal MA procedures as outlined in Article 13-16 Directive  The Traditional Herbal Medicines European Directive Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 109  Table 3. Relevant monograph systems as ba sis for bibliographic applicati ons of THMP and HMP (WEU and mixed applications). The total \nnumber of plant related monographs includes different monographs of diffe rent substances (e.g. herb , root), preparations (fruit , extract, dry \nextract) of the same species as well as  general monographs (e .g. herbal extracts) \n \nOrganisation Included species Total number \nof monographs Comment \nCommission E \n 190 380 Elaborated in the 90s by an Expert committee  formed by the German \ngovernment within the Federal Health Institute (BGA) \n \nESCOP 73 80 Following the work of the Commission E the ESCOP Scientific Committee \n(initially funded by the EC) is revi ewing the therapeutic uses of HMP, \nmonographs are updated/recognized by the EMEA \n \nWHO \n 54 58 Compiled by 120 experts in more than 50 countries and published in 2 \nvolumes (1999, 2002), rather secondary status in Europe \n \nPh Eur 126 \n >180 Quality only. Compiled by expert committee within the EDQM. Mandatory \nstatus in Directives 2001/83/EC, 2003/63/EC, and 2001/82/EC as am. The \nonly official pharmacopoeia quality st andard in Europe to be used for \ninternational trade. Constant ly updated; last June 2007 \nEMEA/HMPC \nWEU 8 (3 drafts) 9 (3 drafts) \nEMEA/HMPC \nTU 2 (10 drafts) 2 (12 drafts) HMPC experts consultation based on Ph. Eur and ESCOP monographs drafts \nare released for public consultation on the web fo r 3 months. Further in \npreparation: 8 monographs where th e draft is under discussion, 33 \nmonographs with assigned rapporteur (June 2007) \n \nTable 4:  Article 16a (1) (2001/83) criteria for the simplified procedure as  traditional medicine, where th e efficacy is supposed to be plausible \nbased on long-standing use and experience and some examples for difficulties in law interpretation. \n \nCriteria Examples for interpretation  \n Includes:  Excludes: \n\u2022 indications exclusively appropriate to \nTHMP  \u2022 design for self medication e.g. with cautios health claims \nsuch as \"symptomatic relief of... \"  \u2022 diagnostic purposes, required prescription, monitoring \ntreatment, required supervision \nof a medical practitioner, serious diseases e.g. HTV\n \n\u2022 specified strength and posology  \u2022 aqueous extract instead of tea \n\u2022 exact/comparable concentration \n\u2022 same or reduced number of ingredients in combinations \n \u2022 tablets instead of tincture \n\u2022 not comparable concentration \n\u2022 replacement of ingredients in \ncombinations \n \n\u2022 for oral, external or inhalation use only  \u2022 tablets, ointments, tinctures etc. \n\u2022 comparable non-traditional m odern dosage forms such as \nsprays \u2022 intravenous, intramuscular \n\u2022 non-comparable non- \ntraditional modern dosage forms \nsuch as sprays \n\u2022 sufficient data on the traditional use \n\u2022 minimum 30 years traditional use, \nincluding at least 15 within the EU \u2022 case by case \n\u2022 geogr. non-European but politically European areas such as \nFrench Guyana \n\u2022 all new EU member states \u2022 case by case \n\u2022 when less than 30/15 years \n(but other conditions can apply \n= HMPC but not National \ndecision) \n\u2022 prove not to be harmful in the \nspecified conditions  \u2022 in general given with tradit ional use and expert statement  \u2022 new data situation indicating \nrisks \n\u2022 genotoxicity/cancerogenicity \nnot excluded by traditional use \n \nCuadro 1:  recommended websites for further inform ation on European regulatory affaires. \n \nhttp://www.mhra.gov.uk   \nhttp://www.agemed.es   \nhttp://www.bfarm.de   \nhttp://ec.europa.eu/enterpri se/pharmaceuticals/eudralex/http://www.hma.eu   \nhttp://www.emea.eu.int   \nhttp://www.who.int   \nhttp://www.efpia.orghttp://www.ifpma.org   \nhttp://www.ich.org   \nhttp://www.phrma.org   \nhttp://www.escop.com\n  The Traditional Herbal Medicines European Directive Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 110  2001/83/EC. A simplified registration procedure for \nthose products placed on the market without therapeutic indications is specifically envisaged by \nArticle 14(1) of Directive 2001/83/EC as amended. \nA homoeopathic MP is according to Directive \n2004/27/EC (amendment to 2001/83/EC) newly \ndefined as: \u201cAny medicinal product prepared from substances called homeopathic stocks in accordance with a homeopathic manufacturing procedure \ndescribed by the European Pharmacopoeia or, in the \nabsence thereof, by the pharmacopoeias currently \nused officially in the MS. A homeopathic medicinal product may contain a number of principles.\u201d These may include non-herbal starting materials, which are \nnot yet considered for the traditional use directive. \nThe homeopathic registration scheme is also a simplified regulatory procedure, whereby products \nare assessed for their quality and safety. The \nsimplified scheme does not allow indications or \ntherapeutic claims. Thus, efficacy data are not \nrequired. Often registration under the scheme is compulsory only in respect of products new to national markets. In order to qualify for registration under the simplified procedure, the products must be for oral or external use. This includes all methods of \nadministration with the exception of injections. In \ngeneral homoeopathic MP must be sufficiently dilute to guarantee their safety. \nOf course companies also have the option of \nobtaining a full marketing authorisation for \nhomoeopathic remedies, provided that the regulatory \nrequirements for safety and efficacy can be satisfied. When a \u201ctraditionally used\u201d homoeopathic stock of plant origin (practically ethanolic extract or tincture) without further dilution is used, in some cases the \nmanufacturer may have the decision between \nsimplified regulation under the traditional use or the \nhomoeopathic category, which in general are \nexempted to each other (see above). In both cases, no efficacy data have to accompany quality (including shelf life tests) and safety data. Differences in \nlabelling and marketing ( no indication and health \nclaims for homoeopathic products), existing \nmonographs and listing and the data situation to \nsupport the WEU will contribute considerably to the manufacturers case by case choice of the appropriate regulatory strategy. \nComparable to allopathic herbal medicine the \nregulation of homeopathic products is predominantly \ncharacterized by National traditions and rules. In UK for instances the Advisory Board on the Registration of Homeopathic Products (ABRHP) gives advice in respect of which a certificate of registration could be granted. However, the European harmonisation process is on track and various European \norganisations will find each other under the umbrella \nof the Homeopathic Medicinal Product Working Group (HMPWG), which informal meetings first started in 1999. The participants of HMPWG are assessors and regulatory experts from the National Competent Authorities, as well as representatives \nfrom the EC, Ph Eur, EMEA and WHO. The group \nwas formalised by the Head s of Medicines Agencies \n(HMA) in 2004. The HMPWG is a forum of \nexchange of regulatory and scientific expertise as \nwell as elaboration and provision of guidance to \nassessors and applicants and expertise and advice on \nrequest regarding procedural, regulatory and scientific issues arising from the MRP/DCP. It was started because there was a clear need for a European solution for the regulation of homeopathic MP due to \nthe particular characteristics of this therapeutic \nsystem. \n6. HERBAL PRODUCTS OUTSIDE MEDICINE LEGISLATION \nThe traditional use directive is most \ncontroversially discussed in European countries were \nthe majority of HP were classified as food \nsupplements, which facilitated market access without provision of detailed quality and safety data. Herbal remedies equally to minera ls or vitamins have a \nclassical \u201cdual-use\u201d \u2013 character, where nutrition/diet \npurposes are paralleled by health promoting/ \ntherapeutic purposes. The classification a herbal product in the borderline is  still dominantly national \ndecision according to case by case studies based on law and tradition. But similarly to the Traditional Use Directive, the market of the single member states will \nbe influenced by the pan-European food legislation in \nthe future. The \u201cgeneral opinion\u201d will consider the \npossible risk, the pharmacological characteristic due to current scientific knowledge, the degree to which the consumer is familiar with the product and the way \nin which the product is used. For many manufacturers \nof herbal products, it is getting more and more important to deal with the legal differentiation between medicine and food (respective cosmetics) which includes questions like: \n\u2022 Which constituents are legal in food or \ncosmetics? \n\u2022 Do they have any phamacological effect? \n\u2022 Are there concentration limits? The Traditional Herbal Medicines European Directive Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 111  \u2022 Which effects has the demarcation on \nadvertisement, labelling and marketing? \n\u2022 Is there already binding harmonised European law or are national niches still feasible? \n\u2022 Which nutrition declarations have to be stated on package and leaflet? \n\u2022 How to deal with health claims? \nStep by step the EU will also harmonise the food \nlaw in terms of food supplements and their safety. A first definition of foodstuffs has been introduced with regulation 178/2002/EC for a harmonised demarcation between foodstuffs and medicinal \nproducts. Directive 2002/46/EC contains a definition \nfor food supplements for the first time. Primarily there were no maximum/ minimum levels for \nnutrients and/or substances with nutritional effect; which are important for drawing the borderline \nbetween food supplements and medicinal products. \nFurthermore, the directive covers only vitamins and \nminerals. In the near future, however, the directive \ncould substantially limit the potency of nutrients in \nsuch products by reducing maximum permitted levels. And it may be applied to other nutrient groups \nsuch as fatty acids, amino acids, fibre, and plant \nextracts. It became fully implemented on August 2005, but further demarcation activities are also expected by EFSA (European Food Safety Authority), EMEA and the EC. A helpful overview \non current European food legislation in terms of \nherbal products is given by Gulati & Ottaway (2006).  \n7 CONCLUSIONS \nThe manufacturer of a herbal medicinal product \nhas now five main regulatory pathways for marketing in Europe. Within medicine law a full application, a \nwell established use application or simplified \nregistration as either traditional herbal medicinal product or as homoeopathic medicinal product are possible. The food supplements pathway will remain, but is likely to be further restricted. At least until \n2011 old national regulatory pathways will linger. In \ngeneral, the national procedure dominates clearly, however the number of European procedures in \nparticular the mutual recognition (MRP) is expected \nto increase also for HP as soon as advantages for \nmarketing in various member states is less inhibited \nby uncertainties of the new administrative trail. The \ndirective 2004/24/EC for THMP is put to test in all member states and the solution of practical issues specifically associated with the transfer from old to new registrations a challenge to all national regulatory bodies and the EMEA/HMPC. A market clarification and increased safety level can be expected, however manufacturer and product \ndiversity may be diminished. \n8 REFERENCES \nBarnes J. 2003. Quality, efficacy and safety of \ncomplementary medicines: Fashions, facts and the \nfuture. Part I. Regulation and quality. British J. Clin. \nPharmacol.  55(3):226-233. \nBenzi G, Ceci A. 1997. Herbal Medicines in European \nRegulation. Pharmacol. Res. 35:355-362. \nErnst E. 2002. Toxic heavy metals and undeclared drugs in \nAsian herbal medicines. Trends Pharmacol. Sci. ; 23: \n136-139. \nGruenwald J, Skrabal J. 2003. Kava ban highly \nquestionable: a brief summary of the main scientific findings presented in the \"in depth investigation on \nEU member states market restrictions on kava products\". Seminars Integrative Med.  1:199-210. \nGulati OP, Berry Ottaway P. 2 006. Legislation relating to \nnutraceuticals in the European Union with a particular \nfocus on botanical-sourced products. Toxicol. ; 221:75-\n87. \nElvin-Lewis M. 2005. Safety Issues Associated with \nHerbal Ingredients. In Steve LT (Ed): Advances in \nFood and Nutrition Research, Vol.50. Academic Press, pp 219-313. \nKrisper J. 2007. Registration of THMP - Austrian \nApproach and Experience. Conference documentation: The New Regulatory Framework for \nHerbal Medicinal Products 2nd Annual Summit \nINFORMA, Vienna, Austria, 27-28 June. \nNortier JL, Vanherweghem JL. 2002. Renal interstitial \nfibrosis and urothelial carcinoma associated with the use of a Chinese herb ( Aristolochia fangchi ). Toxicol . \n181-182: 577-580. \nRoether B. 2006. How to Re gister Herbal Medicinal \nProducts in the European Union. Oral presentation at the 3rd ECA conference Quality aspects of Herbal \nMedicinal Products in Europe. Nov. \nSingh YN. Potential for interaction of kava and St. John's \nwort with drugs. Journal of Ethnopharmacology 2005; \n(100): 108-113. \nStickel F, Baumuller H M, Seitz K, Vasilakis D, Seitz G, \nSeitz H K, Schuppan D. 2003. Hepatitis induced by Kava ( Piper methysticum rhizoma ). J. Hepatol.  39:62-\n67. \nWoodfield R. 2007. MHRA's early experience of operating \nthe traditional herbal registration scheme in the UK. Conference documentation: The New Regulatory \nFramework for Herbal Medicinal Products 2nd \nAnnual Summit, INFORMA, Vienna, Austria, 27-28 June.   \n \n\u00a9 2007 Los Autores \nDerechos de Publicaci\u00f3n \u00a9 2007  Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 112 - 117 \nBLACPMA ISSN 0717 7917 \nEspecial Regulaci\u00f3n de Fitomedicinas / Sp ecial Issue on Regulation of Phytomedicines \nThe Impact of the European Tradit ional Use Directive on the Herbal \nProduct Markets in the United Kingdom, Germany and Spain  \n[El impacto de la Directiva Europea de  Uso Tradicional en los mercados n acionales del Reino Unido, Alemania y \nEspa\u00f1a] \nWieland PESCHEL \nCentre for Pharmacognosy and Phytotherapy, Sc hool of Pharmacy, Un iversity of London, \n29-39 Brunswick Square, WC1N  1AX London, United Kingdom \n*Contact: wieland.pesche l@pharmacy.ac.uk\nRecibido el 13 de Abril de 2007; Aceptado el 19 de Julio de 2007 \nAbstract \nHerbal products have been regulated in different European member  states either predominantly as medicinal product, as \u201ctraditio nal\u201d \nmedicinal product, registered as food or remained unregulated. With the European Directive (2004/24/EC) for a simplified regist ration of \ntraditional products a new era of centralis ed medicinal product regulation has started also for manufacturers of herbal medicin e. The \nregulatory impact on the industry will vary between European member  states according to the respective starting point. It is li kely to be larger \nin countries, where much of the industry has been operating in a rather unregulated market. In other countries, manufacturers a re better \nprepared, because they had already to meet high quality standards,  GMP requirements, or pharmacovigilance procedures. This paper \nsummarises the current situation in three Eu ropean member states with different hist ory of herbal medicinal product regulation.  The examples \nof UK, Spain and Germany  demonstrate th e challenges of regulation and harmonisation processes for herbal products which may be  relevant \nalso for Latin American countries in the future. \nKeywords: Traditional European Medicine, herbal  medicine regulation, Spain, UK, Germany. \nResumen \nLos productos herbales han sido regulados en Europa de manera diferente, ya sea como producto medicinal, como \u201cproducto herbal \ntradicional\u201d, como suplemento a limentario o incluso dejados en un ambiente desregulado. Con la nueva Directiva Europea (2004/24 /EC) para \nel registro simplificado de productos trad icionales ha empezado una nueva era de regul aci\u00f3n de productos medicinales  para los productores \nde medicinas herbales. El impact o de esta regulaci\u00f3n en la indus tria variara entre los distinto s estados europeos de acuerdo a sus respectivos \npuntos de partida en lo que a regulaci\u00f3n na cional refiere. El impacto se r\u00e1 posiblemente mayor en pa\u00eds es donde la industria ha v enido \noperando en un mercado m\u00e1s o menos desregulado. En otros pa\u00edses, los productores estan mejor preparados ya que ven\u00edan largo tie mpo \nobligados a cumplir normas de calidad elevad as incluyendo GMPs, farmacovigilancia o ensa yos de estabilidad. Este art\u00edculo resum e la \nsituaci\u00f3n actual de tres miembros de la Uni\u00f3n Europea con diferent es historias de procedimientos para la regulaci\u00f3n y armonizac i\u00f3n de los \nproductos herbales. Los ejemplos de Espa\u00f1a, Reino Unido y Alem ania pueden ser relevantes para los pa\u00edses Latinoamericanos en el  futuro. \nPalabras clave: Medicinas Tradicinales Europeas, regulaci\u00f3n de me dicamentos herbales, Espa\u00f1a, Reino Unido, Alemania. \n \nList of Abbreviations: \nAGEMED Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios  (Spain) \nEC European Commission \nHMP Herbal Medicinal Product(s) \nMA Marketing Authorisation \n \nMHRA Medicines and Healthcare Pr oducts Regulatory Agency (UK) \nMP Medicinal Product(s) \nTHMP Traditional Herbal Medicinal Product \nWEU Well Established Use   Websites used: \nhttp://www.mhra.gov.uk    \nhttp://www.agemed.es   \nhttp://www.bfarm.de   \nhttp://ec.europa.eu/enterprise /pharmaceuticals/eudralex/   \nhttp://www.hma.eu/   \nhttp://www.emea.eu.int   \nhttp://www.efsa.europa.eu   \nhttp://europa.eu/rapid/pressReleases Action.do?reference=IP/07/403&for\nmat=HTML&aged=1&langua ge=EN&guiLanguage=en   \n The Impact of the European Traditional Use Directive on UK, Germany and Spain  Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 113 1 FROM AN UNREGULATED TO A \nREGULATED ENVIRONMENT \u2013 THE NEW CHALLENGE IN UK \nBefore implementation of the European \nTraditional Use Directive 2004/24/EC herbal products (HP) reached the UK market usually by three different routes: (1) as a fully licensed medicine, (2) as from a full licence exempted herbal remedy (so called section 12( 2) exempts), or (3) as \nfood supplement. (1) A marketing authorisation (MA) can be obtained under the Medicines for Human Use Regulations 1994 (SI 3144/1994) which largely transposed Directive 2001/83/EC into UK law. Under the Regulati ons most industrially \nproduced MP that are placed on the market are required to be authorised demonstrating standards of \nquality, safety and efficacy. This full MA pathway \nincluding simplified bibliographic applications was practically irrelevant for HP. \n(2) Section 12(2) of the Medicines Act 1968 (and \nregulation 1(3) of the 1994 Regulations) exempted herbal remedies that are not required to have a MA providing the remedy meets various conditions. Certain ingredients are prohibited or restricted, but otherwise there are no specific requirements as to \nsafety, quality or efficacy. No written claims are \npermitted and there is no specific requirement in terms of consumer information and safe usage. The original idea was to facilit ate HMP market access for \nherbal practitioners to make up herbal remedies \nwithout license on the premises from which they are \nsupplied and to prescribe such remedies for an \nindividual patient following a one-to-one \nconsultation. Unfortunately this pathway has converted over the years into an easy market access also for industrially produced remedies (tablets, \ncapsules etc.) in large scale. \n(3) HP were often licensed as food supplement, \nwhich was uncomplicated \u201cif the safe food use can be \ndemonstrated for a herb\u201d. It also allowed health maintenance claims, but no claims to treat, cure, or \nprevent a clinical condition. This health maintenance \nclaim must be substantiated, if requested by Trading Standard Officers or the Advertising Standards Authority. A typical health claim is: \u201cMay help to maintain a healthy digestion\u201d. However, neither demonstration of safe use nor the rational for health \nclaims required pre-marketing activity by \nmanufacturers. Some herbs were excluded if they are \ndefined by the MHRA as \u201cmedicinal by function\u201d such as Hypericum , Echinacea , Valeriana  or \nCimicifuga. \nBecause of missing quality standards and a lacking \npharmacovigilance system, the categories (2) and (3) \nare the predestined trouble maker and responsible for major safety concerns. Colonial history and ongoing multiple immigration formed a market particularly vulnerable to \u201cnon-regulation\u201d. The extensive international trade in unlicensed HP lead to various \ncases of substitution, contamination or adulteration, \ne.g. with undeclared prescription-only-drugs, poisons, or mislabelling. For example, in December 2004 the MHRA confiscated a consignment of 90,000 tablets containing a toxic ingredient, and in \n2003 the MHRA found that a product containing \n11.7% mercury by weight was available in 35 \ntraditional Chinese medicine outlets. But not only \nrisk to public health and public confidence, but also a risk to responsible bus inesses was stated by \nauthorities: Manufacturers working under high quality standards have complained to the MHRA that they are undercut on price by those who formulate their products with low grade ingredients inadequately tested in terms of identity and purity (MHRA website; Anderson, 2007).Directive \n2004/24/EC has been fully implemented by the \nBritish authorities and provides a new fourth category, by now mostly as transitional protection for products on the market before 30/04/2004. Already 5 products have been newly licensed under this \ncategory so far. However, many of the old Section \n12(2) products will automatically fall under the traditional use category and reap the benefit of the long transitional period until 30/04/2011. By then, all THMP requirements have to be fulfilled otherwise the product has to be withdrawn from the market. \nThe extraordinary new requirements for the \nBritish food industry lead to a costs and benefit calculation by the MHRA. Several tens thousands of pounds are the additional costs associated with registering a product under the Directive as compared \nwith the cost for an unli censed herbal remedy placed \non the largely unregulated market. This will vary \naccording to the nature of the product and the circumstances of the individual company. Size may be relevant, for example, micro and small companies may be insufficiently equipped to carry out certain \nactivities in-house and may need to buy in help. On \nthe other hand, a medium sized or larger company \nthat wishes to enter a number of European markets \nmay well decide it is worth having state of the art dossiers and quality controls in order to minimise the The Impact of the European Traditional Use Directive on UK, Germany and Spain  Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 114 risk of delay arising from queries from the various \nregulatory authorities. If by 2011 around 500 products had been register ed incurring various costs \nrelating to registration at an average of \u00a340,000 per registration, and if about 50% of the registrations related to UK companies, this would represent a cost to UK companies of about \u00a310m spread over 6 years for bringing these products into regulation. This does not include some additional expenditure, notably in \npremises or equipment improvement, that some \ncompanies have recognised were needed in the \ninterests of good standards (Anderson, 2007; Barnes, \n2003; Helliwell, 2007; Mills, 2006; Woodfield, 2007, MHRA website) \n2 NEW BORDERLINES \u2013 THE DEVELOPMENT IN GERMANY \nCompared to the UK, the new European directive \nis of minor impact for regulators, customers and manufacturers in Germany because of four reasons: \n(1) HP with health claims have been traditionally \ntreated as MP with similar quality and safety standards, (2) several monographs originating from the commission E of the former BGA (Federal Health Authority) facilitated already a \u201cwell established use\u201d bibliographic application before ESCOP or WHO \nprovided similar core-data, (3) a comparable \nparagraph for traditional use remedies has been created with the 5th amendment of German drug law (5. AMG-Novelle, 1994) after a long cleaning \nprocess of the pharmaceutical market, and (4) HMP \nwere produced by small and medium pharmaceutical \nenterprises, which were working under pharma-specific production/documentation standards including control/inspection by regional, federal and international authorities. \nThe acceptance of traditi onal use as prove for \nquality and safety (point 3) is a transitional regulation only, caused by major delays in the revalidation of all German products on the market (\u00a7105 AMG together with \u00a7109a). Traditional MP, which were on the market before 1978, got a provisional MA until the \npost-marketing procedure has been completed. New \nproducts couldn\u2019t get the \u201ctraditional status\u201d, even if they were traditionally used. This refers not only to herbal MP, but also to any other \u201ctraditional\u201d remedies. Because of its specific history Germany \nimplemented as the first MS the Directive   \n \nTable 1. General overview on types of applications and market \nsize for HMP in Germany (BfArM 2005)  \nFull Marketing \nauthorisation \nprocedure \naccording \u00a7\u00a7 21,22 AMG Requirements as for all non herbal \nMP according \u00a7 22 \nff. and AM-Pruef-RL. (Annex I RL \n2001/83) \nMostly based on well established \nuse according monographs of the \nformer \ncommission E In total 4551 herbal, \ntraditional, \nhomeopathic or anthroposopic \nmedicinal \nproducts are \nlicensed (Dec \n2005) \nRegistration as Traditionally \nused according \n\u00a7109a AMG (implementation \nof 2004/24/EC) \n Simplified \nprocedure \ndeveloped for a \ntransitional period due to German \nretarded \nrevalidation procedure in \naccordance with \u00a7 \n105 AMG in conjunction with \u00a7 \n109a AMG, valid \nfor traditional MP \nwhich were on the \nmarket before \n1978 (not for \nherbals only!), 1050 traditional \nmedicinal \nproducts with \ncompleted post-marketing \napproval \nprocedure are available on the \nGerman \nmarket(Dec \n2005) \nRegistration as \nTraditionally used according \n\u00a739a AMG \n As Implementation \nof 2004/24/EC recent amendment \nto the 14th Version \nof the German drug law (AMG) 5 (April 2007) \nRegistration as \nhomoeopathic \nproduct according \u00a738-39 \nAMG \n Simplified registration \nprocedure already established, only \nslightly changed \naccording European \nguidelines 3730 homeopathic \nmedicinal products are \nregistered (Dec \n2005) \n \nNotification under food or cosmetic law \n LMBG, \u00a7 5 of NemV No statistics available \n \n \n \n The Impact of the European Traditional Use Directive on UK, Germany and Spain  Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 115 2004/24/EC into national law (\u00a7 39a \u2013 39d AMG), \nwhich applies since September 2005. Now, traditional remedies have access to the market as \n\u201cnew products\u201d, if they are comparable to \npreparations which fulfil 30 years traditional use (15 years thereof in Europe). This European traditional HMP will replace in the long term the above mentioned transitional regulation of \u00a7105 in combination with \u00a7109a for \u201cnational traditional \nMP\u201d. By now , 2004/24/EC and 39a AMG refer to \nherbal products only, but in future the extension to \ntraditional remedies of animal, mineral or synthetic \norigin can be expected. \nAs in other countries, Germany had already a \nlevelled 3 class system (full MA, WEU, traditional MP) for herbals under medicine law. For historical and market size reasons it may have influenced the European process noticeably (Table 1). But there exist also some specific exemptions such as \n\u201cStandardzulassungen\u201d (s pecialities), which are \nstandard market authorisations without need for a \nsingle case MA procedure (German peculiarity of common/traditional remedies, \u00a736 AMG). These standard preparations can be e.g. non-industrially produced (licensing for the manufacturer not \nnecessary etc.) and sold outside pharmacies as for \ninstance drug stores or supermarkets. Also \nhomeopathic remedies ha d already a simplified \nregistration procedure (\u00a738-39 AMG). The new \ntraditional use category might establish another \noption for homeopathic manufacturers, provided that \nthe product is obviously more than 30 years on the market and health claims may strengthen the market position. \nLast but not least exists a large variety of food \nsupplements containing mixtures of vitamins, \nminerals etc. plus herbal substances, which fall under \na less restrictive food law (LMBG). This means that only notification at the Federal Institute for Consumer Protection and Food Safety (Bundesamt f\u00fcr Verbraucherschutz und Lebensmittelsicherheit, \nBVL) including submission of sample and mock-ups is required but no registration or marketing authorisation (\u00a7 5 of Verordnung \u00fcber Nahrungserg\u00e4nzungsmittel = NemV). Often \nvitamins/minerals get a dummy function in order to \navoid the regulatory burden of pharmaceutical law. \nFood supplements which contain the same \ningredients in similar or lower concentrations of HMP reach frequently the market. Consequently, pharmaceutical SMEs -facing competition by cheap uncontrolled products- support the work of authorities to observe the market. Manufacturers and wholesalers of food supplements are often challenged legally and have to justify the priority of food over \nmedicine. Hence, the market control is partly \nperformed by self-regulating forces with considerable impact of regional courts. This competition between highly regulated expensive HMP and low regulated cheap food supplement has been increased, since herbal medicine, apart from very few exemptions, are \nnot any longer reimbursed by health insurances. \nFurthermore the high price sale of HMP via pharmacies is increasingly challenged by drugstores, supermarkets and the internet market. \nNevertheless it will be likely interesting for \nmanufacturers to access the market with \u201cEuropean traditionals\u201d as an alternative to well-established-use bibliographic procedures. The justification of the traditional use in Europe will be in some cases easier than the reference to consolidated monographs or \ngeneration of own data, specifically when deviating \nfrom WEU monograph standards. However, it may also happen that a product -listed according to the national \u00a7109a- has been sold for more than 30 years,  but changes of compounds or increase of concentrations for instance would exclude the \nautomatic transfer to an European THMP. In \nsummary, the new borderline between WEU \n(German/European) and THMP and the transitional \nborderline between \u201cGerman traditional\u201d and \u201cEuropean traditional\u201d product with differing \nconditions is the prominent concern for the small and \nmedium phytopharmaceutical industry. Product history and existing data, as well as toxicity potential and market strategy including heath claims and distribution paths will determine the regulatory strategy case by case (Roether, 2006; BfArM \nwebsite).  \n3 THE PROBLEMATIC DEAL WITH OLD \nLICENSING CATEGORIES \u2013 THE TRANSITION IN SPAIN \nSpain represents countries with a complicated \nsituation, although \u201cherbals\u201d are treated formally in two categories: either as \u201creal MP\u201d with all MA requirements but also HP specific bibliographic applications or, the traditional ones, with less quality, safety and efficacy standards. The first mentioned is practically fractional in comparison to the amount of \ntraditional HMP based on several exemption \npathways. The Impact of the European Traditional Use Directive on UK, Germany and Spain  Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 116 Basically, herbal products (defined in Article 42, \nparagraph 1 of the Spanish Medicines Law 25/1990) \nwith a particular therapeutic/pharmaceutical activity \nare considered as MP as defined in Article 8.1. of \n25/1990. Therefore manufacturing, distribution and sale of these products must follow the same pharmaceutical rules as any other MP. Pharmacological, toxicological and clinical studies may be in principle replaced by bibliographic \ndocumentation for non-prescription MP. These so \ncalled E.F.P. products (Especialidad Farmac\u00e9utica \nPublicitaria) according to the Ministerial order of \n17/09/1982 are extract-based HP which are transferred now into the European WEU category. \nAdditionally, article 42, paragraph 3 of 25/1990 \nmention \u201ctraditional plants considered as medicinal\u201d, but it refers just to the sale (freely but not ambulant) not restricted to pharmacies when no therapeutic claims are made, but without a clear definition or \nlisting. This Law also distinguishes between Herbal \nMedicinal Products and \u201cPhytotraditional Medicinal Products\u201d in Title X article 117 (fees for MA), again without giving definitions or listings. \nPreparations consisting solely of one or more \nmedicinal plants or parts of plants in a cut or \npowdered state must be included in the Special \nRegister of Medicinal Plants of the AGEMED established in the Ministerial Order of 03/10/1973 and usually referred to as P.M. products (planta medicinal). Similarly to E.F.P. also P.M. products are \ncharacterised by quality documentation, bibliographic \nsafety/efficacy data, exclusive sale in pharmacies and possible health claims. \nExempted from this are those preparations that \ncontain just one species and included in the Annex of the this Ministerial Order of 03/10/1973 (without \nindications): \u201cmedicinal plants and their preparations \n(as single species) without an indication claim that \nare included in an Annex, do not need to register and no indication claim may be made.\u201d In this case, it is sufficient with an administrative notification \nfollowing the terms of the Royal Decree 3176/1983. \nThe 1973 annex of 110 plants has been officially updated only once in 1976. But it was possible to apply for the inclusion of medicinal plants or its parts. This has been happening without official \npublication throughout the years containing now \naround 170 species. \nIn addition, with the order SCO/190/2004 a \nnegative list amends the Annex with toxic plants \nwhose sale to the public is prohibited or restricted. Acute specific risks associated with some herbs are also addressed by  public statements (mensajes publicitarios). A regulation for industrially produced homeopathic compounds exists with the \nRoyal \nDecree 2208/1994.  \nOutside medicine law With the Royal Decree of \n16/11/1983 (Regulation on manufacturing and trade of 23 vegetal species of use in food) the registration of the most common herbal teas has been located under responsibility of the Ministry of Agriculture, \ni.e. outside medicine law. Unfortunately the majority \nof these 23 plants are also  included in the described \nlist of herbal species for medicinal use under AGEMED responsibility.  There is no clear demarcation between foodstuff and medicine which \nshould be determined in each case by the intention of \nuse. Apart from that, food supplements were \ntraditionally not defined in the Spanish law and could \ntherefore not compete with (traditional) HP of other \ncategories. First regulation started with the EU \ndirectives in the 90s. Whereas E.F.P. and P.M. \nproducts and all other listed species reap the benefits \nof graded but relatively low market barriers, other herbal products of non-listed species are per se considered as pharmaceuticals with the elaborative authorisation procedure. Plant extracts containing \nproducts , such as guaran\u00e1, ginseng, or passiflora, \nwhich are legally marketed as food supplements in other MS, could however not be imported into Spain. Already imported supplements are frequently withdrawn from the national market. This has lead to \ncomplaints from importing food supplement \ncompanies and formal legal action. In March 2007 the European Commission has even decided, to take Spain to the European Court of Justice for its systematic barrier for the import plant based products from other MS as it is infringing the current rules of \nthe free movement of goods in the internal market. \nThe EC states that the Spanish restrictive \ninterpretation of the relevant law goes beyond what is \nnecessary in terms of public health. (European Commission, 2007) \nSummarising, it can be stated that the HP \nlegislation in Spain -as historically developed- generated a series of categories in order to reflect the practical use and associated necessary quality/safety standards. However, due to partial overlapping of these categories and lacking modernisation of the law \nit is somewhat orphaned and will face a radical \nchange by EU legislation. Although 2004/24/EC will offer a new host for Spanish traditional HP, a major issue for re-classification is that HP, which are considered as medicine, can be distributed only via The Impact of the European Traditional Use Directive on UK, Germany and Spain  Peschel \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 117 pharmacies. In 2004 around 15 manufacturers \nproduced around 300 HMP reaching the market via 20.000 pharmacies. In contrast around 200 small \nmanufacturers of around 4000 HP sold via 3800 \nherbolerias. Clear demarcation avoiding duplication would leave only 250 out of 410 traded species for free sale in \u2018herboristerias\u2019. Considering the estimated HP annual turnover of 360 million Euro a political hot potato has to be touched by Spanish \nregulators which is further aggravated by pressure of \nfood supplement manufacturers of other European \nMS claiming free access to the Spanish market \n(Casero, 2003; Ricq, 2004; AGEMED, 2007). \n4 CONCLUSIONS \nThe example of UK, Germany and Spain \ndemonstrate the diversity of regulatory situation for herbal medicine at the starting point of the European harmonisation process - in particular the grey area between foodstuffs and medicine and the borderline \nbetween well established use and traditional use. The \nDirective 2004/24/EC, community monograph/listing systems and other European standards force now the national competent authorities to simplify and harmonise the herbal product market. New regulatory hurdles for herbal medicinal products are justified by \nthe safety argument and the political (and \ncommercial) goal of an unrestricted European \nmarket. The consumer/patient should benefit in long \nterm from those regulations, even if partially higher prices can be expected for mainly increased \nstandards. Primarily the major burden is put on \nnational regulators when trying to find pragmatic solutions during the adaptation process. But also manufacturers are obliged to  react soon and decide \nalready now for the right strategy within the transition period. The introduction of GMP conform \nproduction, complicated quality control of \ncombination products and stability tests with determination of quality relevant markers do not \nallow further delay in order to complete necessary documents before 2011. Ahead of moaning over \nadditional requirements it should not be forgotten, \nthat national HP will have easy market access across \nEurope, once they comply with European standards set in community list, monographs and guidelines. \nThe European harmonisation process is \nhistorically the first attempt of HMP regulation at \nmultinational scale. Subsequently a trial and error \npath will unfold issues and solutions on the way to the right balance between support for local industry, freedom of the market and consumer protection. The attentive observation \u2013 facilitated by a transparency of web based information of European and national \norganisations \u2013 may help regulators in Latin America \nand elsewhere taking decisions for their own countries or regions (e.g. Me rcosur). Furthermore any \ngrower, manufacturer or importer of herbal starting materials who envisages the European market should be familiar with the currently changing situation. \n5 REFERENCES \nAnderson L. Quality of herbal medicinal products - a UK \nregulatory perspective. Proceedings Traditional \nHerbal Medicine Symposium, London 2007. \nBarnes J. 2003. Quality, efficacy and safety of \ncomplementary medicines: Fashions, facts and the future. Part I. Regulation and quality. British J. Clin. \nPharmacol.  55(3): 226-233. \nBast A, Chandler R F, Choy P C, Delmulle L M, \nGruenwald J, Halkes S B A, Keller K, Koeman J H, \nPeters P, Przyrembel H. 2002. Botanical health products, positioning and requirements for effective \nand safe use.  Environ. Toxicol. Pharmacol.  12: 195-\n211. \nBenzi G, Ceci A. 1997. Herbal Medicines in European \nRegulation. Pharmacol. Res. 35: 355-362. \nEuropean Commission. 2007. European Commission \nrefers Spain to European court for ban on import of herbal products. Europa Press Room, Brussels, March \n23. \nHelliwell K. 2007. Good manufacturing practice - \nChallenges for the herbal in dustry. Oral presentation \nat the Symposium Traditional Herbal Medicines. \nLondon, School of Pharmacy, London, February. \nMills S. Monitoring herbal safety: Current debate and \nresources: Symposium report: Pharmacovigilance of herbal medicines: Current st ate and future direction, \nLondon, 24-26 April 2006. Phytomedicine  (In Press, \nCorrected Proof). \nRicq O. Will the new legislation really be helpful for the \nSpanish market?  AENFP/AESGP Herbal committee \npresentation 2004.  \nRoether B. 2006. How to Re gister Herbal Medicinal \nProducts in the European Union. Oral presentation at \nthe 3rd ECA conference Quality aspects of Herbal \nMedicinal Products in Europe. Nov. \nVidal Casero C. 2003. El De sarrollo De La Legislacion \nSobre Plantas Medicinales En La Comunidad Europea y su Incorporaci\u00f3n  en el Ordenamiento Juridico \nEspa\u00f1ol. Su Problem\u00e1tica. Derecho y Salud 11: 85-\n107. \nWoodfield R. 2007. MHRA's early experience of operating \nthe traditional herbal registration scheme in the UK. Conference documentation: The New Regulatory \nFramework for Herbal Medicinal Products 2nd Annual Summit. INFORMA, Vienna, Austria, June.  \n \n\u00a9 2007 Los Autores \nDerechos de Publicaci\u00f3n \u00a9 2007  Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 118 - 124 \nBLACPMA ISSN 0717 7917 \nEspecial Regulaci\u00f3n de Fitomedicinas / Sp ecial Issue on Regulation of Phytomedicines \n Antecedentes y situaci\u00f3n reguladora de la medicina herbaria en Cuba \n[Antecedents and current situation of the regulation of herbal medicines in Cuba] \nMaritza GONZ\u00c1LEZ RAM\u00cdREZ, Diadelis REMIREZ, Olga Lidia JACOBO \nCentro Estatal para el Control de la Calidad de los Medicame ntos (CECMED). Calle 200 No. 1706 e/ 17 y 19, Rpto. Siboney, Playa, Ciudad de La Habana. Cuba CP 11600\n*Contacto: maritzag@cecmed.sld.cu ; Apdo. Postal 16065 Telf. (+537) 2718645, 2718622. \nRecibido el 13 de Abril de 2007; Aceptado el 19 de Julio de 2007 \nAbstract \nVery few plant species have been studied fo r medical purposes and we have data about their safety a nd efficacy only for an even  smaller \nnumber of them. Most countries don\u2019t have a legal framework for the control of herbal medicines, and they adopted different foc uses in the \nauthorization and commercialization of gerbil medicines. Cuba ha s a long tradition of use of medi cinal plants since the Spanish  colonisation \nand Traditional Medicine is both recognized and integrated in its National System of Health in the 1990. The State Centre for t he Quality \nControl of Drugs (CECMED) as Regulatory Authority of Drugs of C uba has the task of both and establishing the framework to assure the \nquality, the security and the efficacy of the herbal medicines by implementing the necessary policies. It also identifies futur e needs and \nanticipates solutions to address these regulatory issues. \nKeywords: Cuba, herbal medicines, regulatory affairs. \nResumen \nMuy pocas especies de plantas se han est udiado con prop\u00f3sitos m\u00e9dicos y un n\u00famero menor de ellas tienen estudios realizados sob re su \nseguridad y eficacia. La mayor\u00eda de los pa\u00edses no cuentan con un marco legal para el control de los medicamentos herbarios, ado pt\u00e1ndose \ndiversos enfoques en la autorizaci\u00f3n y comercializaci\u00f3n de los mi smos. Cuba tiene una tradici\u00f3n de uso de las plantas medicinal es desde la \n\u00e9poca de la colonia espa\u00f1ola y reconoce la Medicina Tradicional en  su Sistema Nacional de Salud en  el a\u00f1o 1990. El Centro Estatal para el \nControl de la Calidad de los Medicamentos (CECMED) como Autori dad Reguladora de Medicamentos de Cuba establece nuevas pol\u00edticas  y \nel marco legal para asegurar la calidad, la seguridad y la efic acia de los medicamentos herbarios e identifica nuevas proyeccio nes referidas en \neste trabajo. \nPalabras clave: Cuba, medicamentos herbarios, regulaci\u00f3n. \n \nINTRODUCCION \nDurante las \u00faltimas d\u00e9cadas la utilizaci\u00f3n de las \nplantas medicinales y productos que se originan de \nellas se han extendido en el mundo y han ganado una \ngran popularidad, sin embargo, muy pocas especies y productos se han estudiado con fines m\u00e9dicos y un \nn\u00famero menor cuenta con estudios realizados sobre su \nseguridad, eficacia y calidad (C\u00e1ceres, 1999). Tampoco existe un marco legal sobre las plantas \nmedicinales y los medicamentos herbarios en la mayor\u00eda de los pa\u00edses, adopt\u00e1ndose diversos enfoques en la autorizaci\u00f3n y comercializaci\u00f3n de los mismos \n(OMS, 2002). Por los problemas anteriores y teniendo en cuenta \nla tradici\u00f3n hist\u00f3rica y popularidad sobre el uso de las \nplantas medicinales y medicamentos herbarios, el Centro Estatal para el Control de la Calidad de los Medicamentos (CECMED) como Autoridad Reguladora de Medicamentos de Cuba ha establecido \nnuevas pol\u00edticas y el marco legal para asegurar la \ncalidad, la seguridad y la eficacia de los mismos para proteger la salud de los consumidores. \nEl presente trabajo tiene como objetivo mostrar \nalgunos antecedentes en Cuba sobre el uso de las plantas medicinales y el trabajo realizado en el marco \nlegal para el registro y control de los medicamentos \nherbarios, as\u00ed como algunas proyecciones de trabajo. Regulaci\u00f3n de medicamentos herbales en Cuba Gonz\u00e1lez Ram\u00edrez  et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 119 DESARROLLO \nAntecedentes en Cuba. \nEn Cuba, la introducci\u00f3n de la Medicina \nTradicional comienza en el siglo XV, primero por la \ncolonia espa\u00f1ola y m\u00e1s tarde por africanos, chinos y \nyucatecas. No es hasta mediados del siglo XX que alcanza su m\u00e1xima expresi\u00f3n con el Doctor Juan Tom\u00e1s Roig, quien identifica 595 especies que eran empleadas por la poblaci\u00f3n cubana para diferentes \nusos curativos (Roig, 1945) y hace un llamado a la \ncomunidad cient\u00edfica nacional para que se estudien \ndichas plantas con el objetivo de comprobar su seguridad y eficacia, planteando adem\u00e1s la necesidad de desarrollar la industria farmac\u00e9utica nacional. \nEn los a\u00f1os 60 la investigaci\u00f3n cient\u00edfica sobre las \nplantas medicinales comienza a desarrollarse en el pa\u00eds de manera ascendente,  aunque de forma aislada \npor distintos investigadores y m\u00e1s bien con fines acad\u00e9micos. \nEn los a\u00f1os 70 se inaugura la Estaci\u00f3n \nExperimental de Plantas Medicinales \u201cJuan Tom\u00e1s Roig\u201d con el objetivo de realizar estudios completos con las plantas medicinales de Cuba, pero no fue hasta la d\u00e9cada de los 90 que se establece un Programa Nacional para el Desarrollo y la Generalizaci\u00f3n de la Medicina Tradicional y Na tural con participaci\u00f3n de \ntodas las unidades e instituciones de Atenci\u00f3n M\u00e9dica del Sistema Nacional de Salud y otras instituciones de investigaci\u00f3n y desarrollo. Posteriormente se crea el Centro Nacional de Medicina Tradicional y Natural quien tiene como funci\u00f3n establecer las bases \nmetodol\u00f3gicas necesarias para desarrollar, controlar y \nevaluar la aplicaci\u00f3n del Programa. \nEn el a\u00f1o 1989 se crea oficialmente por el \nMinisterio de Salud P\u00fablica el CECMED como Autoridad Reguladora de Medicamentos de Cuba, encargado de promover y proteger la salud p\u00fablica a \ntrav\u00e9s de un sistema regulador capaz de garantizar el \nacceso al mercado de los medicamentos con calidad, seguridad, eficacia e informaci\u00f3n veraz para su uso racional. \nEn 1996 fue instituido el Bur\u00f3 Regulatorio para la \nProtecci\u00f3n de la Salud P\u00fablica como m\u00e1xima autoridad estatal para actuar en defensa de la salud, al que se subordina el CECMED y otras entidades para conformar el \u00d3rgano Regul ador Nacional para la \nProtecci\u00f3n de la Salud. \nEn el a\u00f1o 2002 se crea el acuerdo No. 4282 del \nComit\u00e9 Ejecutivo del Consejo de Ministro que establece las disposiciones para la consolidaci\u00f3n en el pa\u00eds de las estrategias de la Medicina Tradicional. \nSituaci\u00f3n reguladora sobre medicamentos \nherbarios en Cuba. \nEl Ministerio de Salud P\u00fablica ha elaborado una \nserie de Normas Ramales sobre especificaciones \ngenerales de las drogas vegetales y sobre m\u00e9todos de ensayo y procesos tecnol\u00f3gicos de extractos fluidos y tinturas con el objetivo de guiar y orientar el trabajo de elaboraci\u00f3n y estandarizaci\u00f3n de los medicamentos \nherbarios. Se publica en el a\u00f1o 1992 una Gu\u00eda \nTerap\u00e9utica de Fitof\u00e1rmacos y Apif\u00e1rmacos sobre la base de algunas investigaciones realizadas en Cuba con plantas medicinales cubanas y sobre reportes de la literatura cient\u00edfica y monograf\u00edas farmacop\u00e9icas internacionales. En la misma se incluyen un total de \n233 formulaciones de   fitof\u00e1rmacos para uso en \ndiferentes indicaciones terap\u00e9uticas (Tabla 1) \nEn el a\u00f1o 2000, el CECMED identifica la \nnecesidad de incorporar a los productos naturales dentro de la pol\u00edtica de medicamentos, en el proceso \nnormal de registro, control, producci\u00f3n y \ncomercializaci\u00f3n, y traza estrategias para tratar los temas relacionados con la pol\u00edtica, la seguridad, la eficacia, la calidad, el acceso y el uso racional de los medicamentos herbarios, seg\u00fan las recomendaciones de la OMS. En un principio, la implementaci\u00f3n de las \nestrategias se ha basado f undamentalmente en los dos \nprimeros objetivos, a partir de los cuales, se \nproporcionar\u00e1n las bases neces arias para conseguir los \nobjetivos de acceso y uso racional. \nUno de los aspectos m\u00e1s im portantes para asegurar \nla calidad, la seguridad y la eficacia de los \nmedicamentos herbarios lo constituye el registro y control de los mismos. En el a\u00f1o 2002 se establecen por el CECMED los Requisitos para el registro de los medicamentos herbarios (CECMED, 2002) y como parte de la regulaci\u00f3n 16/2006 \u201cDirectrices sobre \nBuenas Pr\u00e1cticas de Fabricaci\u00f3n de Producto \nFarmac\u00e9utico\u201d, el anexo No. 3 de Buenas Pr\u00e1cticas de Medicamentos Herbarios. \nEl Registro de Medicamentos de Origen Natural de \nuso humano en la Rep\u00fablica de Cuba, tiene una \nvigencia de 5 a\u00f1os, al igual que la Renovaci\u00f3n que \npodr\u00e1 ser solicitada por per\u00edodos iguales y sucesivos \n90 d\u00edas antes del vencimiento del Registro. En caso de modificaciones, el Titular del Registro o fabricante del producto tiene la obligaci\u00f3n de solicitar la aprobaci\u00f3n \nde las modificaciones dentro del per\u00edodo de vigencia \ndel Registro del medicamento. Regulaci\u00f3n de medicamentos herbales en Cuba Gonz\u00e1lez Ram\u00edrez  et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 120 La estructura de los requisitos para el registro de \nlos medicamentos herbarios es la siguiente: \n \na) Informaciones generales:  Incluye informaci\u00f3n \ngeneral sobre las solicitudes de tr\u00e1mites, los \nproductos que ser\u00e1n o no objeto de inscripci\u00f3n y las categor\u00edas (A, B y C) establecidas para estos productos. \nCuadro 1:  Categor\u00edas de los medicamentos de origen natural en la \nlegislaci\u00f3n cubana. \n \nA Medicamentos Herbarios Nuevos y \nMedicamentos Herbarios Tradicionales con \nuna nueva v\u00eda de administraci\u00f3n y/o \nindicaci\u00f3n , respaldados por estudios \nfarmacol\u00f3gicos, toxicol\u00f3gicos y cl\u00ednicos \ncontrolados. \nB Medicamentos Herbarios Tradicionales  \nrespaldados por estudios farmacol\u00f3gicos y \ntoxicol\u00f3gicos y por algunos estudios cl\u00ednicos \nrealizados (estudios de cohorte, estudios de \nutilizaci\u00f3n, caso control, series de casos y \npublicaciones indexadas). \nC Medicamentos Herbarios Tradicionales  \nrespaldados por informaci\u00f3n etnom\u00e9dica y \netnoalimentaria del lugar de procedencia del \nmaterial vegetal, por documentaci\u00f3n \ntecnocient\u00edfica y por estudios de toxicidad \naguda. \n \n \nb) T\u00e9rminos y Definiciones:  Incluye los t\u00e9rminos y \ndefiniciones adoptados por el CECMED en este campo, que permiten una mejor comprensi\u00f3n del tema. \n \nc) Documentaci\u00f3n de solicitudes de tr\u00e1mites:  Este \ncap\u00edtulo incluye las cuatro  partes que forman la \ndocumentaci\u00f3n del expediente del medicamento, relacionadas a continuaci\u00f3n:  \n\u2022 PARTE 1. Informaci\u00f3n administrativa. \nIncluye los datos generales del solicitante y \nfabricante, una informaci\u00f3n general del producto terminado, as\u00ed como las muestras a incluir del \nproducto terminado, sustancias de referencia, \nmaterial de envase y material informativo del producto que se desee promocionar.   \n\u2022 PARTE II. Informaci\u00f3n  Qu\u00edmico-Farmac\u00e9utica \ny Biol\u00f3gica. Se presentan todos los aspectos relacionados con la \ncalidad del producto.  \n\u2022 PARTE III. Informaci\u00f3n Precl\u00ednica. \nIncluye los aspectos relacionados con la  toxicidad \ndel producto y las propiedades farmacol\u00f3gicas comprobadas. \n\u2022 PARTE IV. Informaci\u00f3n Cl\u00ednica. \nIncluye los aspectos relacionados con los estudios cl\u00ednicos, para demostrar la eficacia, incluyendo los datos cl\u00ednicos y biol\u00f3gicos m\u00e1s significativos para \nel establecimiento de la seguridad, para la \nindicaci\u00f3n propuesta y si la dosificaci\u00f3n prevista es la adecuada . \nd) Anexos: Incluye los modelos e informaci\u00f3n que se \nanexa como parte del contenido de la regulaci\u00f3n. \n \ne) Bibliograf\u00eda: Se relacionan las referencias \nbibliogr\u00e1ficas consultadas sobre esta materia. \n \nLas fuentes primarias sobre las que se han \ndesarrollado estos requisitos para el registro y control, \nhan sido las directivas de la OMS y las legislaciones \nde 15 pa\u00edses de Iberoam\u00e9rica sobre productos naturales (WHO, 1998, 2001, 2004a, 2004b, 2005; OMS, 1993, 2003; Garc\u00eda y C\u00e1ceres, 2000; Fuentes et \nal, 2000). Las instituciones implicadas con el \ncumplimiento de la Regulaci\u00f3n que estable los \nrequisitos para el registro y control de los \nmedicamentos herbarios, se presentan en la figura 1. \nEl resultado de la implementaci\u00f3n y generalizaci\u00f3n de la Regulaci\u00f3n ha tenido un gran impacto para el trabajo de la Autoridad Reguladora en funci\u00f3n del \ncontrol y regulaci\u00f3n de los medicamentos que se \ncomercializan en el pa\u00eds, al disponer por primera vez de una regulaci\u00f3n nacional donde se establecen los Requisitos para el registro y control de los medicamentos herbarios de uso humano y ha \npermitido adem\u00e1s servir de gu\u00eda a las instituciones de \ninvestigaci\u00f3n y desarrollo, la  industria, las farmacias y almacenes en el desarrollo, la evaluaci\u00f3n y el control \nde tales productos.   En las unidades de Atenci\u00f3n \nPrimaria y Secundaria de Sa lud, tambi\u00e9n ha jugado un \npapel importante la implementaci\u00f3n de esta \nregulaci\u00f3n, donde cada vez el acceso a estos \nmedicamentos es mayor y la realizaci\u00f3n de estudios cl\u00ednicos que corroboren la eficacia de los mismos va permitiendo su uso racional al mismo tiempo. Regulaci\u00f3n de medicamentos herbales en Cuba Gonz\u00e1lez Ram\u00edrez  et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 121 Tabla 1. Relaci\u00f3n de algunos medicamentos herbarios m\u00e1s utilizados, incluidos en la Gu\u00eda Terap\u00e9utic a de Fitof\u00e1rmacos y Apif\u00e1rmacos del \nMinisterio de Salud P\u00fablic a de la Rep\u00fablica de Cuba. \nMedicamento herbario Especie bot\u00e1nica incluida en \nsu composici\u00f3n Indicaci\u00f3n Terap\u00e9utica/s \nCrema de Cebolla Allium cepae L. Cicatrizante y queloides  \nTintura de Ajo 20 % Allium sativum L. Antirreumatico, antifungico, \nhipoglicemiante. \nExtracto de Aloe \n(Jarabe de Aloe 50 %; Crema de Aloe 25 % y 50%; Ung\u00fcento de Aloe rectal) Aloe vera L. Cicatrizante, antiiflamatoria \nExtracto Flu\u00eddo de Bija Bixa orellana L. Antiseptico, antiiflamatorio \nExtracto Fluido de Cal\u00e9ndula \nTintura de Cal\u00e9ndula 10 y 20 % Cal\u00e9ndula officinalis L. Antiseptico, antiinflamatorio \nCrema de Aj\u00ed guaguao Capsicum annum L. Antirreum\u00e1tico  \nJarabe de Ca\u00f1andonga 20 % \nCrema de Ca\u00f1andonga Cassia grandis L. Antian\u00e9mico, antif\u00fangico \nTintura de Lim\u00f3n \nJarabe de Lim\u00f3n Citrus aurantifolia C. Antiespasm\u00f3dico \nTintura de Naranja Agria 20 % Citrus aurantium L. Flebot\u00f3nico, diur\u00e9tico \nJarabe de Naranja dulce Citrus sinensis L.  Diur\u00e9tico, flebot\u00f3nico \nJarabe de Ca\u00f1a santa \nCrema de Ca\u00f1a santa 5 % Cymbopogon citratus D.C. Diur\u00e9tica, antihipertensivo, antiinflamatorio.  \nExtracto Flu\u00eddo de Eucalipto  Eucalyptus citriodora H. Antis\u00e9ptico, antitus\u00edgeno  \nTintura de Hinojo 20 % Foeniculum vulgare M. Antiespasm\u00f3dica \nExtracto Flu\u00eddo de Tilo \nJarabe de Tilo 20 % Justicia pectoralis J. Sedante \nExtracto alcoh\u00f3lico de Quitadolor Lippia alba M. Analg\u00e9sico \nTintura de Manzanilla 20 % \nCrema de Manzanilla Matricaria recutita L. Antiiflamatorio, antif\u00fangico, \nantiespasm\u00f3dico \nTintura de Cayeput Melaleuca leucadendron L. Antis\u00e9ptico, antiinflamatorio \nTintura de Menta japonesa 20 % Mentha arvensis L.  Antiespasm\u00f3dico, antiiflamtorio de v\u00edas respiratorias \nJarabe de Toronjil de menta Mentha piperita L. Antiespasm\u00f3dico \nTintura de Hierba Buena 20% Mentha spicata L. Antiespasm\u00f3dico \nTintura de Albahaca blanca 20 % \nJarabe de Albahaca blanca Ocimum basilicum L. Antiespasm\u00f3dico \nExtracto Flu\u00eddo de Te de ri\u00f1\u00f3n \nJarabe de Te de ri\u00f1\u00f3n 20 % Orthosiphon aristatus B. Diur\u00e9tico  \nExtracto Flu\u00eddo de Pasiflora Passiflora incarnata L. Sedante \nTintura de Itamo real 20 % Pedilanthus tithymaloides L. Estomatitis, gingivitis y afta bucal \nCrema de Anam\u00fa Petiveria alliacea L. Antiinflamatorio, hipoglicemiante \nExtracto Flu\u00eddo de Pino macho Pinus caribaea M. Antif\u00fangico \nJarabe de Caisim\u00f3n de an\u00eds Piper auritum H.B.K. Antiespasm\u00f3dico, antirreum\u00e1tico \nExtracto flu\u00eddo de Llant\u00e9n menor  Plantago lanceolata L. Antiinflamatorio, antis\u00e9ptico \nColutorio de Llant\u00e9n major  Plantago major L. Aftas bucales, estomatitis, inflamaciones de la enc\u00eda \nJarabe de Or\u00e9gano franc\u00e9s Plecthranthus amboinicus L. Expectorante, antitusivo \nTintura de guayaba 20 % \nElixir de Guayaba \nTalco de Guayaba Psidium guajaba L. Antif\u00fangico, antidiarr\u00e9ico  \nMelito de Mangle rojo Rhizophora mangle L. Cicatrizante, antiulcerosa, antis\u00e9ptico \nJarabe de Romero Rosmarinus officinalis L. Antis\u00e9ptico \nJarabe de Salvia de castilla Salvia officinalis L. Broncodilatador, expectorante  \nTintura de Guacamaya francesa 20 % Senna alata R. Antif\u00fangica  \nJarabe de Ma\u00edz Zea mays L. Diur\u00e9tico \nExtracto de Jengibre \nTintura de Jengibre Zingiber officinale R. Tratamiento de flatul encia, dispepsias, \nc\u00f3licos gastrointestinales v\u00f3mitos , diarreas. Regulaci\u00f3n de medicamentos herbales en Cuba Gonz\u00e1lez Ram\u00edrez  et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 122 Tabla 2. Tiempos (en d\u00edas naturales) establecidos para cada tipo de solicitudes de tr\u00e1mites de registro. \nSolicitud Tipo  Inicial Completamiento de la \nDocumentaci\u00f3n Total  \n CECMED Solicitante CECMED  \nInscripci\u00f3n A 180 90 105 375 \nInscripci\u00f3n B y C 150 90 105 345 \nRenovaci\u00f3n 120 90 105 315 \nModificaci\u00f3n 120 90 105 315 \nTabla 3. Plantas Medicinales que ser\u00e1n incl uidas en futuras ediciones de la Farmacopea Cubana de Plantas Medicinales del Ministerio de \nSalud P\u00fablica de la  Republica de Cuba. \nEspecie/s bot\u00e1nica/s Nombre com\u00fan Cate gor\u00eda(s) Terap\u00e9utica/s o Indicaciones \nAllium cepae L. Cebolla Cicatrizante y queloide  \nAllium sativum L. Ajo Antirreum\u00e1tico, antif\u00fangico, hipoglicemiante \nAloe vera L. S\u00e1bila Cicatrizante, antiifla matorio, inmunomodulador \nAnacardium occidentale L. Mara\u00f1\u00f3n Antidiarreico, antibacteriano \nAnethum graveolens B. Eneldo Antiespasm\u00f3dico \nArtemisia absinthium L. Artemisa Carminativo, antiespasm\u00f3dico \nBidens piloso L. Romerillo Antiulceroso \nBixa orellana L. Bija Antis\u00e9ptico, antiinflamatorio \nBrassica juncea L. Mostaza de la tierra Antiinflamatorio \nCal\u00e9ndula officinalis L. Cal\u00e9ndula Antiseptico, antiinflamatorio \nCapsicum annum L. Aj\u00ed picante antirreum\u00e1tico \nCassia grandis L. Ca\u00f1andonga Antian\u00e9mico \nCitrus aurantifolia C. Lim\u00f3n Diur\u00e9tico, flebot\u00f3nico \nCitrus aurantium L. Naranja agria Flebot\u00f3nico, diur\u00e9tico \nCitrus nobilis L. Mandarina Antigripal \nCitrus sinensis L.  Naranja dulce Diur\u00e9tico, flebot\u00f3nico \nCoriandrum sativum Cilantro Cefaleas, \u00falcera, reum atismo, estom\u00e1tico, carminativo, \nantiespasm\u00f3dico, estimulante de secreciones de jugos g\u00e1stricos, \nantimicrobiano  \nCurcubita moschata D. Calabaza Antihelm\u00edtico \nC\u00farcuma longa Yuquilla Trastornos hep\u00e1ticos, icteri cia, afecciones gastrointestinales y \nrespiratorias, dismenorrea, diabetes  \nCymbopogon citratus D.C. Ca\u00f1a santa Diur\u00e9tica, antihipertensivo, antiinflamatorio  \nErigium foetidum L. Culantro Antiespasm\u00f3dico, tos, antitusivo, emenagogo y febr\u00edfuga. \nEucalyptus citriodora H. Eucalipto de lim\u00f3n Antis\u00e9ptico, antitus\u00edgeno \nFoeniculum vulgare M. Hinojo Antiespasm\u00f3dica \nHibiscus elatus Sw. Majagua Antihistam\u00ednico  \nIndigofera suffructicosa M. A\u00f1il cimarr\u00f3n Anticonvulsivante, pediculicida \nJasminum officinale L. Jazmin de 5 hojas Antihistam\u00ednico \nJusticia pectoralis J. Tilo Sedante \nLepidium virginicum L. Mastuerzo Diur\u00e9tico, antirreum\u00e1tico \nLippia alba M. Quitadolor Analg\u00e9sico \nMang\u00edfera \u00edndica L. Mango Antiinflamatorio y antioxidante \nMaranta arundinacea L. Sag\u00fa Diarr\u00e9ico, emoliente, enfermedades de la uretras y la vejiga. \nMatricaria recutita L. Manzanilla Antiiflamatorio, antif\u00fangico, antiespasm\u00f3dico \nMelaleuca leucadendron L. Cayeput Antis\u00e9ptico, antiiflamatorio \nMelissa officinalis L. Toronjil Sedante \nMentha arvensis L.  Menta japonesa Antiespasm\u00f3dico, antiiflamatorio de v\u00edas respiratorias \nMentha piperita L. Toronjil de menta Antiespasm\u00f3dico \nMentha spicata L. Hierba buena Antiespasm\u00f3dico \nMorinda citrifolia  Noni Antiinflamatorio, antihistam\u00ednico, antibacteriano \nMorinda royoc Gara\u00f1\u00f3n Antioxidante Regulaci\u00f3n de medicamentos herbales en Cuba Gonz\u00e1lez Ram\u00edrez  et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 123 Tabla 3 (Continuaci\u00f3n). Plantas Medicinales que ser\u00e1n incluidas en futuras edicio nes de la Farmacopea Cubana de Plantas Medicinales del \nMinisterio de Salud P\u00fablic a de la Republica de Cuba. \nEspecie/s bot\u00e1nica/s Nombre com\u00fan Cate gor\u00eda(s) Terap\u00e9utica/s o Indicaciones \nMurraea exotica L. Muraya Pediculicida  \nMussa paradisiaca L. Pl\u00e1tano Pediculicida \nOcimum basilicum L. Albahaca blanca Antiespasm\u00f3dico \nOcimum gratissimum L. Or\u00e9gano cimarr\u00f3n Antiespasm\u00f3dica, an timicrobiano, antigripal y febr\u00edfuga. \nOcimum tenuiflorum L. Albahaca morada Hipoglicemiante \nOriganum majorana L. Mejorana Flatulencia, diarrea, t\u00f3nico y sedante del SNC, digestiones lentas. \nOrthosiphon aristatus B. T\u00e9 de ri\u00f1\u00f3n Diur\u00e9tico  \nParthenium hysterophorus L. Escoba amarga Champ\u00fa anticaspa \nPassiflora incarnata L. Pasiflora Sedante \nPedilanthus tithymaloides L. Itamo real Estomatitis, gingivitis y afta bucal \nPetiveria alliacea L. Anam\u00fa Hipoglicemiante, antiinflamatorio \nPiper auritum H.B.K. Caisim\u00f3n de an\u00eds Antiespasm\u00f3dico, antirreum\u00e1tico \nPiper ossanum C. Platanillo de Cuba Antiinflamatorio \nPlantago lanceolata L. Llant\u00e9n menor  Antiinflamatorio, antis\u00e9ptico \nPlantago major L. Llant\u00e9n major  Aftas bucales, estomatitis, inflamaciones de la enc\u00eda \nPlecthranthus amboinicus L. Or\u00e9gano franc\u00e9s Expectorante, antitusivo \nProtium cubense R. Copal Antiinflamatorio antis\u00e9ptico \nPsidium guajaba L. Guayaba Antifungico, antidiarr\u00e9ico  \nRhizophora mangle L. Mangle rojo Cicatrizante, antiulcerosa, antis\u00e9ptico \nRosmarinus officinalis L. Romero Antis\u00e9ptico \nRuta graveolens L. Ruda Sedante \nSalvia officinalis L. Salvia de castilla Broncodilatador, expectorante  \nSenna alata R. Guacamaya \nfrancesa Antif\u00fangica  \nStachytharpheta jamaicensis \n(L) Vahl Verbena cimarrona Antiparasitario, afecciones renales y de la piel, antimicrobiano. \nTamarindus indica L. Tamarindo Antiinflamatorio  \nThymus vulgaris L. Tomillo Afecciones respiratorias agudas y cr\u00f3nicas \nXanthium occidentalis Guisazo de caballo Diur\u00e9tico \nZea mays L. Ma\u00edz Diur\u00e9tico \nZingiber officinale R. Jengibre Problemas digestivos, tonificante \n \n  \nHasta la fecha el CECMED ha registrado un total \nde 60 medicamentos herbarios nacionales y de \nimportaci\u00f3n que se producen en la industria. Los \nmedicamentos que se elaboran de manera semi-industrial, que son la mayor\u00eda de los que se producen en el pa\u00eds en los centros de producci\u00f3n local y dispensarios farmac\u00e9uticos, con condiciones \ntecnol\u00f3gicas y recursos materiales m\u00ednimos, \nrelacionados en la tabla 1 , siguen otros requisitos \nestablecidos en la Regulaci\u00f3n 29/2000 \u201cRequisitos para las solicitudes de autorizaci\u00f3n de uso de \nmedicamentos de origen natural de uso humano, de \nproducciones locales y dispensariales\u201d, para su \nautorizaci\u00f3n que est\u00e1n espec\u00edficamente relacionados \ncon la calidad del prod ucto y que responden a \nproductos que se elaboran a partir de un listado de plantas autorizadas para el cu al se tuvo en cuenta la \ntradici\u00f3n de uso en Cuba con fines medicinales y las investigaciones realizadas en el pa\u00eds y otros reportes de la literatura cient\u00edfica sobre seguridad y eficacia. \nLos tiempos establecidos en el reglamento de \nregistro para las solicitudes de tr\u00e1mites de inscripci\u00f3n, renovaci\u00f3n y modificaci\u00f3n en el registro, se presentan en la tabla 2. \nProyecciones de trabajo \nEl CECMED ha establecido proyecciones de \ntrabajo con el objetivo de perfeccionar la base legal para la regulaci\u00f3n de medicamentos herbarios con la elaboraci\u00f3n y actualizaci\u00f3n de pautas, directrices t\u00e9cnicas y metodolog\u00edas nacionales para evaluar la seguridad, la eficacia y la calidad de las plantas medicinales y medicamentos herbarios, entre las que \nse pueden mencionar, gu\u00edas sobre m\u00e9todos de ensayos \npara el control de la calidad, gu\u00eda sobre especificaciones de calidad y criterios de aceptaci\u00f3n Regulaci\u00f3n de medicamentos herbales en Cuba Gonz\u00e1lez Ram\u00edrez  et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 124 de las drogas vegetales y productos terminados y \nmetodolog\u00edas para la investigaci\u00f3n de las plantas medicinales. Estos documentos ser\u00e1n elaborados \nteniendo en cuenta las directrices de la OMS y \nnuestras condiciones de trabajo. Tambi\u00e9n est\u00e1 en ejecuci\u00f3n el proyecto de elaboraci\u00f3n de las monograf\u00edas de las plantas cubanas que formar\u00e1n parte de la primera edici \u00f3n de la Farmacopea Cubana \nde Plantas Medicinales con las especies relacionadas \nen la  tabla 3 , as\u00ed como la elaboraci\u00f3n de las buenas \npr\u00e1cticas agr\u00edcolas, de recolecci\u00f3n y de conservaci\u00f3n \nde las plantas medicinales. Otra de las proyecciones \nest\u00e1 relacionada con el desarrollo de las pautas para el consumidor sobre la informaci\u00f3n necesaria para el uso \ncorrecto de las plantas medicinales. \nCONCLUSIONES \n\u2022 Cuba integra la Medicina Tradicional en el \nSistema Nacional de Salud y crea en el a\u00f1o 1995 \nun Programa Nacional para el Desarrollo y Generalizaci\u00f3n de la Medicina Tradicional. \n\u2022 El CECMED como Autoridad Nacional \nReguladora de Medicamentos, en el a\u00f1o 2000, traza algunas estrategias de trabajo para asegurar la calidad, la seguridad y la eficacia de las plantas medicinales y medicamentos herbarios. \n\u2022 Se implementa y perfecc iona el marco legal \npara el registro y control de los medicamentos \nherbarios a partir del a\u00f1o 2002. \n\u2022 Se trazan proyectos de elaboraci\u00f3n de \ndocumentos regulatorios relacionados con las \nbuenas pr\u00e1cticas agr\u00edcolas, de recolecci\u00f3n y conservaci\u00f3n de las plantas medicinales, sobre la calidad, la seguridad y la eficacia de los medicamentos herbarios y sobre las pautas para el \nconsumidor sobre la informaci\u00f3n necesaria para el \nuso correcto de las plantas medicinales. \nBIBLIOGRAF\u00cdA \nCECMED. 2002. Requisitos para las solicitudes de tr\u00e1mites \nde inscripci\u00f3n, renovaci\u00f3n y modificaci\u00f3n de los \nmedicamentos de origen natural de uso humano. CECMED Regulaci\u00f3n  No. 28-2002, La Habana, Cuba. \nC\u00e1ceres A. 1999. Plantas de uso medicinal en Guatemala, \nEditorial Universitaria,  Ciudad de Guatemala, Guatemala. \nFuentes Fiallo VR, Lemes Hern\u00e1ndez CM, Rodr\u00edguez \nFerrad\u00e1 CA, Germos\u00e9n-Robineau L. 2000. Manual de cultivo y conservaci\u00f3n de plantas medicinales , Tomo \nII, Cuba . Editora Centenario, S.A., Santo Domingo, \nRep\u00fablica Dominicana. Garc\u00eda M, C\u00e1ceres A. 2000. Legislaci\u00f3n en Iberoam\u00e9rica \nsobre Fitof\u00e1rmacos y Productos Naturales . Ed. \nCYTED-LEBi-ASACIMSS-EU, Costa Rica. \nRoig Mesa JT. 1945. Plantas medicinales, arom\u00e1ticas o \nvenenosas de Cuba, Editorial Cient\u00edfico-T\u00e9cnica, La \nHabana, Cuba. \nOMS, UICN, WWF. 1993. Directrices sobre conservaci\u00f3n \nde plantas medicinales.  UICN, Gland, Suiza. \nOMS. 2002. Estrategias de la OMS sobre la Medicina \nTradicional 2002-2005 . WHO/EDM/TRM/2002.1, \nGinebra, Suiza,  \nOMS. 2003. Directrices de la OMS sobre buenas pr\u00e1cticas \nagr\u00edcolas y de recolecci\u00f3n (BPAR) de plantas medicinales. Ediciones de la OMS, Ginebra, Suiza. \nWHO. 1998. Quality Control Me thods for Medicinal Plants \nMaterials. Editions of the OMS, Geneva, Switzerland. \nWHO. 2001. Legal Status of Traditional Medicine and \nComplementary/Alternative Medicine: A Worldwide \nReview. WHO/EDM/TRM/2001.2. Editions of the \nOMS, Geneva, Switzerland. \nWHO. 2004a. WHO Guidelines on Safety Monitoring of \nHerbal Medicines in Pharmacovigilance Systems, Editions of the OMS, Geneva, Switzerland. \nWHO. 2004b. WHO Guidelines on Developing Consumer \nInformation on Proper Use of Traditional, Complementary and Alternat ive Medicine. Editions of \nthe OMS, Geneva, Switzerland. \nWHO. 2005. National Policy on Traditional Medicine and \nRegulation of Herbal Medicine. Report of WHO \nGlobal Survey. Editions of the OMS, Geneva, Switzerland.  \n \n\u00a9 2007 Los Autores \nDerechos de Publicaci\u00f3n \u00a9 2007  Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 125 - 128 \nBLACPMA ISSN 0717 7917 \nEspecial Regulaci\u00f3n de Fitomedicinas / Sp ecial Issue on Regulation of Phytomedicines \nPhytomedicines in Jamaica: regulatory issues \n[Fitomedicinas en Jamaica: regulaci\u00f3n] \nDiane ROBERTSON \n10, Halcot Crescent. Kingston 8. Jamaica W.I \nContact: diane.robertson@gmail.com   \nSubmitted on 11th October 2007; Accepted on 18th October 2007 \nAbstract \nJamaica is making its way towards a full regulation of herbal medicines and related products, namely food supplements. This has  been \npushed by the increasing imports of unregulated herbal products into the Island crea ting a need for protecting both our citizen s and local \nproducers alike. From a practical legal point  of view the current legal framework was based mainly in the Food and Drug Act 196 4, and the \nFood and Drug Regulations 1975, established by  the Ministry of Health, but they did not  refer to herbals and herbal medicines i n its contents. \nFrom 1999, Jamaican governmental and private institutions are working on the amendment of these acts and pa rticipating actively  in \ninternational workshops to regulate phytomed icines both within the country and the Ca ribbean/Centro American region. However th e law \nwill force growers to perform adequate laboratory tests that are often out of their economical reach, and the help of the admin istration has \nbeen proposed to solve this problem. Despit e theses developments the an swer to \u201cwhat is the status  on the Amendment?\u201d is still in limbo. \nKeywords: Jamaica, herbal medicines, regulatory affairs. \nResumen \nJamaica esta haciendo progresos hacia la re gulaci\u00f3n completa de los medicamentos herbar ios y productos relacionados como los su plementos \nalimentarios. Esto ha sido impulsado por el  aumento de importaciones de productos herbarios no regulados en la isla, lo que cre o una \nnecesidad de proteger tanto al consumidor como al productor local. Desde un punto de vista practico el marco legal basado en la  Ley de \nAlimentos y Medicamentos de 1964 y las Regulac iones de Alimentos y Medicamentos de 1975, establecidas por el Ministerio de Salu d, pero \nestas no hac\u00edan menci\u00f3n de los productos herb arios. Desde 1999, el gobierno jamaicano e in stituciones privadas trabajan en la actualizaci\u00f3n \nde estas leyes por enmienda, adem\u00e1s de part icipar activamente en grupos de trabajos in ternacionales para regular tanto la situaci\u00f3n interna \ncomo la regional (Caribe/Centroam\u00e9rica). Sin embargo la regulaci\u00f3n del mercado herbario forzar a a los productores locales a realizar an\u00e1lisis \nque est\u00e1n fuera de su capacidad econ\u00f3mica, y la ayuda estatal ha  sido propuesta como soluci\u00f3n. A pesar de todos estos avances l a respuesta a \nla situaci\u00f3n de la enmienda se encuentra aun en el limbo. \nPalabras clave: Jamaica, medicamentos herbarios, regulaci\u00f3n. \n \nINTRODUCTION \nHerbs are always difficult to characterise because \nof their complexity of active ingredients or \ncompounds that are usually not known. History has shown that multiple choices exist for protecting \nhuman health. Since 1994 the revived interest of \nnatural products as preventative and therapeutic agents accompanied by the high demand for natural remedies and herbals have drawn the attention of the Ministry of Health in Jamaica\n. The Ministry has a responsibility to protect the \nhealth of citizens, and therefore has to set laws to govern the registration, importation, manufacture, storage, distribution, sale and use of herbal medicinal products. The Food and Drug Act 1964, and the Food \nand Drug Regulations 1975, established by the \nMinistry of Health did not refer to herbals and herbal medicines in its contents. Regulation of herbal medicines in Jamaica Robertson \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 126 DEFINITIONS BY LEGISLATION SECTION 2- \nJAMAICA FDA \nFood-  \u201cany article used for food or drink by man, \nincluding chewing gum and any ingredient that may be mixed with food or drink for any purpose.\u201d \nDrug - \u201cany substance or mixture of substance \nmanufactured, sold or represented for use in the diagnosis, treatment, mitigation or prevention of disease, disorder, abnormal physical state or \nsymptoms thereof in man or animal; restoring, \ncorrecting or modifying organic functions in man or animal; dis-infection in pr emises in which food is \nmanufactured, prepared, preserved, packaged or stored for sale or sold for control of vermin or insects in such \npremises.\u201d \nThe regulations pursue to address two important \nissues related with herbal medicines: Quality and \nEfficacy. Q uality  is an asset. The primary reason why \nstandardization exists for herbal extracts is to achieve \nas much control in clinical double blind studies as \npossible. It is also to protect consumer interests specially relating to product claims and maintain requisite standards-batch to batch consistency. \nEfficacy  is the ability to effect label claim-\nindication/action, identifying the pharmacological \nactivity, the potency for eff ective doses and to justify \nthe claims on the labels. Safety contributes to improve \nthe quality of life. Safety is the fundamental principle \nand the critical component of quality management. There is the common misconception that all natural \nproducts or plants are safe! Safety eliminates/ control \ntoxicity and drug interactions. Today good agricultural practices (GAP) are now in place so as to avoid growing where the soil is contaminated with heavy metals, as well as collection of the wrong species and adulteration with other herbs. \nTHE CURRENT STATE OF THE INDUSTRY \nIn 1994, the Ministry of Health (MOH) saw the \nnecessity to intervene in the escalating importation of herbal materials and dietary supplements by treating these as \u201cdrugs\u201d.  The Wholistic Herbal Association \n(WHA), which was founded by this author among \nother stakeholders and consumers in the industry, took the M.O.H to task to prove if an \u201cherb\u201d is a drug or a \u201cfood\u201d. The Association engaged the Ministry into a legal tangle along with media \u201cwar\u201d with the medical practitioners during 1995-1999 . The former Chairman \nDr. Robertson and the former President Dr. Vance Lannaman \nNMD,  along with the stakeholders in the industry lobbied with the M.O.H before the Houses of Parliament.  \n On March 22nd 1999, the Honourable Houses of \nParliament took a decision th at a special committee of \nmembers of the Association and \u201cThe Joint Select Committee on Human Resources and Social Development\u201d (appointed by the Houses of Parliament and the Ministry of Health) met for one year preparing documentation to be submitted to Parliament to amend \nthe FDA 1974 to include the following: \n \n1. Herbal Remedies \n2. Health Foods \n3. Herbs \n4. Finished Herbal Products  \n5. Herbal Materials \n6. Dietary Supplements \n7. \u201cOver-The-Counter\u201d OTC herbal products. \n \nThe document was prepared and submitted to the \nPermanent Secretary in the M.O.H for perusal and \nsubmission to the Chief Parliamentary Council. In 2000 the Ministry of Health appointing a representative of each complementary medicinal therapy, formed an Advisory Panel for \nComplementary Medicine. Dr. Sonia Davidson MD. \nwas appointed by the M.O.H as the Chairman.  \nOn November 13-16 2000 the Ministry of health \nhosted a Regional Meeting on Herbal Medicine, which was held in Jamaica. Participants from Barbados, \nBrazil, Canada, Chile, Guatemala, Jamaica, Mexico, \nPanama, USA and representatives from PAHO /and World Health Organisation all attended. This meeting was an opportunity for drug regulators of various countries to come together to discuss the different issues surrounding the production, registration and use \nof herbal products and to develop a proposal on \nharmonized standards and regulations to assure safe safety and quality of products in share markets. It was also hoped that experiences of countries from other \nregions would serve as reference and guide for the \ndiscussion (Pan American Health Organization, \n2002.).  \nThe Advisory Panel completed a document on \nprocedures to harmonise with Complementary Alternative Medicine, which included the operations of herbal practitioners and therapists to be regulated. \nTo date the amendments for Phytomedicines and the \nPractitioners of Complementary Medicine have not been included in the FDA amendments, or submitted for approval by the Honourable Houses of Parliament. Regulation of herbal medicines in Jamaica Robertson \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 127 PRESENT REGULATORY FRAMEWORK \nAfter a period of four years the changes of the \nRegulatory framework have been completed, and \nsubmitted to the Chief Parliamentary Council for \nadjustments since late 2006, but still no amendments are in place. The Ministry of Health has made reference taken by competent authorities in Australia, Canada, Germany, England and the United States, references to WHO guidelines on the assessment of \nherbal products and definitions were also adapted for \nuse (WHO. 1998, 2001, 2004a., 2004b). \nThere is not a Jamaican Pharmacopoeia in place. \nThe British Pharmacopoeia (British Pharmacopoeial \nCommission, 2008)  is instead required to be in all \nPharmacies in the island . In addition, References can \nbe made from \u201cThe Complete German Commission E \nMonographs\u201d  (Blumenthal et al., 1999) published by \nthe American Botanical Council which also includes some Canadian herbal references.  \nThe Pharmacy Council in Jamaica has also made \nrequests for their Laws to be amended to make it possible for herbals to be sold in \u201cspecial shops\u201d \nwhich would be regulated by the Pharmacy Council. This too has not yet been amended.  \nSince 2005 the Director of Standards and \nRegulation MOH and their officials along with representatives of Complementary Medicinal Practitioners met formerly on a monthly basis, but this has fell down tremendously. \nDocumentation Requirements for Registration of \nHerbal Remedies \nIt is interesting that the application form from the \nPharmaceutical and Regulatory Affairs unit is still \nunder the Registration of Herbal products, food and \ndrugs Act of 1964. \nThis form has to answer pertinent questions such \nas a statement of content of the product, the posology, rationale for combinations, toxic/side effects, tests to conform quality and potency.  \nAttached to the form must be: \n\u2022 A\u201cCertificate of Free Sale \u201d that must be endorsed \nby the Jamaican Consulate in the country of \norigin. \n\u2022 A \u201cCertificate of Analysis \u201d indicating tests for \nquality and potency. \n\u2022 Five samples of the product with the labels \nindicating manufacturer, expiry dates, and batch numbers.  \nA fee of J$5000.00 (approx. U$71.00) applies. Table 1. Herbs and by- products restri cted by the M.O.H. for \nimportation. \nCommon name Latin name \nChaparral Ceanothus spp. \nComfrey herb Symphytum officinale \nGermander  Teucrium chamaedrys \nWillow Bark Salix alba \nYohimbe Corymanthe yohimbi \nPausinystalia johimbe \nLobelia Lobelia inflata \nMagnolia Magnolia glauca \nEphedra, Ma Huang Ephedra sinica \nKava Kava Piper methysticus  \nThe Requirements for Health Foods \nHealth food must comply with a simplified procedure \nto be registered in Jamaica: \n\u2022 Evaluation and review of active ingredients and \nconcentration. \n\u2022 Verification of label claims, purity \u2013certificate of Analysis. \n\u2022 Five samples of products \n\u2022 Proof of approval in country of origin. \n\u2022 Scientific support claims may be requested. \n \nAll products are regulated except: \n \n\u2022 Homeopathic preparations more dilute than 1-1000 fold dilution of a mother tincture. \n\u2022 Herbal Teas except where there are claims. \n\u2022 Products, which exist and function principally as food if they make no therapeutic claims e.g. garlic. ( Allium sativa ). Fees are required for \npassive assessment. \nSeveral restrictions apply to this category. First of all injectable presentations are not allowed and they can only be registered as prescription drugs. Secondly, there is a list of herbs and by- products are restricted by the M.O.H. for importation. Restriction is based on \n\u201cadvisory reports \u201creceived from other international \nregulatory bodies (see Table1 for a list of restricted plant species). \nOUR CHALLENGES \nThe need for an adequate laboratory support for \ntesting our raw materials to acquire a Certificate of \nAnalysis is most challenging for growers of raw \nmaterials. At present our Scientific Research Council is planning assistance in this area. This would assist the many applicants to provide requisite documentation for product approval. Regulation of herbal medicines in Jamaica Robertson \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 128 The questions asked daily by stakeholders is \u201cwhat \nis the status on the Amendment?\u201d Its answer is still in \nlimbo. \nREFERENCES  \nBlumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall \nT, Riggins CW, Rister RRS, Klein S,. 1999. The \nComplete German Commission E Monographs: \nTherapeutic Guide to Herbal Medicines. Thieme \nMedical Publishers and Am erican Botanical Council \n(Corporate Author), Austin, TX. \nBritish Pharmacopoeia Commission. 2008. The British \nPharmacopoeia. The Stationery Office, London UK. \nDirector of Standards and Regulation. 2003. \u201cRegulations \nof Herbal Products\u201d. Presentation to the WHA and government officials. November. \nHanda SS. 2007. \u201cQuality Control and standardization of \nMedicinal and Aromatic Plants\u201d; Presentation in collaboration with ICS-UNIDO and CHBA. II CA \n2007. Port of Spain, Trinidad. \nMOH. 2003. Proposed Amendments Submitted to the \nPermanent Secretary MOH. Oct.17.2003. \nRobertson, D. 2005. \u201cLegality Herbs.\u201d Lecture, University \nof Technology Pharmacy students, Kingston, Jamaica. \nWHA, MOH. 2003. Correspondence between WHA and the \nMOH 2001-2003. Ref. No.PS/S11, 8.Aug.2003; Apr. \n22 .2003. \nWHO. 1998. Quality Control Me thods for Medicinal Plants \nMaterials. Editions of the OMS, Geneva, Switzerland. \nWHO. 2001. Legal Status of Traditional Medicine and \nComplementary/Alternative Medicine: A Worldwide \nReview. WHO/EDM/TRM/2001.2. Editions of the \nOMS, Geneva, Switzerland. \nWHO. 2004a. WHO Guidelines on Safety Monitoring of \nHerbal Medicines in Pharmacovigilance Systems, Editions of the OMS, Geneva, Switzerland. \nWHO. 2004b. WHO Guidelines on Developing Consumer \nInformation on Proper Use of Traditional, Complementary and Alternat ive Medicine. Editions of \nthe OMS, Geneva, Switzerland. \nWHO. 2005. National Policy on Traditional Medicine and \nRegulation of Herbal Medicine. Report of WHO \nGlobal Survey. Editions of the OMS, Geneva, \nSwitzerland. \nJamaican Ministry of Health. 1964. Food and Drug Act. \nKingston, Jamaica. \nJamaican Ministry of Health. 1975. Food and Drug \nRegulations. Kingston, Jamaica. \nPan American Health Organization. 2002. Traditional, \nComplementary and Alternative Medicines and Therapies: Evaluation Plan of Work 2000-2001 and \nPlan of Work 2002-2003. Washington, D.C. US. URL \nhttp://www.paho.org/English/HSP/HSO/HSO07/TRM\nENG.pdf  [Last accessed 18/10/07].  \n \n\u00a9 2007 Los Autores \nDerechos de Publicaci\u00f3n \u00a9 2007  Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 129 - 136 \nBLACPMA ISSN 0717 7917 \nEspecial Regulaci\u00f3n de Fitomedicinas / Sp ecial Issue on Regulation of Phytomedicines \nAn Overview on the Development in Re gulation and Control of Medicinal \nand Aromatic Plants in the Indian System of Medicine \n[Una panor\u00e1mica del desarrollo de la regulaci\u00f3n y control de plantas medicinales y arom\u00e1ticas  \nen el sistema indio de medicina] \nPulok K. MUKHERJEE*, M. VENKATESH, V. KUMAR \nSchool of Natural Product Studies, Departm ent of Pharmaceutical Tec hnology, Jadavpur University , Kolkata-700032, India  \n*Contacto: pknatprod@yahoo.co.in ; T. +91 33 24298313; F. +91 33 24146046. \nReceived July 9, 2007; Accepted July 19, 2007 \nAbstract \nIndia have well-recorded and well practiced  knowledge of traditional herbal medicine s under indigenous system s of medicine like  Ayurveda, \nSiddha and Unani. On the other hand, with about 6000 plants repr esenting about 75% of the medicinal needs of the third world co untries \nIndia is a major worldwide exporter of raw medicinal and aromatic  plants and processed plant-based drugs. Government of India h as taken \nvarious initiatives to improve the herbal drug standards and promote Indian system of medicine. Government of India has been st iffening the \nherbal drug regulations from time to time by establishing various bodies to control the manufacture and sales of herbal drug. I t is \ncontinuously taking various corrective measures  by implementing certain acts and rules coping with the developing global standa rds for \nnatural products. A recent major m ove has been the convertion of The Department of  Indian Systems of Me dicines and Homoeopathy (ISM \n& H) established in 1995 into the Department of Ayurveda, Yoga & Naturopathy, Unani, Siddha a nd Homoeopathy (AYUSH) in 2003. Th e \nDepartment made steady progress since them and emphasis was laid  on implementing the schemes whic h address the thrust areas ide ntified \nby the Department like up gradation of educational standards, quality control and standardizat ion of drugs, improving the avail ability of raw \nmaterial, research and development and awar eness generation about the efficacy of the systems domestically and internationally.  \nKeywords: India, herbal medicines, regulatory a ffairs, Ayurveda, Yoga, Naturopathy, Unani, Siddha. \nResumen \nIndia tiene un uso de medicinas herbarias tr adicionales bien documentado y bien establ ecido bajo diversos sistemas ind\u00edgenas como el \nAyurveda, Siddha y Unani. Por otro lado, con mas de 6000 especies de plantas representado el 75% de las necesida des medicinales de pa\u00edses \ndel tercer mundo, India es un exportador mundial de drogas vege tales y especias. El gobierno hind\u00fa  ha tomado varias iniciativas  para mejorar \ny endurecer las normas de calidad en el sect or y establecer varios organismos de cont rol de su producci\u00f3n y venta. Tambi\u00e9n esta  \ncontinuamente tomando medidas correctivas medi ante la implementaci\u00f3n de leyes y regula ciones tomadas de orga nismos reguladores \ninternacionales. La mas reciente e importante accion ha sido la reconversi\u00f3n del Departamento de sistemas Indios de medicina y homeopatia, \nestablecido en 1995, en el Departamento de Ayurveda, Yoga y Naturopatia, Un ani, Siddha y Homeopat\u00eda (AYUSH) en 2003. Este \ndepartamento a hecho progresos c ontinuos en la regulaci\u00f3n de sist emas tradicionales con \u00e9nfasis en aumentar los niveles de educ aci\u00f3n, \ncontrol de calidad y estandarizaci\u00f3n de drogas, aumentando la disponibilidad de materiales crudos, investigando y desarrollando  as\u00ed como \nconcienciando de la eficacia  de los sistemas tradic ionales tanto a nivel domes tico como internacional. \nPalabras clave: India, medicamentos herbarios, re gulaci\u00f3n, Ayurveda, Yoga, Naturopatia, Unani, Siddha. \n \nINTRODUCTION \nDespite the achievements of synthetic chemistry \nand the advances towards rational drug design, \nnatural products continue to  be essential in providing \nmedicinal compounds and as starting points for the development of synthetic analogues. In some particular cases, such as antitumor and antimicrobial drugs, about 60% of the medicines currently \navailable on the market and most of those in the late \nstages of clinical trials are derived from natural products, mainly from higher plants (Calixto, 2000). With the increasing power of screening programs and Regulation of Traditional Medicines in India  Mukherjee et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 130 the increasing interest in the reservoir of untested \nnatural products, many futu re drug developments will \nbe based, at least in part, on natural products.  \nIndia is having a well-recorded and well practiced \nknowledge of traditional herbal medicine (Kamboj, 2000). Medicinal herbs have been in use in one form or another, under indigenous systems of medicine like Ayurveda, Siddha and Unani. India is a major exporter of raw medicinal and aromatic plants and \nprocessed plant-based drugs. It is generally estimated \nthat over 6000 plants in India are in use in traditional, folk and herbal medicine , representing about 75% of \nthe medicinal needs of the third world countries (Dubey et al., 2004; Mukherjee, 2002a). India, with \nthis traditional background,  needs to increase its \nshare in the world market. The US market is expected \nto grow to 5 trillion US dollars in 2050 (Joshi et al., \n2004; Rai et al., 2006). This can be achieved by judicious product identification based on diseases \nfound in the developed world for which no medicine \nor only palliative therapy is  available; such herbal \nmedicines will find speedy access into those countries. Also, harmonization and improvement in the processes of regulation is the need of the day, since it will be possible for the people to obtain high \nquality herbal medicines (Calixto, 2000; Verproote, \n2005). In this context, India has acknowledged the need for addressing the issue of the use of herbal medicines along with other regulatory measures.  \nNot many nations have launched initiatives to \ninculcate traditional herbal regulatory measures into their drug regulatory system. In the herbal boom world wide it is estimated that high quality phyto-medicinals will provide safe and effective medication and people engaged ther ein should have wide \nknowledge in every respects of the production and \nutilization of herbals. In this context quality control \nof botanicals has been given priority on which several guidelines have been reported. (Mukherjee, 2002b). In India, separate Department or the Indian \nSystem of Medicine and Homeopathy (ISM & H) has \nbeen made who are specially dealing with the rules \nand regulations for the herbals along with the Drugs and Cosmetic act and rules which has come up with the rules for the implementation of GMP in herbals, which will not only help to make the quality herbal products but also to safeguard the adverse effects of \nthe herbals too. An attempt has been made to make a \ncomplete review on every aspect of the development in the regulations of Indian System of Medicine. THE ANCIENT INDIAN TRADITIONAL MEDICINE \nThe World Health Organization (WHO) estimates \nthat about 80% of the populations living in the developing countries rely almost exclusively on traditional medicine for their primary health care needs. India has an ancient heritage of traditional medicine. India possesses a well-recorded and traditionally well-practiced knowledge of herbal \nmedicine. It is generally estimated that over 6000 \nplants in India are in u se in traditional, folk and \nherbal medicine, representing about 75% of the medicinal needs of the world countries. Materia \nmedica  of India provides lots of information on the \nfolklore practices and traditional aspects of \ntherapeutically important natural products. Indian Materia medica  includes about 2000 drugs of natural \norigin almost all of which are derived from different traditional system and folklore practices. Out of these \ndrugs derived from traditional system, 400 are of \nmineral and animal origin while the rest are of vegetable origin. Three of the ten most widely selling herbal medicines in the developed countries, namely preparations of Allium sativum, Aloe barbedensis and \nPanax sp. are available in India. It mainly consists of \nthree major systems namely Ayurveda, Siddha and Unani (ASU). With the emerging interest in the world to follow Indian system of Medicine, the government of India is trying their best to bring out therapeutic approaches available in original system of \nmedicine as well as help in generating data to put \nthese products on national health care program (Mukherjee, 2002b, 2003a,2006).\n \nAyurveda \nAyurveda is a system of healing from India. The \norigin of Ayurveda has been lost in prehistoric \nantiquity, but their characteristic concepts appeared \nto have been nurtured between 2500 and 500BC in India (Mukherjee, 2001). Ayurveda is usually translated as \u201cthe science of life\u201d (Anonymous, 2006a). In Indian system of traditional medicine, it is \naccepted as the oldest written medical system that is \nalso supposed to be more effective in certain cases \nthan modern therapies. Formulations and dosage forms have great importance in Ayurveda. Generally Ayurvedic formulations are multi-component mixtures containing plant and animal derived \nproducts, minerals and me tals. During the Samhita \nperiod (1000 BC), Ayurveda developed into eight \nbranches of specialties. Whereas, during the last 50 Regulation of Traditional Medicines in India  Mukherjee et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 131 years it has developed into twenty-two specialties. \nDespite the increasing popularity of herbal medicines and herbal cosmetics abroad, it would seem that \nAyurveda is yet to gain wider acceptance among \nmedical scientists internationally (Mukherjee et al., 2005a; Mukherjee, 2003b). Ayurveda is effective in the hands of an experienced practitioner, and most of the herbs used are fairly saf e. Unfortunately, lack of \nregulation, quality issues in some products has led to \nserious concerns about the safety of ayurvedic \nmedicines. \nSiddha System of Medicine \nSiddha system is one of the oldest systems of \nmedicine in India, which blends medicine and \nmysticism. The word Siddha was coined from word \n\u2018Siddhi\u2019, which means attainment of perfection and the art was mastered, practiced and teached by wise men known as \u2018siddhars\u2019. A lthough Siddha medicine \nresembles the aspects of Ayurveda, they possess \ndifferent origin. Siddha medicine originated from the \nsouth of Indian subcontinent rather than the north. The diagnosis of diseases involved identifying its causes. Identification of causative factors is through \nthe examination of pulse, urine, eyes, study of voice, \ncolor of body, tongue and the status of the digestive \nsystem. The Siddha system of medicine emphasizes \nthat medical treatment is oriented not merely to disease but has to take into account the patient, environment, the meteorological consideration, age, sex, race, habits, mental frame, habitat, diet, appetite, \nphysical condition, physiological constitution etc. \nThis means the treatment has to be individualistic which ensures lesser chance of committing mistakes in diagnosis or treatment. \nUnani System of Medicine \nUnani Tibb ( Unani means Greek [Ionnian] and \nTibb, from the Arabic, means medicine) is a system of medicine practiced today in the South Asian countries of India, Pakistan, and Bangladesh. Its origins lie in ancient Greek, Arabic, and Persian medicine. In India, Arabs introduced the Unani \nsystem of medicine, which was developed by the \nMughal emperors who invaded India. (Williamson, 2006; Mukherjee and Wahile, 2006). Here diseases are considered as a natural process and its symptoms are the reaction of the body  to the diseases. Unani, \nwith its humoral philosophy, views nature and \nmankind as ideally coexisting in a balanced manner. \nSpecifications for a range of behaviors and events that could lead to sickness and disease are outlined in the Unani texts. In common with many traditional sources of medicine, Unani-Tibb emphasizes the use \nof flavors and tastes to adjust the imbalances which \ncontribute to disease. The choices of foods and the \nmanner in which they are prepared are considered to \nbe among the most important issues to consider when \nchoosing a diet to improve or  maintain health (Grotte, \n2004; Mukherjee, 2005b). Skillful use of warming \nand cooling spices and herbs contribute heavily to the \nappropriateness of the meal to correct the root causes of imbalances. \nWith the emerging interest in the world to adopt \nand study the traditional system and to exploit their \npotentials based on different healthcare systems, \nGovernment of India is exploring several possibilities for the evaluation of these systems to bring out therapeutic approaches available in original system of medicine as well as to help in generating data to put \nthese products on national health care program. The Indian herbal products including Ayurveda, Unani, Siddha and Homeopathy are regulated under the Drugs & Cosmetics Act and licensing of such products remains a state subject. Provision relating to the regulatory aspects of natural products \nmanufacture and control has been prescribed in \nDrugs and Cosmetics Act 1940, Govt. of India; \nvarious aspects of the regulation on control of herbal medicinal products has been described in Table 1. \nDEPARTMENT OF AYURVEDA, YOGA & \nNATUROPATHY, UNANI, SIDDHA AND \nHOMOEOPATHY (AYUSH) \nThe Department of Indian Systems of Medicines \nand Homoeopathy (ISM & H) established in Ministry of Health & Family Welfare in March, 1995 was renamed as the Department of Ayurveda, Yoga & \nNaturopathy, Unani, Siddha and Homoeopathy \n(AYUSH) in November, 2003. The Department made steady progress during the year 2005-2006. Emphasis was laid on implementing the schemes which address the thrust areas identified by the Department like up \ngradation of educational standards, quality control \nand standardization of drugs, improving the \navailability of raw material, research and \ndevelopment and awareness generation about the efficacy of the systems domestically and internationally (Anony mous, 2006b; Anonymous. \n2003a). \n Regulation of Traditional Medicines in India  Mukherjee et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 132 Table 1:  Regulatory aspects of natural products ba sed on Drugs and Cosmetics Act of India  \nItem Section Criteria \nMisbranderd drugs 33 E ASU drugs are deemed to be misbranded: \n9 If colored or coated to conceal the damage or made appear better than therapeutic value \n9 If it is not labeled in prescribed manner \n9 If label or container accompanying drug bears any false claim or misleading. \nAdulterated drugs 33EE ASU drugs are deemed to bne adulterated  \n9 If it consists filthy, or decomposed material \n9 If prepared, packed or stored under insanitary conditions \n9 If its container contains any poisonous or deleterious substance \n9 colour other than one which is prescribed \n9 harmful or toxic substance \n9 If any substance mixed to reduce its quality or strength. \nSpurious drugs 33EEA ASU drugs are deemed to be spurious  \n9 If it is sold or offered under another name. \n9 If it is an imitation or substitute for another drug \n9 If the label or container bears the name of an  individual or company which is fictious. \n9 If it has been substituted by other drug \nRegulation of manufacture for sale \nof ASU drugs. 33EEB . \n No person shall manufacture for sale or distribution, any ASU drug except in accordance with prescribed standards. \nProhibition of manufacture and sale of certain ASU drug. 33EEC. \n No person shall manufacture ASU drugs which are: \n9 misbranded, adulterated or spurious \n9 patent or proprietary medicine, \n9 contravention to any of the provisions of the act \nPower of Central Government to prohibit manufacture of ASU drugs in public interest. 33EED. \n Central govt. can prohibit manufacture of ASU if: \n9 Drug involve any risk to human beings or animals \n9 Drug does not have the therapeutic value claimed \nGovernment Analysts. 33F. Central or Stat e govt. can appoint any person with the prescribed qualification and do not have \nany financial interest in ASU drug. \nInspectors. 33G. Central or State govt . can appoint any person with the pres cribed qualification and do not have \nany financial interest in ASU drug. \nPenalty for manufacture, sale, etc., of Ayurvedic, Siddha or Unani drug in contravention of this Chapter. 33I manufactures for sale or for distribution of any ASU drugs  deemed to be adulterated or  without \na valid licence as required. \nPenalty for subsequent offences. 33J. Shall be punishable with imprisonment for a term not less than two years but which may ex tend \nto six years and with fine not less than 5000 INR. \nConfiscation. 33K. Any person convicted under the act, th e respective stock of ASU drug can be confiscated. \nCognizance of offences. 33M. \u0083 No prosecution under this Chapter shall be instituted except by an Inspector. \n\u0083 No Court inferior to that of a [Metropolitan Magistrate] or of a [Judicial Magistrate] of the first class shall try an offence punishable under this Chapter. \nPower of Central Government to make rules. 33N The Central Government may -after consultati on with, or on the recommendation of, the Board- \nand after previous publication by notification in the Official Gazette, make rules for the purpose \nof giving effect to the provisions of this Chapter: \nApplication for licence to manufacture Ayurvedic (including \nSiddha) or Unani drugs. 153 An application for the grant or renewal of a licence to manufacture for sale any ASU drugs shall \nbe made in Form 24-D to the Licensing Authority along with a fee of rupees sixty. \nForm of licence to manufacture \nAyurvedic (including Siddha) or \nUnani drugs: 154. Subject to the conditions of rule 157 being fulfilled, a licence to manufacture for sale \nany ASU drugs shall be issued in Form 25-D. \nLoan Licence. 153-A. An application for the grant of renewal of a loan licence to manufacture for sale of any ASU \ndrugs shall be made in Form 25-E to the Licensing Authority along with a fee of rupees thirty. \nCertificate of award of G.M.P. of \nAyurveda, Siddha and Unani Drugs. 155 B shall be issued to licensees who comply with the requirements of GMP of ASU drugs as laid \ndown in Schedule T. \nStandards to be complied with in manufacture for sale or for distribution of Ayurvedic, Siddha and Unani Drugs. 168. Single drugs : The standards for identity, purity and stre ngth as given in editions of Ayurvedic \nPharmacopoeia of India. \nAsavas and Arishtas : The upper limit of alcohol as self generated alcohol should not exceed \n12% v/v. \n \n \n \n  \n \n Regulation of Traditional Medicines in India  Mukherjee et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 133 Department of AYUSH drafted certain rules \nfurther to amend the Drugs and Cosmetics Rules, \n1945 in the Gazette of India. The draft claims that the \ncertificate of Good Manufacturing Practices (GMP) to \nmanufacturers of Ayurveda, Siddha or Unani drugs shall be issued to licensee who comply with the requirements of Good Manuf acturing Practices (GMP) \nof Ayurveda, Siddha and Un ani drug as laid down in \nSchedule T (Mukherjee et al., 2003c). \nThe Good Manufacturing Practices (GMP) is \nprescribed to ensure: \ni. Raw materials used in the manufacture of drugs are authentic, of prescribed quality and are free from contamination. \nii. The manufacturing process is as has been prescribed to maintain the standards. \niii. Adequate quality control measures are adopted. \niv. The manufactured drug which is released \nfor sale is acceptable quality. \n \nTo achieve the objectives listed above, each \nlicensee should follow the prescribed process of \nmanufacture of drugs which should be documented as \na manual and kept for reference and inspection. \nFACTORY PREMISES \nThe manufacturing plant should have adequate \nspace for receiving and storing raw material, manufacturing process areas, Quality Control section, finished goods store, office, rejected goods/drugs \nstore. It also gives directives for herbal industries \nregarding the Location and surroundings, buildings, water Supply, disposal of waste, container\u2019s cleaning, stores, raw materials, packaging materials, finished goods stores, working space, health clothing, sanitation and hygiene or workers, medical services, \nmachinery and equipments, batch manufacturing \nrecords, distribution records, record of market \ncomplaints, quality control and the requirements for sterile products viz., manufacturing areas, precautions against contamination and mix. It also provided the \nlist of recommended machinery, equipment and \nminimum manufacturing spaces required for the manufacture of various categories of ayurvedic, siddha and unani system of medicine and also in-house quality control section. \nHEAVY METAL CONTENTS  \nHeavy metal contamination may be a particular \nproblem with traditional remedies from India, which are currently becoming prevalent in the USA, Australia, Europe and other countries.  Due to unsatisfactory Agricultural and cultivation practices \nrelating to the medicinal plants used in preparation of \nAyurveda, Siddha & Unani (ASU) and general environmental pollution, the presence of heavy metals above the permissible limit therein cannot be ruled out in the herbal preparations (Ramachandran, 2006). Strictly speaking, heavy metals are not contaminants \nof such drugs but are seen as active ingredients by \nproponents of traditional Indian medicine (Ernst, 2002). The Indian government introduced regulations in October 2005 with regard to heavy metal content in Ayurvedic formulations. De partment of Ayurveda, \nYoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH), in an order made testing for heavy metals namely, Arsenic, Lead, Mercury and Cadmium mandatory for export purposes in respect of \nevery batch of purely herbal ASU drugs by every \nlicensee. Permissible limits for Arsenic, Lead and \nCadmium will be as recommended by WHO publication \u201cQuality Control Methods for Medicinal Plants & Materials\u201d. In case of Mercury, the permissible limit will be one ppm. Conspicuous display on the container of purely herbal ASU drugs \nto be exported the word s \u201cHeavy metals within \npermissible limits\u201d will be mandatory.  \nGOOD MANUFACTURING PRACTICES \nAYUSH directs all the State Drug Licensing \nAuthorities to take action against the defaulting ASU drug manufacturers for revocation of their licenses \nunder Rules 157, 158 and 159 of the Drugs & Cosmetics Rules, 1945 for failure to comply with the Good Manufacturing Practices notified under Schedule \u2018T\u2019 of the Drugs & Cosmetics Rules, 1945. AYUSH directs the State Licensing Authorities of \nASU drugs to ensure full compliance by all ASU drug \nmanufacturers of the provisions of Rule 161 (1) and (2) relating to displaying on the label of the container \nor package of an Ayurveda, Siddha and Unani drug, \nthe true list of all the ingredients (official and \nbotanical names) used in the manufacture of the \npreparation together with the quantity of each of the ingredients incorporated therein. In case all the ingredients cannot be mentioned on the label because of their large number the same shall be indicated in the leaflet to be inserted in the package. Further that \nthe container of a medicine shall conspicuously \ndisplay the words \u2018Caution to be taken under medical supervision\u2019 if the list of ingredients contains a Regulation of Traditional Medicines in India  Mukherjee et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 134 substance specified in Schedule E(1) of the Drugs and \nCosmetics Rules, 1945.  \nNATIONAL MEDICINAL PLANTS BOARD  \nGovernment of India decided to establish an \nindependent body called \u201cNa tional Medicinal Plants \nBoard\u201d under the chairpersonship of ministry of health and family welfare. Its objectives are to assess the demand/supply, policy matters, guidance, inventorization, promotion of conservation or \ncultivation, promotion of co-operative efforts \ndissemination of information, matters relating to import or export, value addition, research and development, agro technology development and IPR related issues etc. The main objective of establishing \nthe Board is to have an ag ency at National level which \nwould be responsible to co-ordinate all matters \nrelating to development of medicinal plants including \ndrawing up policies and strategies for conservation, proper harvesting, cost-effective cultivation and \nmarketing etc. of raw material in order to protect, \nsustain and develop this  sector (Anonymous, 2002a). \nTo achieve these objectives 27 state medicinal plants boards were established. The National Medicinal Plants Board has been setup as a follow-up of recommendations of the Task Force on conservation \nand sustainable utilization of medicinal plants by \nPlanning Commission, vide Cabinet Resolution notified on 24th November, 2000.  \nPHARMACOPOEIA COMMITTEES \nLaying down the Pharmacopoeial standards for \nAyurveda, Siddha and Unani medicine both for single and compound drugs is an essential item of work. The Indian ministry had taken up the task of developing pharmacopoeial standards through Pharmacopoeia \nCommittees viz Ayurvedic Pharmacopoeia Committee (APC), Unani Pharmacopoeia Committee (UPC), \nSiddha Pharmacopoeia Committee (SPC) and \nHomoeopathic Pharmacopoeia Committee (HPC). They work for preparing official formularies/pharmacopoei as to evolve uniform \nstandards in preparation of drugs of Ayurveda, \nSiddha, Unani and Homoeopathy and to prescribe \nworking standards for single drugs as well as \ncompound formulations. TRADITIONAL KNOWLEDGE DIGITAL \nLIBRARY (TKDL) \nSince time immemorial, India has a rich traditional \nknowledge. Documentation of this existing knowledge, available in public domain, on various traditional systems of medicine has become imperative to safeguard the sovereignty of this traditional knowledge and to protect them from being misused in patenting on non-patentable inventions. \nThe TKDL is an original proprietary database, which \nis fully protected under nati onal and international laws \nof Intellectual Property Rights. TKDL, based on a \nnovel way of decodification software, allows \nautomatic conversion of information from Sanskrit \ninto various languages. The information includes \nnames of plants, Ayurvedic description of diseases under their modern names and therapeutic formulations, etc. During the current year, approximately 65,000 formul ations will be taken up \nfrom 45 selected Ayurvedic books, out of which 23,000 will be transcribed after excluding the duplicate references. The activity on identification of the formulations has been initiated. So far more than 34000 formulations have been identified from the Ayurveda texts and they have been checked for the \nduplicates. Transcription of 25000 formulations has \nbeen completed from 14 texts out of the targeted 45 texts. A similar work is also being carried out in other Indian system of Medicines. \nThe Indian government has also established 10 \nnew drug testing laboratories for Indian systems of medicine and is upgrading existing laboratories to provide high quality evidence to licensing authorities of the safety and quality of herbal medicines. This replaces an ad hoc  system of testing that was \nconsidered unreliable. These laboratories are also \ninvolved in the preparation of drug formulation and \npharmacopoeias for Ayurveda, siddha, Unani and Homoeopathy drugs and also in imparting training to ISM drug industry and drug inspecting staff on \nstandardization and quality control (Mukherjee et al., \n1998, 2005a). Randomized controlled clinical trials of \nselected prescriptions for Indian systems of medicine also have been initiated. These will document the safety and efficacy of the prescriptions and provide the basis for their inter- national licensure as medicines rather than simply as food supplements \n(Bodeker, 2001). Regulation of Traditional Medicines in India  Mukherjee et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 135 THE INDIAN MEDICINES DEVELOPMENT \nCORPORATION BILL, 2005  \nIn the ancient times, India has been the leader in \nthe medicines. Several systems, mostly indigenous, were used to cure diseases. Many herbal plants were used for manufacture of medicines. Later allopathy system of medicine came into being. Allopathy system being mostly of chemicals has its own effects while temporarily curing diseases. While Indian system of \nmedicine provides permanent relief, allopathy system \nprovides only temporary relief. Moreover, allopathy system has its own side effects which spoil the body system. Further the system is costlier also and poor people cannot afford to use this system. India has \nimmense resources of herbal plants. They have not \nbeen properly explored and exploited. Moreover, there \nis a huge potential for export of Indian system of \nmedicines. Therefore, it is proposed to establish a Corporation exclusively to promote and develop \nIndian system of medicines (Anonymous, 2005a). \n \nThe Corporation shall perform the following \nfunctions: \ni. To identify and locate herbal plants which are \nnecessary for manufacture of medicine; \nii. To protect herbal plants area; \niii. To manufacture and process Indian system of \nmedicine; \niv. To distribute and set up outlets for selling Indian \nsystem of medicine; \nv. To extend financial and technical assistance to \npersons involved in research in Indian system \nof medicine; \nvi. To export medicines based on Indian system; \nand \nvii. To advocate the extensive use of Indian system \nof medicine. \nTRADITIONAL HERBAL MEDICINES ACT, 2006 \nThe market in the urban and semi-urban area in \nIndia is full of traditional herbal preparations. These \nmedicines claim to cure various ailments from general \nfatigue to diabetes to cancer. According to a report, a causal and random checking and testing of these medicines by the Department of Pharmacology of one of the premium referral hospitals in India revealed that many of them were contaminated containing steroids \nwhich in the long run could lead to suppression of \nimmune system, growth retardation in children, diabetes and cataracts. Under the pretext of ancient texts and without any legal requirement of any license to sell these medicines, these unchecked traditional medicines are causing serious ailments to their \ninnocent users. The traditional herbal medicines act, \n2006 was introduced in the Indian Parliament in May, 2006 to regulate the sale of the traditional herbal \nmedicines which are being marketed without any \nlicense and control under the cover of being \nmanufactured by formulation provided in the ancient \ntexts and to provide for compulsory listing and verification of ingredients of traditional herbal medicines and for matters connected therewith and incidental thereto (Anonymous, 2006c). \nThe functions of the Authorities are: \n \n(i) To ensure quality control of the traditional \nherbal medicines. \n(ii) To arrange to verify the ingredient of any \nmedicine. \n(iii) To act on the complaint received in respect of \nany medicine. \n(iv) To recommend cancellation of license for \nselling of any traditional herbal medicine. \n(v) To make the people aware about its findings of \nvarious spurious medicines. \n(vi) To conduct survey and inspection and random \nsample checking of every manufacturer at least once in a year through its laboratories. \n(vii) Any other function that may be assigned. \n \nAccording to the act no traditional herbal medicine \nshall be sold or made available over the counter, every retailer or seller of traditional herbal medicines shall have to obtain a license to sell traditional herbal medicines from the Authority in such manner as may be prescribed. Every manufacturer of traditional \nherbal medicine shall list the ingredients of each \nmedicine on the packing of the medicine along with their accurate quantity. Every manufacturer of traditional herbal medicine shall clearly and boldly \nindicate on the packaging of the medicine any side \neffects and warning of contraindications in such \nmanner as may be prescribed. \nCONCLUSION \nThe market for medicinal plants is difficult to \nobtain as there is no clear distinction between medicines, food, spices and aromatic usage of these \nplants. Facing a multi-billion dollar international trade \nof herbal medicines, many countries in Asia are positioning themselves to boost their share of this Regulation of Traditional Medicines in India  Mukherjee et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 136 business and implement appropriate regulatory \nmeasures to safeguard public health. To maximize the \nutilizations of the natural resources, there should be an \ninternational co-ordination leading to harmonization \non various regulations of diffe rent countries. With this \ninternational harmonization, the botanicals should be explored further in the context of modern development.  \nMost of the herbal medicines in the world originate \nfrom developing countries, although the export volumes from most of these countries are small.  There are ample opportunities for these countries to expand their global export.  The Indian government has drawn up regulations for good manufacturing \npractice for traditional Indian systems of medicine \nsuch as ayurveda, siddha, and unani, so that the industry can compete in international markets. Government of India has taken various initiatives to improve the herbal drug standards and promote Indian \nsystem of medicine. Government of India has been \nstiffening the herbal drug regulations from time to \ntime by establishing various bodies to control the manufacture and sales of herbal drug. It is continuously taking various corrective measures by implementing certain acts and rules coping with the \ndeveloping global standard s for natural products.  \nREFERENCES \nAnonymous, 2002a. AYUSH, Govt. of India. 2002. Final \nReport. mohfw.nic.in \n/Annual0506/Ayush%20annual%20report%20final.pdf  \nAnonymous, 2003a. Ministry Of Health And Family \nWelfare (Department Of Indian Systems Of Medicine And Homoeopathy), Notification.  \nhttp://www.ipapharma.org/Schedule%20T.pdf  .  \nAnonymous, 2005a. The Indian Medicines Development \nCorporation Bill, 2005. \nhttp://164.100.24.208/ls/Bills/144,2005.pdf  . \nAnonymous, 2006a. Department of Ayurveda, Yoga & \nNaturopathy, Unani, Siddha and Homoeopathy) \n(AYUSH )  Government Of India Ministry Of Health & \nFamily Welfare  Dated: October 14, 2005 o r d e r \nAnonymous, 2006b. Ayurveda Fact sheet. \nhttp://www.catie.ca/pdf/supple-e/ayurveda.pdf    P a g e  \n1-3. \nAnonymous, 2006c. The Traditional Herbal Medicines \n(Regulation of Sale and Compulsory Evidence Based \nTrial) Bill, 2006. http://rajyasabha.nic.in/bills-ls-\nrs/2006/XXXVIII_2006.pdf\nAnonymous, 2007. Hope for Ayurveda as US FDA okays \nGerman Herbal drug. http://www.techno-\npreneur.net/ScienceTechMag/feb07/News_Diary.pdf\nBodeker G. 2001. Lessons on integration from the \ndeveloping world's experience. BMJ  322: 164-167. Calixto JB. 2000. Efficacy, safety, quality control, \nmarketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Braz. J. Med. \nBiol. Res . 33: 179-189. \nDubey NK, Kumar R, Tripathi  P. 2004.  Global promotion \nof herbal medicine: India\u2019s opportunity. Curr. Sci . \n86(1): 37-41. \nErnst E. 2002. Heavy metals in traditional Indian remedies. \nEur J Clin Pharmacol . 57: 891\u2013896. \nGrotte LB. 2004. Unani Medicine.  \nhttp://natheal.com/NaturalHealingSufiTraditions/Articles/U\nnani_Medicine2.pdf\nJoshi K, Chavan P, Warude D and Patwardhan B. 2004. \nMolecular markers in herbal drug technology. Curr. \nSci. 87(2): 159-165. \nKamboj VP. 2000. Herbal medicine . Curr. Sci . 78(1): 35-\n39. \nMukherjee PK, Shau M, Suresh B. 1998. Indian herbal \nmedicine. East. Pharm . 42(8): 21-24. \nMukherjee PK. 2001. Evaluation of Indian traditional \nmedicine. Drug. Inf. J.  35(2): 623-632. \nMukherjee PK. 2002a. Quality Control of Herbal Drugs: An \nApproach to Evaluation of Botanicals. Business \nHorizons Ltd, New Delhi, India, pp.1-6. \nMukherjee PK. 2002b. Problem s and prospects for the \nGMP in herbal drugs in Indian systems of medicine. Drug Inf J .; 63(3): 635-644.  \nMukherjee PK. 2003a. Explor ing botanicals in Indian \nsystems of medicine- regulato ry perspectives. Clinical \nRes. Reg. Affairs. 20(3):249-264. \nMukherjee PK. 2003b. Plant products with \nhypocholesterolemic potentials. Adv Food and Nutr \nRes.  47:278-324. \nMukherjee PK, Saha BP. 20 03c. Quest for GMP for the \nProduction of Quality Botanicals. GMP for Botanicals  \n\u2013 Regulatory and Qualtiy Issues on Phytomedicine. \nEastern Publishers, Business Horizons Ltd, New Delhi, \nIndia, pp.165-190. \nMukherjee PK, Mukherjee K. 2005a. Evaluation of \nBotanical-Perspectives of Quality Safety and Efficacy. Advances in medicinal plants (Vol 1). Asian. Med. \nPlants  : 87-110. \nMukherjee PK. 2005a. Promotion and Development of \nBotanicals with International Coordination. Allied Book Agency, Kolkata, India. \nMukherjee PK. 2005b. Exploring Green Resources for Drug \nDevelopment through Ethno botany. In: Chemistry for \nGreen Environment.  Srivastava MM, Sanghi R (Ed.). \nNarosa Publishing House, New Delhi, India:287-301. \nMukherjee PK, Maiti K, Mukherjee K, Houghton PJ. 2006. \nLeads from Indian medicinal plants with hypoglycemic \npotentials. J. Ethnopharmacol. 106:1-28. \nMukherjee PK, Wahile A. 20 06. Integrated Approaches \ntowards Drug Development from Ayurveda and other \nIndian System of Medicines. J. Ethanopharmacol . 103: \n25\u201335. Regulation of Traditional Medicines in India  Mukherjee et al.  \nBol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 137 Rai S, Mukherjee K, Mal M, Atul W, Saha BP,  Pulok K. \nMukherjee. 2006. Determination of 6-gingerol in ginger \n(Zingiber officinale ) using high-performance thin-layer \nchromatography. J  Sep. Sci . 29: 2292-2295. \nRamachandran R. 2006. For better regulation. Frontline . \n23(2). \nVerpoorte R, Kim HK, Choi YH. 2005. New perspectives \nof medicinal plants in a globalized world. Promotion and Development of Botanicals with International \nCoordination. Allied Book Agency, Kolkata, India. \nWilliamson E. 2006. Ayurveda: Introduction for \npharmacists, Pharm. J. 276: 108-110.  \nLaboratorio Regional Latinoamericano \nsobre Medicina Tradicional \n  \n \nBol. Latinoam. Caribe Plant. Med. Aromat. Vol. 6 (4) 2007 138 Entre el 10 y 12 de Mayo pasado se realiz\u00f3 en la \nciudad de Leticia, Colombia  el Laboratorio Regional \nLatinoamericano sobre Medicina Tradicional \n\u201cDi\u00e1logo de saberes: plantas medicinales, salud y cosmovisiones. Experiencias de medicina tradicional \nal servicio de la salud p\u00fablica\u201d, Este evento fue \norganizado por AIFO, M onserrate, Cooperazione \nItaliana, COE, MLAL Progettomondo, Universidad de Los Andes y Universidad Nacional de Colombia \u2013 Sede Leticia. Cont\u00f3 con la organizaci\u00f3n y sacrificio \nque bien valieron la pena de Enrico Neri, quien \nencabez\u00f3 el evento. Cont\u00f3 con la participaci\u00f3n de \ndestacados investigadores internacionales: Armando \nHerrera (M\u00e9xico) y Miguel Angel Guti\u00e9rrez (M\u00e9xico), Elaine Elisabetsky (Brasil), Elena Li (Per\u00fa), Jorge Alonso (Argentina) y Jos\u00e9 Luis \nMart\u00ednez (Chile). Adem\u00e1s de varios investigadores de \nColombia y tambi\u00e9n muchos grupos \u00e9tnicos. El logo del evento y algunas fotos se muestran a continuaci\u00f3n: \nLdo. Jos\u00e9 L. Martinez \nEditor Jefe de BLACPMA \n \n \nFoto 1: Parte de los participante s posan para la foto oficial. \nFoto 2: El Editor Jefe de BLACPMA junto a Enrico Neri. \n \nFoto 3: Invitados junto a Enrico Neri, de izquierda a derecha: Enrico \nNeri, Miguel Angel Guti\u00e9rrez, Elena Li, Jos\u00e9 Luis Mart\u00ednez, Jorge \nAlonso, Elaine Elisabetsky y  Harold Gomez. \n \n \nFoto 4 Jos\u00e9 Luis Mart\u00ednez junto a Humberto Andoque, cacique y jefe \nm\u00e1ximo de la Comunidad Andoque. \n Canto IX\nDesde all\u00ed da\u00f1osos vientos llev\u00e1ronme nueve d\u00edas \npor el ponto, abundante en peces, y al d\u00e9cimo arribamos a la tierra de los lot\u00f3fagos, que se alimentan con un florido manjar. Saltamos en tierra, hicimos aguada, y pronto los compa\u00f1eros empezaron a comer junto a las veleras naves.\nY despu\u00e9s que hubimos gustado los alimentos y la \nbebida, envi\u00e9 algunos compa\u00f1eros -dos varones a quienes escog\u00ed e hice acompa\u00f1ar por un tercero que fue un heraldo- para que averiguaran cu\u00e1les hombres com\u00edan el pan en aquella tierra. Fu\u00e9ronsepronto y junt\u00e1ronse con los lot\u00f3fagos, que no tramaron ciertamente la perdici\u00f3n de nuestros amigos; pero les dieron a comer loto, y cuantos probaron este fruto, dulce como la miel, ya no quer\u00edan llevar noticias ni volverse; antes deseaban \npermanecer con los lot\u00f3fagos, comiendo loto, sin acordarse de volver a la patria. Mas yo los llev\u00e9 por fuerza a las c\u00f3ncavas naves y, aunque lloraban, los \narrastr\u00e9 e hice atar debajo de los bancos. Y mand\u00e9\nque los restantes fieles compa\u00f1eros entrasen luego en las veloces embarcaciones: no fuera que alguno comiese loto y no pensara en la vuelta. Hici\u00e9ronlo en \nseguida y, sent\u00e1ndose por orden en los bancos, comenzaron a batir con los remos el espumoso mar.\nHomero, La Odisea. Canto IX \n(TRADUCCION DE LUIS SEGALA Y ESTALELLA) \nDisponible en http://www.odisea.com.mx/\nPlantas Medicinales en la LiteraturaISSN 0717 7917\nwww.blacpma.cl\nCon el auspicio de\nQUALIS\u00ae, INDEX COPERNICUS\u00ae, LATINDEX\u00ae, \nIMBIOMED\u00ae, REDALYC\u00ae\n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}